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ABSTRACT 
 
MONOAMINE TRANSPORTER PHOTOAFFINITY LIGANDS BASED ON 
METHYLPHENIDATE AND CITALOPRAM: RATIONAL DESIGN, CHEMICAL 
SYNTHESIS, AND BIOCHEMICAL APPLICATION 
 
 
 
By 
Nageswari Yarravarapu 
May 2015 
 
Dissertation supervised by Dr. David J. Lapinsky 
Monoamine transporters (MATs) are a family of proteins that include the 
dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine 
transporter (NET).  Specifically, dysregulation of MAT function is associated with a host 
of disease states including drug abuse, major depressive disorder, and anxiety.  
Additionally, several drugs acting as MAT inhibitors are clinically available to treat 
multiple disorders.  However, details regarding the transport inhibition mechanism 
created by these drugs, as well as their discrete ligand-binding pockets within their target 
MAT proteins, remains poorly understood.  This knowledge gap in turn hinders rational 
development of novel therapeutics for numerous MAT-associated disorders.  The 
objective of this research dissertation was to develop irreversible chemical probes based 
 v 
on methylphenidate (MP) and citalopram (CIT), two therapeutically significant MAT 
inhibitors, in order to map their binding sites and poses within their major MAT target 
protein.  The central hypothesis was that MP and CIT could be rationally derivatized, 
without significant loss in pharmacological activity, to contain a tag moiety and a 
photoreactive group capable of forming a covalent bond to their target MAT protein, thus 
allowing application of a “Binding Ensemble Profiling with (f)Photoaffinity Labeling 
(BEProFL)” experimental approach.  Specifically, BEProFL rationally couples 
photoaffinity labeling, chemical proteomics, and computational molecular modeling in 
order to map the binding sites and poses of ligands within their target proteins.  This 
central hypothesis was tested by pursuing three specific aims: 1) identification of non-
tropane photoprobes based on MP suitable for DAT structure-function studies, 2) 
identification of photoprobes based on CIT and (S)-CIT suitable for SERT structure-
function studies, and 3) development of a tandem photoaffinity labeling-bioorthogonal 
conjugation protocol for SERT structure-function studies.  In the first aim, MP was 
structurally modified to contain an aryl azide photoreactive group and a 125I radioisotope 
tag.  The compounds were then subjected to DAT pharmacological evaluation in order to 
identify suitable candidates for DAT structure-function studies.  In the second aim, CIT 
and (S)-CIT were structurally modified to contain an aryl azide or benzophenone 
photoreactive group and 125I, a terminal alkyne, or an aliphatic azide as a tag.  Likewise, 
these compounds were subjected to SERT pharmacological evaluation in order to identify 
suitable candidates for SERT structure-function studies.  Finally, under the third aim, a 
tandem photoaffinity labeling-bioorthogonal conjugation protocol was developed to label 
purified hSERT expressed in HEK-293 cells using a (S)-CIT-based benzophenone-alkyne 
 vi 
clickable photoprobe.  Probe-labeled hSERT samples from this protocol are currently 
being analyzed by high resolution mass spectrometry in order to map the (S)-CIT-binding 
site(s) within the hSERT. 
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CHAPTER ONE 
1.  Biological Literature Review 
1.1.  Introduction to Monoamine Transporters (MATs) 
The neurotransmitters (Figure 1.1) dopamine (1.1), serotonin (1.2), and 
norepinephrine (1.3) are monoamine chemical messengers that mediate complex 
functions such as locomotion, memory, appetite, sleep, cognition, mood, reward, fear, 
sexual drive, and motivation (Grant et al., 1988; Barnes and Sharp, 1999; Greengard, 
2001; Girault and Greengard, 2004).  The duration and intensity of monoamine chemical 
signaling is dependent on extracellular neurotransmitter levels, which are regulated by 
monoamine transporters (MATs).  MATs are transmembrane proteins located in plasma 
membranes of monoaminergic neurons, and their main function is to terminate 
neurotransmission by inward transport of released monoamines (Benarroch, 2013).  
MATs include dopamine (DAT), serotonin (SERT), and norepinephrine (NET) 
transporters, and they belong to the Na+- and Cl--coupled solute carrier 6 (SLC6) gene 
family (also known as the neurotransmitter sodium symporter (NSS) family) (Rudnick et 
al., 2014).  The size of these three MATs is fairly similar, wherein the DAT, SERT, and 
NET have 617, 630, and 620 amino acid residues, respectively.  These three MATs also 
share a common membrane topology that is characterized by 12 transmembrane (TM) 
helices and intracellular N- and C-termini. 
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Figure 1.1.  The chemical structures of dopamine, serotonin, and norepinephrine as monoamine 
neurotransmitters. 
Dopamine, serotonin, and norepinephrine imbalances are implicated in numerous 
neurological disorders (Hahn and Blakely, 2002) like anxiety, depression (Klimek et al., 
1997), alcoholism (Heinz et al., 2001), drug abuse (Howell and Negus, 2013), 
Parkinson’s disease (Seeman and Niznik, 1990), and schizophrenia (Abdolmaleky et al., 
2014).  More than thirty MAT inhibitors are Food and Drug Administration (FDA) 
approved to treat disorders such as anxiety, depression, smoking cessation, and attention 
deficit hyperactivity disorder (ADHD).  While the tricyclic antidepressants (TCAs) target 
all three MATs, the current standard of treatment for generalized anxiety and depression 
is to use selective serotonin reuptake inhibitors (SSRIs), whose primary target is the 
SERT (Stahl et al., 2013).  Several antidepressants can also bind to DAT and NET with 
lower affinity.  MATs are also targets for drugs of abuse (Figure 1.2) including cocaine 
(1.4), amphetamine ((±)-1.5), methaphetamine ((±)-1.6), and 
methylenedioxymethamphetamine ((±)-1.7, MDMA, ecstasy) (Howell and Negus, 2013).  
However, these psychostimulants differ in their relative affinity for DAT, SERT, and 
NET.  For example, cocaine has approximately equal affinity for DAT, SERT, and NET, 
whereas amphetamine, methamphetamine, and methylphenidate have relatively lower 
affinity for SERT compared to their affinity for DAT and NET (Howell and Kimmel, 
2008).  
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Figure 1.2.  Examples of drugs of abuse that target DAT, SERT, and NET. 
Over the last few decades, drug discovery efforts for the treatment of mood 
disorders have mainly focused on drugs targeting the DAT, SERT, or NET.  TCAs (e.g., 
imipramine (1.8), clomipramine (1.9), and desipramine (1.10), Figure 1.3) are the first 
generation antidepressants that target MATs (Lader, 2004).  TCAs can also target G 
protein-coupled receptors and cardiac sodium channels giving rise to several side effects 
(Zohar and Westenberg, 2000).  In order to avoid these side effects, subsequent drugs 
were mainly developed to act on specific monoamine transporters.  Eventually, selective 
serotonin (SSRIs) (e.g., citalopram ((±)-1.11), escitalopram ((S)-1.11), fluoxetine (1.12), 
sertraline (1.13), paroxetine (1.14), and fluvoxamine (1.15), Figure 1.3) and 
norepinephrine reuptake inhibitors (NRIs) (e.g., reboxetine (1.16) and atomoxetine 
(1.17), Figure 1.3) were developed.  SSRIs generally possess fewer side effects when 
compared to TCAs, principally due to their high selectivity.  As a result, they represent a 
treatment of first choice for depression (Stahl et al., 2013).  In contrast, NRIs and DAT 
inhibitors (e.g., methylphenidate (1.18), Figure 1.3) are mainly used for the treatment of 
ADHD.  DAT inhibitors (e.g., benztropine (1.19), Figure 1.3 and analogues) are also 
being pursued for the treatment of cocaine addiction (Howell and Negus, 2013).  
Additionally, serotonin and noerpinephrine reuptake inhibitors (SNRIs) (e.g., 
desvenlafaxine (1.20) and duloxetine (1.21), Figure 1.3) and norepinephrine and 
dopamine reuptake inhibitors (NDRIs) (e.g., bupropion (1.22) and nomifensine (1.23), 
Figure 1.3) represent dual acting MAT inhibitors, wherein the NDRI bupropion is used as 
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a smoking cessation agent (Jorenby, 2002).  Recently, triple reuptake inhibitors that 
equally target DAT, SERT, and NET (e.g., tesofensine (1.24), Figure 1.3) have been 
developed and pursued for treatment of obesity (Astrup et al., 2008).  
 
Figure 1.3.  Examples of inhibitors that target DAT, SERT, or NET. 
Although multiple drugs are available to treat mental illnesses, their drawbacks 
have fueled the quest for novel agents targeting MATs.  For example, currently available 
antidepressants have several limitations such as late onset of action, a high percentage of 
non-responding patients, and numerous side effects such as sexual dysfunction, weight 
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gain, nausea, anxiety, and insomnia (Khawam et al., 2006).  Despite being clinically 
important drugs and drug targets, very little is known about the specific drug-protein 
interactions that lead to their clinical efficacy.  As a result, it is important to understand 
the structural and functional features of MATs, in particular, the binding sites for 
therapeutic drugs within these proteins.  A better understanding of MAT binding sites is 
expected to enable efforts to discover and develop new and improved therapeutics for the 
treatment of numerous diseases associated with these proteins (e.g., depression, anxiety, 
post-traumatic stress disorder, obsessive-compulsive disorder, drug abuse, addiction, 
etc.). 
1.2.  The Dopaminergic System and the Dopamine Transporter (DAT) 
Arvid Carlsson established dopamine as a neurotransmitter in the late 1950’s and 
dopaminergic pathways in the central nervous system were subsequently identified 
(Iversen and Iversen, 2007).  Dopamine neuron cell bodies are localized in the substantia 
nigra, ventral tegmental area, and hypothalamus, and their axons project to the caudate 
nucleus, putamen, nucleus accumbens, and prefrontal cortex (Girault and Greengard, 
2004).  Dopaminergic neurotransmission is involved in important physiological processes 
such as motor control, cognition, arousal, and reward (Greengard, 2001).  Improper 
functioning of the dopaminergic system can result in severe neurodegenerative and 
psychiatric disorders, including attention deficit hyperactivity disorder (ADHD), bipolar 
disorder, Parkinson’s disease (PD), and schizophrenia (Mehler-Wex et al., 2006; Mazei-
Robison et al., 2008; Serretti and Mandelli, 2008).  
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Dopamine is a catecholamine synthesized in dopaminergic neurons from the 
amino acid tyrosine, and is stored in presynaptic vesicles.  In response to a presynaptic 
action potential, dopamine is released into the synaptic cleft via calcium-mediated 
exocytosis (Westerink, 2006), where it subsequently binds to dopamine receptors to 
produce chemical impulses signaling reward or satisfaction (Iversen and Iversen, 2007).  
The dopamine transporter (DAT) is a neuronal membrane protein that mediates the 
reuptake of dopamine into the presynaptic neuron.  It is primarily responsible for 
regulating the intensity and duration of the dopaminergic neurotransmission (Jaber et al., 
1997) (Figure 1.4).  Once dopamine is transported by the DAT into neurons, it is either 
degraded by monoamine oxidase (MAO) enzymes or stored in vesicles. 
Historically, inhibition of DAT by stimulant drugs was an important finding.  The 
behavioral, reinforcing, and euphorogenic effects of stimulant drugs such as cocaine and 
amphetamine has been explained via a dopamine hypothesis, and numerous studies have 
identified the DAT as the primary drug target associated with the abuse and addiction 
potential of these compounds (Koob, 1992; Woolverton and Johnson, 1992; Rothman and 
Glowa, 1995; Lile and Nader, 2003; Fleckenstein et al., 2007;  Natarajan and Yamamoto, 
2011).  In rodents, the self-administration capacity of cocaine-like stimulants is correlated 
with their potency in inhibiting the DAT (Ritz et al., 1987). 
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Figure 1.4.  Cartoon of dopaminergic neurotransmission (Reprinted with permission from 
https://www.cnsforum.com/educationalresources/imagebank/substance_abuse/mao_cocaine.  Copyright 
2015, accessed on 01/26/2015). 
It is known that cocaine binds to DAT proteins present on presynaptic membranes 
and increases extracellular dopamine concentration by blocking the reuptake activity of 
DAT.  The resulting excess dopamine continuously activates dopamine receptors present 
on postsynaptic membranes.  This phenomenon causes an increased activation of the 
dopaminergic reward pathways resulting in the “high” traditionally associated with 
cocaine use (Figure 1.5).  This “high” reported by cocaine users, appears to be a function 
of both the rate of DAT occupancy by cocaine and the speed of cocaine delivery into the 
brain (Volkow et al., 2000).  
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Figure 1.5.  Inhibition of dopamine reuptake upon binding of cocaine to the dopamine transporter 
(Reprinted with permission from 
https://www.cnsforum.com/educationalresources/imagebank/substance_abuse/mao_cocaine.  Copyright 
2015, accessed on 01/26/2015). 
1.2.1.  Chemical Composition and Structure of the Dopamine Transporter  
The human dopamine transporter (hDAT) is an 80 kDa integral protein that 
contains 620 amino acids (Benarroch, 2013).   Its size is relatively similar to that of other 
monoamine transporters, such as the norepinephrine (NET) and serotonin (SERT) 
transporter, and alignment of the amino acid sequences of these transporters reveals that 
some segments within these proteins share a high degree of homology.   Monoamine 
transporters belong to the neurotransmitter sodium symporter (NSS) or solute carrier 6 
(SLC6) family of proteins, which may account for their homologous sequences (Rudnick 
et al., 2014). 
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 The DAT is composed of 12 transmembrane (TM) domains connected by 
alternating intracellular and extracellular loops, with the amino and carboxyl-terminals 
located on the intracellular side of the membrane (Figure 1.6).  There are three potential 
N- glycosylation sites on the large extracellular loop of DAT between TM3 and TM4.  
Stability and plasma membrane trafficking of the DAT is strongly influenced by 
glycosylation (Li et al., 2004).  The DAT also contains a number of potential 
phosphorylation sites on the intracellular domains, which correlate with the transporter’s 
activity and trafficking (Chen et al., 2010).  TM1 and TM6 have residues important for 
transport of the substrate dopamine (Huang and Zhan, 2007; Indarte et al., 2008) and are 
also important for the binding of inhibitiors like cocaine (Vaughan et al., 2007; Ukairo et 
al., 2005; Parnas et al., 2005; Reith et al., 2001). 
The hDAT also contains a Zn2+-binding motif between extracellular loop 2, TM7, 
and TM8 (Norregaard et al., 1998).  Zn2+ serves to mediate conformational changes of 
hDAT that are critical for the transport process.  In addition to having a Zn2+-binding 
motif, DAT also has a leucine zipper-like motif within TM2 and TM9.  Leucine 
mutations within TM2 and TM9 suggest that the leucine zipper motif in TM2 contributes 
to the oligomerization and trafficking of DAT, which are essential to the functionality of 
the transporter (Torres et al., 2003).  The cellular orientation of DAT, along with its 
trafficking, contributes significantly to the function of the transporter.  Results from these 
studies show that the proper assembly and trafficking of DAT to the plasma membrane 
are necessary for the function of the transporter. 
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Figure 1.6.  Diagram of membrane topology of the human dopamine transporter based upon bacterial 
leucine transporter crystal structures. Full TM helices are numbered 1–12 and intra- and extracellular loops 
are numbered 1–5 with prefixes either ‘i’ or ‘e’ respectively (Schmitt et al., 2008.  Reprinted with 
permission from J. Neurochem. 2008, 107, 928-940.  Copyright 2008, International Society for 
Neurochemistry). 
Ligand-binding and site-directed mutagenesis studies have been used to 
characterize DAT structural features such as substrate translocation mode and 
conformational preferences when bound with different DAT ligands (Chen and Reith, 
2003; Uhl and Lin, 2003; Chen et al., 2004; Volz and Schenk, 2005; Schmitt et al., 2008; 
Loland et al., 2008).  Simultaneously, photoaffinity labeling agents based on cocaine and 
other known DAT inhibitors have been used to identify potential binding sites within the 
DAT (Grigoriadis et al., 1989; Kline et al., 1994; Vaughan et al., 1998, 1999, 2001, 
2005, and 2007; Dutta et al., 2001; Zou et al., 2001; Newman et al., 2006; Parnas et al., 
2008; Dahal et al., 2014).  However, the molecular mechanism and exact binding sites of 
cocaine and other DAT inhibitors, as well as the molecular determinants of inhibitor 
selectivity, remains largely unknown.  In particular, currently it is not possible to 
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comprehensively understand the DAT at the molecular level due to the lack of three-
dimensional (3D) high-resolution DAT structure.  In particular, the lack of a DAT crystal 
structure has hindered the rational drug design of potential DAT ligands.  Most recently, 
x-ray crystal structures of bacterial (Aquifex aeolicus) leucine transporter (LeuT) 
(Yamashita et al., 2005; Zhou et al., 2007 and 2009; Quick et al., 2009; Singh, et al., 
2007 and 2008; Nyola et al., 2010; Krishnamurthy and Gouaux, 2012; Piscitelli and 
Gouaux, 2012; Wang and Gouaux, 2012; Kantcheva et al., 2013; Loland, 2015; Penmatsa 
and Gouaux, 2014) and the fly (Drosophila melanogaster) dopamine transporter (dDAT) 
(Penmatsa et al., 2013) have become available as templates for computational DAT 
homology modeling (Koldso, Christiansen et al., 2013; Stockner et al., 2013; Seddik et 
al., 2013; Gedeon et al., 2010; Huang et al., 2009; Indarte et al., 2008).  
LeuT has a low level of similarity to DAT (20%), SERT (21%), and NET (24%), 
even though it belongs to the NSS family (Beuming et al., 2006).  Despite this overall 
low sequence homology, a few regions in transmembrane domains 1, 3, 6, and 8, which 
form the ligand-binding site in LeuT, are highly conserved throughout the family, thus 
providing the opportunity to build potentially reliable homology models ( e.g., Indarte et 
al., 2008; Manepalli et al., 2012).  The LeuT crystal structures have principally revealed 
two binding pockets termed S1 (primary substrate-binding site) and S2 (antidepressant-
binding site), which have been verified by molecular docking studies of DAT inhibitors 
(Singh et al., 2007; Zhou et al., 2007).  However, the highly potent DAT inhibitor 
cocaine does not display appreciable inhibitory potency for substrate transport by LeuT 
(Singh et al., 2007).  In addition, antidepressants such as desipramine that were 
cocrystalized with LeuT have little appreciable affinity and inhibitory potency for DAT 
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(Zhou et al., 2007).  Most recently, the tricyclic antidepressant nortriptyline was 
cocrystalized with dDAT and shown to bind in the S1 binding pocket (Penmatsa et al., 
2013).  Though the overall structure of dDAT is similar to that of LeuT, it was observed 
that these proteins also have multiple divergent features.  For example, the 
transmembrane 12 of dDAT has a twist in its center at Pro 572, which is not observed in 
LeuT.  Furthermore and unlike LeuT, there is a latch-like carboxy-terminal helix capping 
the intracellular cytoplasmic gate in dDAT.  Another distinction between LeuT and 
dDAT crystal structures is that dDAT has a cholesterol molecule lodged within a pocket 
surrounded by TMs 1a, 5, and 7.  Additionally, dDAT has made accommodations to 
account for the absence of a carboxylate group in biogenic amine substrates, as compared 
to the interactions between the carboxylate group of leucine substrate and Tyr108 within 
the substrate-binding pocket of LeuT.  In particular, Asp46 present in TM1 of dDAT 
forms a hydrogen bond with the hydroxyl group of Tyr 124, which is equivalent to Tyr 
108 in LeuT (Penmatsa et al., 2013).   As a result, these disparities between dDAT and 
LeuT indicate that more direct and valid experimental approaches are required for hDAT 
structure and function studies. 
1.3.  Proposed Mechanism of Dopamine Reuptake by the Human Dopamine 
Transporter  
The function of DAT is to reuptake dopamine into the presynaptic neuron in order 
to regulate the intensity and duration of the dopaminergic neurotransmission (Jaber et al., 
1997).  Coupling of dopamine influx with an inward flow of Na+ and Cl- drives the 
dopamine reuptake process, as these ions move down a gradient across the cell membrane 
(Figure 1.7).  DAT promotes the transport of dopamine together with Na+ and Cl- ions as 
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co-substrates with a stoichiometric ratio of 2:1:1 for sodium:chloride:dopamine.  Na+K+-
ATPase creates a concentration gradient that moves three Na+ ions out of the cell for 
every two K+ ions into the cell.  According to the alternate accessing model, dopamine, 
Na+, and Cl- bind to DAT on the extracellular side in an outward-facing conformation 
(Jardetzky, 1966).  This binding is proposed to induce a conformational change in the 
transporter such that the dopamine-binding site becomes exposed to the intracellular side 
of the membrane (i.e., an inward-facing conformation), thus allowing dopamine, Na+, and 
Cl-
 
to be transported to the intracellular side (Figure 1.8).  Subsequently, upon 
simultaneous release of potassium ions into the synaptic cleft, the empty transporter 
returns to the outward facing conformation in order to initiate another transport cycle 
(Figure 1.9).  
 
Figure 1.7.  Na+K+-ATPase-induced concentration gradient in the human dopamine transporter (Reprinted 
with permission from 
https://www.cnsforum.com/educationalresources/imagebank/dopaminergic/rcpt_sys_da_reup.  Copyright 
2015, accessed on 01/26/2015). 
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Figure 1.8.  Dopamine influx coupled with inward flow of Na+
 
and Cl-
 
ions as part of the reuptake process 
(Reprinted with permission from 
https://www.cnsforum.com/educationalresources/imagebank/dopaminergic/rcpt_sys_da_reup.  Copyright 
2015, accessed on 01/26/2015). 
 
 
Figure 1.9.  The dopamine transporter returns to an outward-facing conformation in order to facilitate 
another transport cycle (Reprinted with permission from 
https://www.cnsforum.com/educationalresources/imagebank/dopaminergic/rcpt_sys_da_reup.  Copyright 
2015, accessed on 01/26/2015). 
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Single-molecule dynamics studies, molecular simulations, and subsequent crystals 
of LeuT have further verified this alternate access model.  In turn, these studies have 
revealed a third, low-energy state, a dually occluded, substrate-bound intermediate 
conformation, while transitioning between outward-open and inward-open conformations 
during substrate translocation (Penmatsa and Gouaux, 2014; Schmitt et al., 2013).  
 Based on the insights from LeuT, a mechanistic framework for the dopamine 
transport has been proposed, including an outward-facing conformation for dopamine and 
ion pickup, an occluded conformation featuring dopamine and ion bound, and an inward-
facing conformation allowing dopamine and ion release (Penmatsa and Gouaux, 2014;  
Schmitt et al., 2013).  The transport cycle is proposed to start with an ion/substrate-free 
(apo) outward-facing state of the dopamine transporter (Figure 1.10, A).  Binding of Na+ 
and Cl-  ions then equilibriates the apo DAT towards a more stabilized outward-facing 
conformation, which features a fully open extracellular gate readily prepared to bind 
substrate (Figure 1.10, B) (Claxton et al., 2010; Krishnamurthy and Gouaux, 2012). 
Dopamine then binds at the primary substrate (S1) site (Figure 1.10, C) and closes the 
extracellular gate via salt bridge formation between extracellular gating residues Arg85 
and Asp476, thus giving rise to an occluded state.  Subsequent, conformational changes 
in the process promote the transporter from the occluded state towards an inward-facing 
conformation (Figure 1.10, D).  Finally, dopamine, Na+, and Cl-
 
ions are released into the 
cytosol from the inward-facing state of the dopamine transporter due to hydration of its 
binding sites.  Subsequent dopamine transporter changes from the inward- to outward-
facing state allow another dopamine transport cycle to commence (Figure 1.10, A and E; 
Schmitt et al., 2013).  
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Figure 1.10.  Putative dopamine transporter conformational cycle for translocation of dopamine (DA) 
(Schmitt et al., 2013. Adapted with permission from J. Pharmacol. Exp. Ther. 2013, 346, 2-10. Copyright 
2013, JPET Online by American Society for Pharmacology and Experimental Therapeutics). 
Another transport hypothesis features binding of a second dopamine molecule to a 
secondary allosteric site (S2) located 11Å above the S1 site towards the extracellular side 
of the membrane. This is proposed to activate the conformational shift from the occluded 
to inward-facing state (Figure 1.10, C and D) (Shi et al., 2008; Quick et al., 2012).  This 
secondary allosteric S2 site in LeuT was identified to be the binding site for tricyclic 
antidepressants and selective serotonin reuptake inhibitors (Zhou et al., 2007 and 2009).  
However, the existence of the S2 site in hDAT and its role with respect to ligand binding 
is highly debated by researchers in the MAT field.  
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1.4.  Dopamine Transporter Ligands 
1.4.1.  Dopamine Transporter Substrates 
Amphetamines ((±)-1.5) - (±)-1.7), Figure 1.11) are structurally similar to 
dopamine and act as substrates at the dopamine transporter (Robertson et al., 2009). 
Amphetamine and methamphetamine are pschostimulants approved for the treatment of 
ADHD, obesity and narcolepsy (Fleckenstein et al., 2007).  The Drug Enforcement 
Agency (DEA) tightly controls these drugs by categorizing them as Schedule II agents, 
principally because their potential for abuse can lead to severe psychological and 
physiological dependence.  Amphetamines produce their principal effects by increasing 
synaptic levels of dopamine, norepinephrine, and serotonin through multiple 
mechanisms.  Although amphetamines generally target various transporters, the DAT is 
primarily implicated in their reinforcing properties and abuse potential (Fleckenstein et 
al., 2007).   The exchange diffusion / reverse transport model has been used to explain 
the mechanism of action of amphetamines and relies on evidence that amphetamines are 
substrates for the DAT (Figure 1.12).  The DAT transports amphetamines into the 
presynaptic neuron, and this leads to a reverse transport of dopamine into the synaptic 
cleft, thus enhancing extracellular dopamine levels (Sulzer et al., 2005).  Another 
mechanism of amphetamine-mediated dopamine efflux features a channel-like 
configuration of DAT (Kahlig et al., 2005).  Similar to DAT inhibitors, amphetamines 
also increase extracellular dopamine levels by competing with dopamine for the 
substrate-binding site within DAT, thus preventing dopamine reuptake from the synapse 
(Figure 1.12) (Wayment et al., 1998).  
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Figure 1.11.  Chemical examples of amphetamines as monoamine transporter substrates. 
 
Figure 1.12.  Mechanism of action of amphetamine (Adapted with permission from 
https://www.cnsforum.com/educationalresources/imagebank/substance_abuse/drug_amphet_low.  
Copyright 2015, accessed on 01/26/2015). 
1.4.2.  Dopamine Transporter Inhibitors 
Since the DAT has been implicated as the primary target associated with cocaine 
and amphetamines abuse, DAT ligands acting as cocaine antagonists have been pursued 
for the treatment of psychostimulant abuse (Howell and Negus, 2013).  In particular, it 
has been suggested that the ideal DAT inhibitor for treatment of cocaine abuse should 
gradually eliminate craving for cocaine and help users maintain abstinence (Rothman et 
al., 1989; Carroll et al., 1999).  However, a DAT inhibitor has yet to be approved for the 
treatment of psychostimulant abuse, principally because the rational design of such 
compounds are hindered due to limited 3D structural information and poor understanding 
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of the dopamine- and inhibitor-binding sites within the DAT.  To date, existing DAT 
inhibitors have been discovered either by serendipity or ligand-based drug design, and are 
classified as either “cocaine-like” or “atypical” based on their distinct behavioral effects 
(Schmitt et al., 2013).  Earlier, it was believed that both DAT substrates and inhibitors 
have addiction potential equivalent to cocaine, principally due to their ability to increase 
extraneuronal dopamine levels.  However, recently discovered, “atypical” benztropine-
like DAT inhibitors show a lack of addiction potential as compared to cocaine 
(Woolverton et al., 2000; Ferragud et al., 2009; Hiranita et al., 2009).  As a reslut, 
ligands with different chemical structures have been shown to be capable of inducing 
specific conformational changes in the DAT, which can be differentially transduced by 
the cell towards eliciting unique behavioral and psychological effects (Schmitt et al., 
2013).  
1.4.2.1.  “Cocaine-Like” Dopamine Transporter Inhibitors  
1.4.2.1.1.  Tropanes  
Cocaine (1.4, Figure 1.13) is a powerful CNS stimulant that has been an abused 
substance for more than 100 years (Ciccarone, 2011).  According to a National Survey on 
Drug Use and Health (NSDUH), the national prevalence of cocaine dependence or abuse 
was 1.1 million persons in 2012, third in illicit drugs after marijuana and misuse of 
prescription medications (see http://www.samhsa.gov/data/NSDUH/2012SummNatFind 
DetTables/NationalFinds/NSDUHresults2012.htm). Cocaine abuse and addiction remains 
a major health and economic problem that continues to plague our society.  Currently, 
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there are no FDA-approved medications for this type of addiction. As a result, the 
development of agents for cocaine dependence is vitally important. 
Cocaine is a nonselective, competitive inhibitor of monoamine transporters that 
binds to the DAT, NET, and SERT, and functions to inhibit uptake of dopamine, 
norepinephrine, and serotonin, respectively (Newman et al., 2001; Katz et al., 2001).  
Although cocaine affects all three monoamine transporters, decades of studies have 
established that binding of cocaine to the DAT is primarily responsible for its reward and 
reinforcement effects (Koob, 1992; Woolverton and Johnson, 1992; Rothman and Glowa, 
1995; Lile and Nader, 2003; Fleckenstein et al., 2007;  Natarajan and Yamamoto, 2011).  
Since the neurochemical basis for the dependence-producing properties of cocaine were 
elucidated, numerous approaches to develop a therapeutic for cocaine addiction have 
been under investigation (Howell and Negus, 2013).  Towards this goal, many 
researchers have hypothesized a dopamine-sparing cocaine antagonist approach.  Such a 
compound would be expected to partially mimic the effects of cocaine without intense 
craving, thereby gradually withdrawing abusers into abstinence. 
In an attempt to identify dopamine-sparing cocaine antagonists, tropane analogs 
such as WIN-35,428 (1.25, Figure 1.13) and benztropine (1.19, Figure 1.14) have been 
identified.  WIN-35,428 has high DAT affinity and inhibitory potency showing 
approximately 8-fold increased binding affinity towards DAT as compared to cocaine 
(Clarke et al., 1973; Madras et al., 1989).  The radioisotope [3H]-WIN-35,428 is 
commonly used to assess binding affinity of novel ligands to the DAT (Carroll et al., 
1994), mainly because WIN-35,428 has a longer half-life relative to cocaine due to the 
absence of the metabolically labile benzoate ester. 
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Figure 1.13.  Chemical examples of “cocaine-like” DAT inhibitors and their MAT pharmacology 
(Javanmard et al., 1999). 
1.4.2.1.2.  Methylphenidate 
The psychostimulant methylphenidate ((±)-1.18), Figure 1.13), a non-tropane 
DAT inhibitor, has higher binding affinity for DAT than the other monoamine 
transporters (Gatley et al., 1996).  The binding affinity of methylphenidate to DAT has 
been shown to be twice that of cocaine (Gatley et al., 1996), even though both 
compounds have comparable functional groups (i.e., a basic nitrogen, methyl ester, and 
an aromatic ring).  Most importantly, methylphenidate is a U.S. Food and Drug 
Administration (FDA) approved therapeutic for treatment of attention deficit 
hyperactivity disorder (ADHD) (Golubchik et al., 2014). Animal behavioral studies 
suggest methylphenidate has reinforcing effects similar to that of cocaine (Bergman et 
al., 1989).  However, in humans, methylphenidate’s reinforcing ability appears to be 
substantially lower and has been shown to reduce cocaine cravings (Yano and Steiner, 
2007).  These results suggest that methylphenidate has the attributes necessary to serve as 
a lead candidate for the treatment of cocaine dependence, and currently, methylphenidate 
analogs are being pursued as therapeutics for drug abuse (Misra et al., 2010).  Recently, 
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Misra and coworkers have reviewed structure-activity relationships for methyphenidate 
(Misra et al., 2010). 
1.4.2.2.  “Atypical” Dopamine Transporter Inhibitors  
1.4.2.2.1.  Benztropines 
Benztropine (Cogentin, 1.19, Figure 1.14) is a tropane-based DAT inhibitor (Zou 
et al., 2003) and anticholinergic agent used in symptomatic treatment of Parkinson’s 
disease (Katzenschlager et al., 2002).  Benztropine restores the balance between the 
neurotransmitters acetylcholine and dopamine due to its anticholinergic activity, which 
may improve the symptoms of early Parkinson's disease.  Benztropine is also given to 
psychotic patients being treated with neuroleptic medications to reduce some of the 
movement-associated side effects (Soares and McGrath, 2000).  Both benztropine (1.19) 
and cocaine (1.4) have a N-methyl tropane as their structural core.  While cocaine is 
fuctionalized with a methyl ester at the 2-position and β-benzoyl ester at the 3-position of 
the tropane, benztropine contains only an α-diphenylmethoxy functional group at the 3-
position.  It has been observed that select benztropines have high binding affinity for 
DAT, yet these same compounds demonstrate unique behavioral profiles that are 
significantly different from cocaine.  For example, select benztropines do not stimulate 
locomotor activity as effectively as cocaine, and do not completely substitute for cocaine 
in rats trained to discriminate cocaine from saline (Katz, et al., 1999 and 2004; Newman 
et al., 1995; Sanchez et al., 2010).  In addition, self-administration of benztropines in 
rhesus monkeys was less compared to cocaine (Woolverton et al., 2000; Ferragud et al., 
2009; Hiranita et al., 2009) and select benztropines have a comparatively slow onset and 
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longer duration of action relative to cocaine (Tanda et al., 2009).  Because of these non-
addictive behavioral properties, benztropine analogs are currently being pursued as 
potential agents for the treatment of cocaine abuse (Rothman et al., 2008).  
 
Figure 1.14.  Structural and pharmacological comparison of cocaine versus benztropine and GBR-12909  
“atypical” DAT inhibitors (Newman et al., 1995; Husbands et al., 1999). 
1.4.2.2.2.  GBR-12909 
Tropane ring-modified benztropine analogs lead to the discovery of GBR-12909 
(1.26; Figure 1.14), which has a significantly different behavioral profile than cocaine 
(Tella et al., 1996).  Similar to benztropines, GBR-12909 is a high affinity DAT inhibitor 
with a slow onset and long duration of action compared to cocaine (Rothman et al., 
2008).  Owing to its ideal pharmacokinetic and pharmacodynamic properties, GBR-
12909 was progressed into clinical studies as a potential therapeutic for psychostimulant 
abuse.  However, it was withdrawn eventually due to its association with undesirable 
long QT syndrome (Goldsmith et al., 2007). 
1.4.3.  Unique Behavioral Profiles of DAT Inhibitors 
DAT inhibitors with different chemical structures have been shown to 
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preferentially bind to specific conformational states, or induce specific conformational 
changes in the DAT, which are capable of regulating the behavioral profile of a given 
DAT ligand (Loland et al., 2008).  In particular, conformation-specific ligand interactions 
were initially studied by differentiating the reactivity of DAT extracellular-facing 
cysteine residues towards membrane-impermeable sulfhydryl-reducing reagents.  Using 
this experimental approach, cocaine and benztropine were subsequently shown to have 
different effects on the reactivity of particular cysteines, thus indicating that these 
compounds stabilize different DAT conformations (Reith et al., 2001).  Apart from 
accessibility of select DAT cysteine residues to reactive agents, researchers have also 
employed site-directed mutagenesis to further verify DAT conformation-specific ligand 
interactions.  For example, W84L and D313N are mutations known to lead to an 
outward-facing stabilized DAT, and these mutants have shown increased binding affinity 
for both cocaine and methylphenidate. In contrast, decreased or retained binding affinity 
was observed for benztropine and GBR-12909 in these particular DAT mutants (Chen et 
al., 2001 and 2004).  
Simultaneously, DAT mutant Y335A, which stabilizes an inward-facing DAT 
conformational state, completely disrupted the binding of cocaine-like componds, but 
increased the affinity of benztropine analogs.  These observations indicate that cocaine-
like compounds preferentially stabilize an outward-facing DAT conformation state, 
whereas atypical DAT inhibitors stabilize an inward-facing, closed DAT conformation.  
Schmitt and coworkers have postulated that atypical DAT inhibitors first enter the S2-
binding site in the extracellular DAT vestibule and eventually stabilize the inward-facing 
conformation of DAT similar to substrates, but unlike substrates, atypical DAT inhibitors 
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are not released immediately into the intracellular side (Schmitt et al., 2013).  
Additionally, it was observed that DAT inhibitors with a slow onset of action showed 
reduced addiction potential compared to DAT inhibitors with a rapid onset of action 
(Wee et al., 2006).  Overall, the preferential interactions of atypical DAT inhibitors with 
the inward-facing DAT conformation might be responsible for the lower abuse potential, 
or even complete lack of cocaine-like behavioral responses, typically associated with 
these compounds (Loland et al., 2008; Kopajtic et al., 2010; Schmitt and Reith, 2011).  
As a result, further investigation is necessary in order to elucidate the molecular 
requirements of DAT ligands with respect to their behavioral profiles. Such knowledge is 
expected to lead to improved drug candidates for DAT-implicated diseases (e.g., ADHD, 
cocaine addiction, etc.). 
1.5.  The Serotonin Transporter and Its Importance in the Treatment of Depression 
 Similar to DAT, the main function of the serotonin transporter (SERT) is to 
terminate serotonin-mediated neurotransmission by reuptake of serotonin from the 
synaptic cleft into the presynaptic neuron (Rudnick et al., 2014).  SERT is also the 
primary drug target for well-known antidepressants such as selective serotonin reuptake 
inhibitors (SSRIs) (Stahl et al., 2013).  Because of drawbacks associated with existing 
antidepressants, the quest for better antidepressants remains an intense area of research.   
For example, currently available antidepressants have several limitations, such as late 
onset of action, a high percentage of non-responding patients, and side effects like sexual 
dysfunction, weight gain, nausea, anxiety, and insomnia (Khawam et al., 2006).  Novel 
strategies to treat depression are currently being pursued that mainly combine SERT 
inhibition with additional pharmacological mechanisms of action (Stahl et al., 2013).  
 26 
One strategy to achieve this is to combine a SSRI with another drug with a different 
mechanism of action such as DAT/NET inhibition, 5HT2A antagonism, 5HT1A partial 
agonism, and 5HT2C/5HT7 antagonism.  In particular, the combination of an alpha 2 
adrenergic receptor antagonist, mirtazapine (1.27, Figure 1.15), with SSRIs proved 
powerful in the recovery of treatment-resistant depressed patients (Benjamin and 
Doraiswamy, 2011).  Apart from alpha 2 antagonism, mirtazapine displays antagonist 
properties at 5HT2A, 5HT2C, 5HT3, and H1 histamine receptors as well.  Additionally, the 
combination of a 5HT1A partial agonist, buspirone (1.28, Figure 1.15), with an SSRI was 
shown to increase serotonin levels in rodent brains at a faster rate compared to SSRIs 
alone (Dawson and Nyugen, 1998).   
 
Figure 1.15.  Examples of drugs used in combination with SSRIs to treat depression. 
A second strategy for new antidepressants is to develop single molecules with 
multiple mechanisms of action, such as vilazodone (1.29, Figure 1.16) (SERT inhibition 
+ 5HT1A partial agonism) and vortioxetine (1.30, Figure 1.16) (SERT inhibition, 
5HT1A/5HT1B partial agonism, and 5HT3/5HT7-antagonism) (Stahl et al., 2013).  
Vilazodone (1.29) is an FDA-approved drug for the treatment of major depressive 
disorder, and its 5HT1A binding property seems to lower the incidence of sexual 
dysfunction in depressed patients versus SSRIs (Khan, 2009; Singh and Schwartz, 2012).  
Given these novel approaches for antidepressant drug development, SERT continues to 
remain a target of high pharmaceutical interest (Butler and Meegan, 2008; Stahl et al., 
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2013).  However, there are limited details regarding the 3D structure and function of 
SERT (e.g., the molecular mechanisms of substrate binding and transport, SSRI binding 
sites, etc.), which are essential for the development of novel antidepressants. 
 
Figure 1.16.  Examples of antidepressants with multiple mechanisms of action. 
1.5.1.  Chemical Composition and Structure of the Serotonin Transporter 
As mentioned earlier, SERT and its homologous proteins, DAT and NET, are 
monoamine transporters (MATs) and members of the neurotransmitter:sodium symporter 
(NSS) family (Rudnick et al., 2014).  The genes encoding multiple SERT species were 
isolated in the early 1990s, and subsequent studies provided evidence that SERT is a 
hydrophobic protein that contains 630 amino acids (Blakely et al., 1991; Demchyshyn et 
al., 1994; Hoffman, 1994; Mortensen et al., 1999; Benarroch, 2013).  As a NSS family 
member, SERT shares the common feature of 12 transmembrane (TM) domains 
connected by alternating intracellular and extracellular loops (IL and EL, respectively), a 
large second extracellular loop between TM3 and TM4 containing multiple N-linked 
glycosylation sites, and cytoplasmic N- and C- termini (Demchyshyn et al., 1994; Tate 
and Blakely, 1994; Chen et al., 1998; Mortensen et al., 1999; Yamashita et al., 2005).  
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Similar to DAT, several computational homology models have been built using 
LeuT as a template in order to understand the tertiary structure of SERT (Ravna et al., 
2006; Jorgensen, Tagmose, Jorgensen, Bogeso et al., 2007; Jorgensen, Tagmose, 
Jorgensen, Topiol et al., 2007; Gabrielsen et al., 2012; Manepalli et al., 2012; Koldso, 
Autzen et al., 2013; Koldso, Christiansen et al., 2013; Zhou et al., 2013).  Based on this 
information, SERT is proposed to have a high-affinity binding site termed S1 (primary 
substrate-binding site) and a low-affinity allosteric site called S2 (extracellular vestibule-
located site).  In particular, homology molecular modeling (e.g., Jorgensen, Tagmose, 
Jorgensen, Topiol et al., 2007), site-directed mutagenesis (e.g., Barker et al., 1998; 
Andersen et al., 2010), and small molecule SAR studies (e.g., Zhang et al., 2010) have 
suggested that TCAs and SSRIs bind to the S1 site with high affinity in a competitive 
manner (Talvenheimo et al., 1979; Henry et al., 2006; Andersen et al., 2009 and 2011; 
Sinning et al., 2010; Tavoulari et al., 2009; Koldso et al., 2010). 
Most recently, LeuT has been engineered to display monoamine/biogenic amine 
transporter-like pharmacology by mutating key residues near the primary S1 binding 
pocket (Wang et al., 2013).  This mutated LeuT, subsequently named LeuBAT, has also 
been co-crystallized with sertraline, paroxetine, fluoxetine, and fluvoxamine as SSRIs, as 
well as the TCA clomipramine, indicating all of these compounds bind in the primary S1 
binding pocket.  However, and in sharp contrast to LeuBAT, other crystallographic 
studies with LeuT indicate the TCA desipramine (Zhou et al., 2007), and the SSRIs 
sertraline and fluoxetine (Zhou et al., 2009), bind in the homologous S2 site as non-
competitive inhibitors (Singh et al., 2007).  In addition, multiple studies of SERT indicate 
that the S2 binding site acts as a low-affinity allosteric site, wherein ligands binding to S2 
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can inhibit the dissociation of S1-bound SSRIs, thus enhancing their efficacy (Plenge et 
al., 1991, 1997, 2007, and 2012; Chen, Larsen, Neubauer et al., 2005; Chen, Larsen, 
Sanchez et al., 2005; Zhong et al., 2009 and 2012; Neubauer et al., 2006).  Furthermore, 
characterization of the S2 binding site in SERT using computational modeling, as well as 
experimental support by site-directed mutagenesis, Zn+2-site engineering, and cysteine-
reactivity assays, indicates that binding to the allosteric site impedes dissociation of S1-
bound drug, most likely by steric blockade of the exit pathway (Plenge et al., 2012).  In 
short, given the roles of the S1 and S2 binding sites within SERT are not completely 
understood, there is a significant need for further studies that can elucidate the structural 
features of SERT at the molecular level. 
1.5.2.  Proposed Mechanism of Serotonin Reuptake by the Human Serotonin 
Transporter 
In monoamine transporters, the reuptake of substrate is driven by a Na+K+-
ATPase-generated electrochemical gradient, with movement of Na+ ions out of the 
neuron and K+ ions
 
into the neuron (Figure 1.7).  In DAT, the inward transport of one 
molecule of neurotransmitter substrate is accompanied with two Na+ ions and one Cl-
 
ion, 
whereas SERT co-transports one Na+
 
and one Cl-
  
from outside to inside the cell in order 
to drive serotonin uptake.  However, SERT also counter transports one K+
 
ion (inside to 
outside) in order to make the protein available for another serotonin transport cycle 
(Rudnick and Clark, 1993; Gu et al., 1994).  
The substrate translocation by SERT and other NSS family members is thought to 
occur by an alternating access mechanism as proposed by Jardetzky (Jardetzky, 1966).  
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As previously explained for the DAT (Section 1.3), this alternating access model for 
transport is believed to involve the following states: binding of the substrate to the 
outward-facing state (substarte-free/apo), isomerization of the transporter-substrate 
complex to the substrate-bound occluded state, isomerization from occluded to inward-
facing state, and return to the outward-facing state triggered by substrate dissociation 
from the inward–facing state (Krishnamurthy and Gouaux, 2012; Penmatsa and Gouaux, 
2014).  
1.6.  Serotonin Transporter Ligands 
1.6.1.  Serotonin Transporter Substrates 
Amphetamines (Figure 1.11) include amphetamine ((±)-1.5) and its analogs such 
as methamphetamine ((±)-1.6) and MDMA (3,4-methylenedioxy-N-methylamphetamine, 
((±)-1.7 or “ecstasy”).  Though amphetamines are used for management of disorders such 
as attention deficit hyperactivity disorder (ADHD), traumatic brain injury, and 
narcolepsy, these compounds are more popular as drugs of abuse based on their 
rewarding and addictive properties (Fleckenstein et al., 2007).  Amphetamines act as 
“false substrates” for SERT, NET, and DAT (Robertson et al., 2009).  In particular, 
MDMA induces the efflux of [3H] serotonin from membrane vesicles via SERT mediated 
exchange (Rudnick and Wall, 1992).  As previously discussed in Section 1.4.1, 
amphetamine-mediated monoamine efflux is explained by two models: (a) exchange 
diffusion model (Seidel et al., 2005; Sitte and Freissmuth, 2010; Sucic et al., 2010), and  
(b) amphetamine-induced channel-like activity of the transporter (Sonders et al., 1997; 
Sitte et al., 1998; Kahlig et al., 2005).  A recent study on the effects of p-
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chloroamphetamine and methylenedioxyamphetamine on serotonin-induced currents 
through SERT corroborated that a multi-state version of the alternate access model 
explains transporter-mediated efflux of amphetamines (Sandtner et al., 2014). 
1.6.2.  Serotonin Transporter Inhibitors 
1.6.2.1.  Tricyclic Antidepressants (TCAs) 
 
Figure 1.17.  Examples of selected tricyclic antidepressants (TCAs). 
 Tricyclic antidepressants (TCAs, Figure 1.17) such as imipramine (1.8), 
clomipramine (1.9), desipramine (1.10), amitriptyline (1.31), and nortriptyline (1.32) 
have a three- ring molecular core and share the pharmacological property of inhibiting 
serotonin and norepinephrine uptake.  In addition, TCAs also exhibit post-synaptic 
receptor antagonism at H1 histamine, α1 adrenergic, M1 muscarinic, and 5-HT2A 
receptors.  Gillman has reviewed the pharmacology and drug interactions of TCAs and 
this information can be used for choosing the right TCA in a clinical setting (Gillman, 
2007).  Overall, TCAs result in increased synaptic neurotransmitter concentrations 
(Andersen et al., 2009) and are classified as the first-generation antidepressant drugs 
alongside monoamine oxidase inhibitors (MAOIs).  
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1.6.2.2.  Selective Serotonin Reuptake Inhibitors (SSRIs) 
Selective serotonin reuptake inhibitors (SSRIs) started a new era in the treatment 
of depression, and they are categorized as the second-generation antideressants alongside 
serotonin-norepinephrine reuptake inhibitors (SNRIs) and norepinephrine reuptake 
inhibitors (NRIs).  SSRIs (Figure 1.18) include citalopram ((±)-1.11), S-citalopram ((S)-
1.11), fluoxetine ((±)-1.12), sertraline (1.13), paroxetine (1.14), and fluvoxamine (1.15).  
SSRIs are also used for the treatment of generalized anxiety disorder, panic disorder, 
social anxiety disorder, obsessive-compulsive disorder, premenstrual dysphoric disorder, 
bulimia, and post-traumatic stress disorder, depending upon the individual drug (Koen 
and Stein, 2011; Shah et al., 2008).  Inhibition of SERT is the primary mechanism of 
SSRIs.  However, except for S-citalopram, all SSRIs are not entirely selective and display 
indirect actions (Stahl et al., 2013). SSRIs are structurally different versus TCAs and 
selectively bind to SERT with high affinity.  As a result, these compounds possess 
significant advantages over TCAs, namely, similar or improved efficacy, relatively fewer 
side effects, wider therapeutic window, and safer in cases of overdose (Anderson, 2000; 
Henry et al., 1995).  Although SSRIs have no appreciable affinity for α1-adrenergic 
receptors, H1-histamine receptors, and muscarinic cholinergic receptors, and are generally 
better tolerated than TCAs, SSRIs have their own specific problems, such as aggravation 
of sexual dysfunction, suicidality, insomnia, pregnancy problems, and, for many, a 
discontinuation syndrome (Moret et al., 2009). SSRIs also cause side effects such as 
nausea, vomiting, headache, and agitation, which usually subside within 2-3 weeks. 
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Figure 1.18.  Structures of selective serotonin reuptake inhibitors (SSRIs) in clinical use. 
In particular, citalopram ((±)-1.11)) is a potent selective serotonin reuptake 
inhibitor (hSERT Ki = 1.6 nM, serotonin uptake IC50 = 9.6 nM), and is a racemic mixture 
composed of (S)-citalopram (hSERT Ki = 1.1 nM, serotonin uptake IC50 = 2.5 nM) and 
(R)-citalopram (hSERT Ki = 36 nM, serotonin uptake IC50 = 67 nM) (Owens et al., 
2001).  Citalopram has gained special attention with respect to the S1 and S2 binding 
sites of SERT (Sanchez et al., 2004).  The eutomer, escitalopram ((S)-1.11) interacts with 
hSERT uniquely, whereas other SSRIs bind to both the S1 and S2 sites (Chen, Larsen, 
Sánchez et al., 2005).  (S)-Citalopram displays ~30 fold higher binding affinity at SERT 
versus its enantiomer, (R)-citalopram, and (R)-citalopram may attenuate the effects of 
(S)-citalopram via allosteric modulation (Chen, Larsen, Sánchez et al., 2005; Zhong et 
al., 2009 and 2012).  The SERT binding contacts for these citalopram enantiomers are 
unknown, and the importance of the S2 allosteric site with respect to the pharmacological 
profile of existing SSRIs is not well understood.  Most recently, several analogs of 
citalopram were synthesized to understand structure-activity relationships and the 
importance of the allosteric binding site within SERT (Zhang et al., 2010; Banala et al., 
2013). 
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1.6.2.3.  Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 
Four serotonin-norepinephrine reuptake inhibitors (SNRIs, Figure 1.19) are 
clinically available in the United States, venlafaxine (1.33), desvenlafaxine (1.20), 
duloxetine (1.21) and milnacipran (1.34). While venlafaxine, desvenlafaxine, and 
duloxetine are approved for treatment of depression, milnacipran is only approved for 
treatment of fibromyalgia in the United States.  In particular, venlafaxine is approved for 
the treatment of depression, generalized anxiety disorder, social anxiety disorder, panic 
disorder, obsessive compulsive disorder, and post traumatic stress disorder (Phleps and 
Cates, 2005; Pae et al., 2007).  Duloxetine is also effective in the treatment of diabetic 
peripheral neuropathic pain, fibromyalgia, osteoarthritis, and low back pain (Bril 2012; 
Hauser et al., 2012; Citrome and Weiss-Citrome 2012).  The inhibition of both SERT and 
NET not only increases serotonin and norepinephrine levels in the brain but also 
increases dopamine levels in the prefrontal cortex, which potentially adds to the efficacy 
of SNRIs in treatment of depression (Stahl, 2013).  SNRIs are thought to have a faster 
onset of action compared to SSRIs and are useful for depressed patients resistant to other 
treatments, mainly due to reasons of their efficacy and tolerability (Kasper and Pail, 
2010). 
 
Figure 1.19.  Structures of serotonin-norepinephrine reuptake inhibitors (SNRIs) in clinical use. 
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CHAPTER TWO 
2.  Irreversible Chemical Labeling of Protein Drug Targets with Small Molecules 
2.1.  Introduction 
Monoamine transporters (MATs) are associated with several mental health 
disorders (Hahn and Blakely, 2002) such as anxiety (Plieger et al., 2014), depression 
(Stahl et al., 2013), drug addiction (Howell and Negus, 2013), Parkinson’s disease 
(Grachev, 2014), and schizophrenia (Abdolmaleky et al., 2014).  Although many drugs 
are available to treat mental health disorders, attempts are being made to develop novel 
treatments targeting MATs in order to address shortcomings associated with current 
agents.   For example, currently available antidepressants have several limitations 
including late onset of action, a high percentage of non-responding patients, and side 
effects such as sexual dysfunction, weight gain, nausea, anxiety, and insomnia (Khawam 
et al., 2006).  Despite representing important drug targets, very little is known about 
specific drug-protein interactions that lead to the clinical efficacy of agents targeting 
MATs.  In particular, the bottleneck in producing MAT crystal structures is associated 
with an inability to obtain sufficient amounts of pure and stable protein required for 
protein crystallization (Bill et al., 2011).  Apart from X-ray crystallography (Garman, 
2014), other approaches for acquiring detailed 3D structural information of proteins 
include site-directed mutagenesis (Shortle et al., 1981), computational modeling 
(Rodrigues and Bonvin, 2014), and photoaffinity labeling (Sumranjit and Chung, 2013).  
Historically, MAT structure-function information has been obtained via 
biophysical, pharmacological, and molecular biology studies (e.g., characterization of 
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MAT site-directed mutants).  Such techniques have elucidated the general topology of 
MAT proteins in the plasma membrane and indicate two or three probable substrate 
binding sites. However, these experimental techniques have offered little towards 
elucidating transmembrane domains that are juxtaposed, how substrates are translocated, 
or the size and shape of ligand-binding pockets.  Most recently, crystal structures of a 
leucine transporter (LeuT) (e.g., Yamashita et al., 2005), a bacterial MAT homolog, have 
paved a way for multiple research groups to build computational human MAT molecular 
models (e.g., Manepalli et al., 2012; Stockner et al., 2013).  In turn, these computer 
homology models have aided in characterizing ligand-binding sites within the dopamine 
transporter (DAT) (e.g., Beuming et al., 2008; 2006; Bisgaard et al., 2011; Indarte et al., 
2008) and serotonin transporter (SERT) (e.g., Andersen et al., 2010; Celik et al., 2008; 
Henry et al., 2006; Kaufmann et al., 2009; Ravna, et al., 2006; Sarker et al., 2010).  
However, due to significant evolutionary differences between the human DAT, SERT, 
and bacterial LeuT protein template used for computational homology modeling, careful 
experimental validation and critical refinement of these molecular models is necessary in 
order to understand the structure, function, and pharmacological properties of MAT 
proteins.  
To date, DAT and SERT homology models have been experimentally 
investigated mainly by site-directed mutagenesis studies (e.g., for DAT see Severinsen et 
al., 2014; Stockner et al., 2013; Guptaroy et al., 2011; Bisgaard et al., 2011; Schmitt et 
al., 2008; for SERT see Andersen et al., 2010 and 2011; Koldso et al., 2010; Sorensen et 
al., 2012).  In particular, mutagenesis of amino acids in many regions of these proteins 
results in a reduction or loss of transporter activity and/or inhibitor binding (e.g., Henry, 
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et al., 2006; Newman et al., 2006; Zhang et al., 2010).  However, it is difficult in the 
absence of structural information to confirm if the effects of mutations are due to 
disruptions of specific ligand-protein interaction sites, or to alterations of MAT structure 
that indirectly impact ligand-binding sites.  A positive functional approach to address 
these concerns is to use photoreactive irreversible ligands to directly identify binding 
site(s) of MAT inhibitors. 
2.2.  Photoaffinity Labeling 
Photoaffinity labeling (PAL) has contributed significantly to our understanding of 
how a ligand interacts with its biological target, principally because this experimental 
approach allows direct determination of the spatial proximity of molecular components 
(Xu and Wu, 2014).  A photoaffinity probe is typically designed from a ligand of interest 
by rationally incorporating a photoreactive group (PRG) and a reporter group (RG) into 
the chemical structure of the lead compound (Scheme 2.1).  The PRG is inert under 
normal conditions; however, upon irradiation with UV light, it gets converted into highly 
reactive radical intermediate, which is capable of forming a covalent bond between the 
biological target and the photoprobe.  The RG is useful for detection of covalent 
attachment to the biological macromolecule and consequently the site(s) of photoprobe 
modification.  Typically, the irreversible, covalent probe-target complex is then digested 
or fragmented via proteolysis and/or chemical cleavage methods.  Probe-labeled 
fragments can then be analyzed using epitope-specific immunoprecipitation, high-
performance liquid chromatography (HPLC), and mass spectrometry (MS) in order to 
identify the amino acid composition / sequence surrounding the covalent point of 
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attachment of the probe to the biological target (Dorman and Prestwich, 2000; Geurink et 
al., 2012).  
 
Scheme 2.1.  Photoaffinity labeling towards mapping the binding site of a ligand within a drug target.  
(Lapinsky, 2012.  Adapted with permission from Bioorg. Med. Chem. 2012, 20, 6237-6247.  Copyright 
2012, Elsevier) 
The following set of characteristics has been attributed to ideal photoprobes, 
specifically: (a) they utilize a wavelength-selective activation that does not damage other 
components in the biological testing system; (b) they possess high stability in the dark 
under various pH conditions; (c) they form a stable adduct with their target biological 
macromolecule(s) and survive subsequent characterization and detection methodology; 
(d) they bear a structural resemblance to the parent ligand with similar binding affinity 
and pharmacology; (e) they have the ability to react with any type of bond or residue 
without any preference; and (f) they generate highly reactive, short-lived photo-
intermediates upon irradiation with UV light (Das, 2011; Vodovozova, 2007).  Despite 
extensive research in developing photoaffinity labeling agents, so far there are no reports 
of photoprobes that possess all of these desired criteria. 
Photoaffinity labeling represents one the most direct approaches towards 
elucidating ligand-binding sites within target proteins.  Although this experimental 
approach has been employed extensively with the DAT (e.g., Agoston et al., 1997; Lever 
et al., 2005; Newman et al., 2006; Parnas et al., 2008; Vaughan et al., 1999, 2005, and 
 67 
2007; Vaughan and Kuhar, 1996; Zou et al., 2001; Lapinsky et al., 2009, 2011, and 
2012), this dissertation has contributed the first ever clickable photoprobes for SERT and 
a method to conduct SERT photoaffinity labeling using these probes. 
Arguably, the nature of the photoreactive group (PRG) is the most important 
design component of a photoaffinity probe.  The most widely used PRGs in photoaffinity 
ligands are aromatic azides, benzophenones and acetophenones, and aliphatic (Das, 2011) 
and aromatic diazirines (e.g., Dubinsky et al., 2012; Hashimoto and Hatanaka, 2008).  
Photoreactive functional groups can also be characterized according to their 
photochemically-generated reactive species, principally nitrenes, diradicals, and carbenes 
(Fleming, 1995).  Given this dissertation features chemical probes containing either an 
aromatic azide or benzophenone photoreactive group, only these functional groups in 
terms of photoaffinity labeling are reviewed below. 
2.2.1.  Select Photoreactive Groups Employed in MAT Structure-Function Studies 
2.2.1.1.  Aryl Azides 
Among a wide number of photoreactive functional groups, aryl azides are the 
most widely used in photoaffinity probes, mainly because of their comparatively small 
structural variation relative to a parent compound and ease of synthetic incorporation.  
Upon irradiation at a wavelength of 254 nm, aryl azides generate reactive nitrene 
intermediates that can form covalent bonds with amino acid functional groups (Scheme 
2.2).  In general, exposure of an aryl azide (2.1, Scheme 2.2) to UV light (250-350 nm) 
leads to the formation of a nitrene species (2.2) that can either: (1) undergo ring 
expansion to form a ketenimine/azepine (2.3) that can react with a nucleophile (2.4), (2) 
insert into C-H or N-H sites (2.7), or  (3) undergo intersystem conversion (ISC) to a 
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triplet state (2.5) that can subsequently dimerize (2.6) (Preston and Wilson, 2013).  One 
non-productive reaction pathway of aryl-azides is that they can also react with thiols to 
form aryl amines (2.8).  In particular, the singlet nitrene species (2.2) has electrophilic 
character, and therefore incorporation of electron-withdrawing groups on an aromatic 
ring bearing a photoreactive azide is typically used as a strategy to stabilize singlet 
nitrene formation.  For example, (per)fluorinated aryl azides avoid undesirable ring 
expansion reactions and favor bond insertion reactions in a desirable manner (Schnapp et 
al., 1993). Additionally, the triplet nitrene (2.5) can behave as a diradical and form an 
azobenzene (2.6) leading to an undesirable side reaction during photoaffinity labeling.  
Finally, 1,2-didehydroazepine 2.3 is a key intermediate that can selectively react with 
particular protein functional groups.  In aqueous media, 1,2-didehydroazepine 2.3 has 
been shown to preferentially react with amines over hydrocarbon groups (Rizk et al., 
2006). 
The wavelength at which aryl azides are photolysed (typically < 300nm) produces 
a high amount of energy that could potentially damage the biological system being 
exposed to the UV radiation during photoaffinity labeling.  Additionally, due to the lack 
of reaction specificity and side reactions possible (e.g., 2.5 to 2.6), photoaffinity labeling 
with aryl azides often results in low yields of the probe-target complex (<30%).  In order 
to address these issues, the absorption wavelength of a photoreactive azide is typically 
shifted to a higher wavelength, once again by incorporating electron-withdrawing groups 
such as fluorine and nitro groups on the aromatic ring bearing the photoreactive aryl 
azide (Mohr, 2004).  
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Scheme 2.2.  Reaction pathways of aryl azides upon photoactivation. 
2.2.1.2.  Benzophenones 
Upon irradiation with a wavelength of approximately 350 nm, benzophenones 
(2.9 in Scheme 2.3) generate a ketyl biradical (2.10), which can form a covalent bond 
with protein functional groups via a sequential proton abstraction-radical recombination 
mechanism (Dorman and Prestwich, 1994; Preston and Wilson, 2013).  Ketyl biradical 
formation occurs as the benzophenone absorbs UV radiation and excites a non-bonding 
electron into the carbonyl π* orbital.  In the diradical state, the electron deficient oxygen 
has an empty n-orbital that is electrophilic and capable of interacting with C-H bonds in 
the protein.  This results in hydrogen abstraction and produces two ketyl radicals that can 
readily combine to generate a new C-C bond (2.12).  The excitation of benzophenones is 
reversible, and therefore can return to the ground state if hydrogen abstraction does not 
take place. 
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Scheme 2.3.  Activation pathway of benzophenone photoreactive group. 
 Even though the benzophenone photoreactive functional group introduces a 
significant amount of bulkiness and hydrophobicity to the analog (i.e., relative to the lead 
compound), thus potentially affecting proper formation of the reversible photoprobe-
protein complex before photolysis, benzophenones have several advantages over other 
photoaffinity labeling groups (Dorman and Prestwich, 1994).  Benzophenones are 
generally more chemically stable than aryl azides and diazirines, and can be activated at 
350-360 nm, which is safe for photoaffinity labeling cell cultures or other living systems.  
Additionally, benzophenones can preferentially react with inactive C-H bonds even in the 
presence of water and other nucleophiles.  Furthermore, benzophenone derivatives are 
more efficient in labeling the proteome, as they can be repeatedly excited until they 
generate covalent adducts, without loss of their chemical integrity.  Adding to these 
advantages, a number of benzophenone-containing building blocks are commercially 
available, and this functional group is stable in most organic solvents and compatible 
with multiple synthetic reagents for photoprobe synthesis. 
2.2.2.  Select Reporter Groups Employed in MAT Structure-Function Studies 
2.2.2.1.  Radioactive Isotopes 
Radioactive isotopes are widely used for the detection of a variety of 
biomolecules in proteomic applications.  In particular, 125I has been utilized in many 
photoprobes because of its ease of incorporation via simple synthetic steps, relatively 
small size, and highly sensitive signal for easy detection and quantification (Sadaghiani et 
 71 
al., 2007).  However, 125I has a relatively short half-life (t1/2 = ~60 days), which doesn’t 
allow radio-iodinated probes to be stored for long periods of time without significant 
chemical degradation (Seevers and Counsell, 1982).  Additionally, radioisotopes are 
often harmful entities, thus demanding extra care in their handling and use in a laboratory 
environment.  Finally, radio-iodinated probes are mostly used with known targets, or 
when specific antibodies can be used to confirm the identity of the target using gel-based 
read outs (Lapinsky, 2012; Sadaghiani et al., 2007). 
2.2.2.2.  ‘Clickable’ Handles in Tandem Photoaffinity Labeling-Bioorthogonal 
Conjugation 
In addition to radioactive isotopes, alternative tagging methods are available to 
facilitate proteomic analysis after photoaffinity labeling.  Photoaffinity probes can also 
include reporter groups such as biotin, epitope tags (e.g., FLAG peptide), or fluorophores 
to allow easy enrichment, detection, and/or isolation of photolabeled products after 
labeling.  However, biotin, epitope tags, and fluorophores are rather large in size, cell 
impermeable, and may adversely affect pharmacological activity relative to a parent 
compound, principally by sterically disrupting key interactions between the photoprobe 
and target biological macromolecule.  Most recently, the field of photoaffinity labeling 
has been advanced by the introduction of small surrogate tags (e.g., a terminal alkyne or 
aliphatic azide) into photoprobes that serve as click chemistry/‘clickable’ handles thus 
facilitating the attachment of reporter tags to a photoprobe by using highly specific 
bioorthogonal ligation chemistry after photoaffinity labeling.  These ‘clickable’ handles 
are relatively small, easily installed into a parent ligand, and have minimal effects on 
biological activity and cell permeability when compared to a parent compound.  As a 
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result, these significant advantages make clickable handles the current reporter group of 
choice in designing photoprobes for studying biological macromolecules of interest 
(Sadaghiani et al., 2007; Lapinsky, 2012).  
 
Scheme 2.4.  Tandem photoaffinity labeling-bioorthogonal conjugation.  (Lapinsky, 2012.  Reprinted with 
permission from Bioorg. Med. Chem. 2012, 20, 6237-6247.  Copyright 2012, Elsevier). 
In particular, a new proteomic strategy termed “tandem photoaffinity labeling–
bioorthogonal conjugation” (Scheme 2.4) has recently emerged that first involves 
covalent bond formation between a photoprobe and a biological target via 
photoirradiation (Step 1 in Scheme 2.4), followed by a bioorthogonal conjugation 
reaction (Step 2 in Scheme 2.4). In particular, bioorthogonal conjugation chemistry is 
traditionally employed using either a Staudinger-Bertozzi ligation (Saxon and Bertozzi, 
2000) or copper-catalyzed Huisgen 1,3-dipolar cycloaddition (‘click’ reaction or 
CuAAC) (Rostovtsev et al., 2002) (Scheme 2.5).  The only apparent concern with this 
tandem photoaffinity labeling–bioorthogonal conjugation strategy is that yields of the 
bioorthogonal conjugation step (Step 2, Scheme 2.4) can vary in different systems.  In 
particular, it has been reported that higher yields are often observed when copper-
catalyzed Huisgen 1,3-dipolar cycloaddition is employed in the bioorthogonal 
conjugation step versus Staudinger-Bertozzi ligation (Speers et al., 2003).  However, 
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regardless of this variability in bioorthogonal conjugation yield, the noteworthy 
advantages of tag flexibility, high-throughput analysis, and in vivo use makes this 
strategy the current method of choice for analysis of probe-labeled products after 
photoaffinity labeling. 
 
Scheme 2.5.  Bioorthogonal conjugation strategies traditionally employed after photoaffinity labeling.  
2.2.2.3.  Binding Ensemble Profiling with (f)Photoaffinity Labeling (BEProFL) 
Binding Ensemble Profiling with (f)Photoaffinity Labeling (BEProFL) represents 
a novel experimental approach wherein tandem photoaffinity labeling–bioorthogonal 
conjugation can be coupled with LC–MS and molecular modeling studies in order to 
accurately determine the three-dimensional structure of a ligand–target complex (He et 
al., 2009).  In particular, BEProFL can be used to facilitate identification of key ligand–
target binding interactions, conformational-preferences for both the ligand and biological 
target, and facilitate obtainment of valuable information for structure-based drug design.  
Furthermore, detailed molecular information obtained from this combined experimental 
approach can aid in the validation or refinement of biological target molecular models to 
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be used for computer-aided drug discovery and development (e.g., virtual / in silico 
screening, structure-based drug design).  
In particular, our strategy towards understanding the 3D structural features of 
monoamine transporters is by developing photoprobes based on established drugs that 
target DAT or SERT.  Furthermore, utilizing the BEProFL experimental approach with 
these probes is expected to experimentally validate and refine DAT and SERT homology 
models (Scheme 2.6).  Briefly, a DAT or SERT therapeutic agent is functionalized with 
both a photoreactive group (PRG) and a reporter group (RG).  First, the probes are 
pharmacologically tested in order to evaluate binding affinity at their respective target. 
Selection criteria for probes for subsequent photoaffinity labeling experiments are those 
compounds whose binding affinity is < 100 nM and within 10-fold of an appropriate 
parent compound.  Selected candidate probes are then incubated with their natural target, 
allowed to reversibly bind, and then irradiated with UV light.  The resulting irreversible 
ligand-target complex can then be subjected to traditional proteomic experiments such as 
SDS-PAGE, proteolysis, and LC-MS/MS, followed by computational studies in order to 
map the ligand-binding poses and sites of DAT or SERT ligands within their protein 
targets.  Utilization of the BEProFL approach is expected to further refine and/or validate 
DAT or SERT homology models via experimental support, thereby enabling more 
confident computer-aided drug discovery efforts aimed at these targets (e.g., virtual / in 
silico screening, structure-based drug design) (Indarte et al., 2010; Nolan et al., 2011 and 
2014).  
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Scheme 2.6.  Binding ensemble profiling with (f)photoaffinity labeling (BEProFL) towards experimental 
validation and refinement of DAT or SERT homology models. 
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CHAPTER THREE 
3.  Chemical Literature Review 
3.1.  Review of Synthetic Approaches for Racemic threo-Methylphenidate, a Lead 
Compound for DAT Photoprobe Design 
A number of synthetic approaches to (±)-threo-methylphenidate have been 
previously described in the chemical literature. For example, Deutsch and coworkers 
reported an improved synthesis of racemic threo-methylphenidate ((±)-1.18) (Scheme 
3.1) (Deutsch et al., 1996) that was originally developed by Panizzon in 1944 (Panizzon, 
1944).  This improved synthesis is 9 steps in length and produces (±)-threo-MP in 18% 
overall yield.  The synthesis begins with alkylation of 2-bromopyridine (3.2) with the 
anion derived from phenylacetonitrile (3.1) to give diaryl nitrile 3.3 in 50% yield.  Nitrile 
3.3 was then hydrolyzed to amide 3.4 using concentrated HCl.  Hydrogenation of 
pyridine 3.4 then provided the piperidine derivative, which was then subjected to salt 
formation to obtain a diastereomeric mixture of piperidine hydrochloride salts (3.5) in 
good yield (90%).  Subsequently, amide 3.5 was hydrolyzed to the carboxylic acid, 
followed by a 50% KOH epimerization procedure and HCl salt formation, to generate a 
diastereomeric mixture of ritanilic acid (3.6) in 64% yield.  The mixture of ritanilic acid 
stereoisomers was then subjected to esterification followed by recrystallization to provide 
racemic threo-methylphenidate ((±)-1.18) in moderate yield (84%).   
This synthetic method has been used to generate aromatic ring-substituted analogs 
of racemic threo-methylphenidate in order to establish structure-activity relationships 
(SAR) with respect to the dopamine transporter (Deutsch et al., 1996).  One of the 
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disadvantages of this methodology is that it usually gives a mixture of products that are 
difficult to purify via chromatography. 
 
Scheme 3.1.  Synthesis of racemic threo-methylphenidate (MP) according to Deutsch et al., 1996. 
Another synthesis of racemic threo-methylphenidate ((±)-1.18) was reported by 
Axten et al. in 1998 (Axten et al., 1998) and later improved by Gutman et al. in 2004 
(Gutman et al., 2004).  When compared to the synthesis developed by Deustch et al. in 
1996 (Scheme 3.1), this particular synthesis method (Scheme 3.2) is relatively short and 
efficient (5 steps, 56% overall yield).  This synthesis begins with condensation of -keto 
ester 3.7 with piperidine to give -keto amide 3.8 in high yield (91%).  Under acidic 
conditions, ketone 3.8 was then treated with tosylhydrazine to provide tosylhydrazone 3.9 
in moderate yield (85%).  Subsequently, with the aid of phase transfer catalyst Aliquat 
336® under aqueous basic conditions, hydrazone 3.9 underwent thermal cyclization to 
provide lactam 3.10 as a diastereomeric mixture.  In turn, recrystallization in ether gave 
pure racemic threo--lactam (±)-3.10 as the major product in 68% yield.  Finally, lactam 
methanolysis yielded racemic threo-methylphenidate ((±)-1.18). 
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Scheme 3.2.  Synthesis of racemic threo-methylphenidate (MP) according to Gutman et al., 2004. 
Concurrently, a synthesis of racemic threo-methylphenidate ((±)-1.18) (7 steps, 
35% overall yield) was reported by Dias and De Piloto Fernandes (Dias and De Piloto 
Fernandes, 2000).  This synthesis utilizes known -ethoxy carbamate 3.14 (Nagasaka et 
al., 1986) and silyl ketene acetal 3.16 (Tanaka and Fuji, 1992) (Scheme 3.3).  The 
synthesis begins with protection of lactam 3.11 as its carbamate 3.13, which is then 
reduced with NaBH4 followed by treatment with EtOH in HCl to give -ethoxy 
carbamate 3.14 in 63% overall yield (Scheme 3.3-A, Nagasaka et al., 1986).  Silyl ketene 
acetal 3.16 was synthesized in 90% yield by treating ester 3.15 with LDA followed by 
quenching with TMSCl (Scheme 3.3-B, Tanaka and Fuji, 1992).  Subsequent, treatment 
of -ethoxy carbamate 3.14 with silyl ketene acetal 3.16 in the presence of TESOTf then 
provided a distereomeric mixture of N-protected racemic threo-methylphenidate 
derivatives (3.17) in high yield (90%).  Carbamate 3.17 was then subjected to 
hydrogenolysis to provide a mixture of racemic threo- and erythro-methylphenidate free 
bases, which were separable by column chromatography.  Finally, treatment of racemic 
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threo-methylphenidate free base with methanolic HCl provided the hydrochloride salt 
(±)-1.18 in moderate yield (69%) (Scheme 3.3-A, Dias and De Piloto Fernandes, 2000). 
 
Scheme 3.3.  Synthesis of (A) racemic threo-methylphenidate (MP) according to Dias and De Piloto 
Ferandes, 2000 and (B) silyl ketene acetal 3.16 precursor according to Tanaka and Fuji, 1992. 
In 2001, Deutsch and colleagues reported a new synthetic method for racemic 
threo-methylphenidate ((±)-1.18) (8 steps, 7% overall yield) based on the Blaise reaction 
(Scheme 3.4, Deutsch et al., 2001).  In particular, this methodology was used to 
synthesize methylphenidate analogs in which the amine ring size and aromatic ring were 
varied in order to develop SAR with respect to the dopamine transporter.  The synthesis 
began with treatment of 4-chloro-1-butanol (3.18) with KCN in water-ethanol, to provide 
4-cyano-1-butanol, whose alcohol was converted to the corresponding mesylate 3.19 in 
low yield (25%).  A Blaise reaction of mesylate 3.19 with methyl 2-bromo-2-
phenylacetate (3.20) in the presence of zinc provided imine 3.21, which subsequently 
rearranged to form Z-enamine 3.22 in moderate yield (63%).  Enamine 3.22 was then 
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reduced with sodium cyanoborohydride at pH 6, wherein piperidine cyclization occurred 
spontaneously under basic work-up conditions to give a diastereomeric mixture of 
racemic threo- and erythro-methylphenidates 3.23 in moderate yield (78%).  Finally, 
50% KOH epimerization of the diastereomeric mixture of racemic threo- and erythro-
methylphenidates (3.23), followed by salt formation using methanolic HCl and 
recrystallization, provided racemic threo-methylphenidate ((±)-1.18) in 55% yield 
(Scheme 3.4). 
 
Scheme 3.4.  Synthesis of racemic threo-methylphenidate (MP) according to Deutsch et al., 2001. 
3.2.  Known Synthesis of Racemic threo-4-Iodo-Methylphenidate as a Lead 
Compound for DAT Photoprobe Design 
Racemic threo-methyl-2-(4-iodophenyl)-2-(piperidin-2-yl)acetate (4-iodo-
methylphenidate, (±)-3.29) represents a lead compound for DAT photoprobe design 
because it displays 6-fold higher DAT binding affinity when compared to 
methylphenidate ((±)-1.18) (Deutsch et al., 1996).  In particular, Pan and coworkers (Pan 
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et al., 1996) reported a synthesis of racemic threo-4-iodo-methylphenidate ((±)-3.29) 
from racemic threo-methylphenidate ((±)-1.18) (Scheme 3.5).  The synthesis began with 
N-benzoylation of methylphenidate to give amide (±)-3.24 in 96% yield.  Amide (±)-3.24 
was then subjected to electrophilic aromatic nitration to provide p-nitro methylphenidate 
derivative (±)-3.25 in 85% yield.  Conversion of the nitro group to aniline (±)-3.26 was 
then accomplished using iron powder under acidic conditions, followed by diazotization 
and displacement with potassium iodide to provide p-iodo methylphenidate derivative 
(±)-3.27 in 51% overall yield.  Subsequently, strong acidic conditions were required to 
hydrolyse the amide and ester in (±)-3.27 to give racemic threo-4-iodo-ritinilic acid ((±)-
3.28) in 40% yield, which was esterified using methanolic-HCl to provide racemic threo-
4-iodo-methylphenidate ((±)-3.29) in quantitative yield (Scheme 3.5). 
 
Scheme 3.5.  Synthesis of racemic threo-4-iodo-methylphenidate (MP) according to Pan et al., 1996. 
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3.3.  Known Synthesis of Racemic threo-3,4-Dichloro-Methylphenidate as a Lead 
Compound for DAT Photoprobe Design 
Racemic threo-methyl-2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate (3,4-
dichloro-methylphenidate, (±)-3.35) represents a lead compound for DAT photoprobe 
design because it displays 15-fold higher DAT binding affinity when compared to 
methylphenidate ((±)-1.18) (Deutsch et al., 1996).  As previously mentioned, Deutsch 
and colleagues synthesized aromatic ring-substituted analogs of methylphenidate using 
the methodology in Scheme 3.1 (Deutsch et al., 1996).  In particular, their synthesis of 
racemic threo-3,4-dichloro-methylphenidate ((±)-3.35) began with treatment of 3,4-
dichlorophenylacetonitrile (3.30) with 2-bromopyridine (3.2) under basic conditions to 
provide nitrile 3.31, which was then subjected to acidic hydrolysis to provide amide 3.32 
in 40% overall yield.  Hydrogenation of pyridine 3.32 and subsequent treatment with HCl 
provided a mixture of diastereomeric piperidine salts (3.33) in good yield (80%).  Acidic 
hydrolysis of amide 3.33, followed by epimerization under basic conditions and 
subsequent salt formation, provided a diastereomeric mixture of racemic threo-ritanilic 
acid derivatives (3.34) in moderate yield (54%).  Finally, esterification of 3.34 with 
methanolic HCl and subsequent recrystallization provided racemic threo-3,4-dichloro-
methylphenidate ((±)-3.35) in good yield (80%) (Scheme 3.6). 
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Scheme 3.6.  Synthesis of racemic threo-3,4-dichloro-methylphenidate (MP) according to Deutsch et al., 
1996. 
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CHAPTER FOUR 
4.  Statement of Research Problems 
4.1.  Current Knowledge Gaps 
4.1.1.  Dopamine Transporter Structure-Function Knowledge Gap 
Although LeuT-based DAT homology models (e.g., Koldso, Christiansen et al., 
2013; Stockner et al., 2013; Seddik et al., 2013; Gedeon et al., 2010; Huang et al., 2009; 
Indarte et al., 2008) have provided significant insights into the three-dimensional 
structure of the dopamine transporter, details regarding the transport inhibition 
mechanism, conformational states, and ligand-binding sites associated with this protein 
remain poorly understood.  In particular, the molecular mechanisms by which the DAT 
discriminates substrates (e.g., dopamine and amphetamines) versus inhibitors (e.g., 
cocaine, cathinones, methylphenidate, bupropion, benztropine, and GBR-12909) and 
highly abused compounds (e.g., cocaine, amphetamines, and cathinones) versus 
therapeutic compounds (e.g., methylphenidate, bupropion, and benztropine) at the 
molecular level remain unknown.  Additionally, it is not clear how structurally distinct 
dopamine transporter inhibitor classes (e.g., tropane versus non-tropane DAT inhibitors) 
specifically interact with the dopamine transporter leading to specific behavioral and/or 
phenomenological effects (e.g., addictive versus non-addictive behavioral responses). 
4.1.2.  Serotonin Transporter Structure-Function Knowledge Gap  
Selective serotonin reuptake inhibitors (SSRIs) represent first-line antidepressants 
in the treatment of anxiety disorders and major depressive disorder (Fuller, 1995).  
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However, despite the well-documented clinical success of SSRIs, the specific drug-
protein interactions that dictate the affinity, potency, and selectivity of these compounds 
remain poorly characterized. 
Similar to the DAT, X-ray crystal structures of the bacterial homolog leucine 
transporter (LeuT) (e.g., Yamashita et al., 2005) have provided insight into the tertiary 
structure of hSERT via homology modeling (e.g., Ravna et al., 2006; Jorgensen et al., 
2007; Zhou et al., 2013; Koldso, Autzen et al., 2013; Koldso, Christiansen et al., 2013; 
Gabrielsen et al., 2012).  Based on these studies, the serotonin transporter is proposed to 
contain a high-affinity binding site termed “S1” (also known as the primary substrate-
binding site) and a low-affinity allosteric site termed “S2” (also known as the 
extracellular vestibule-located site).  In particular, homology molecular modeling (e.g., 
Jorgensen et al., 2007), site-directed mutagenesis (e.g., Barker et al., 1998; Andersen et 
al., 2010), and small molecule structure-activity relationship (SAR) studies (e.g., Zhang 
et al., 2010) have suggested that TCAs and SSRIs bind to the S1 site with high affinity in 
a competitive manner (Talvenheimo et al., 1979; Henry et al., 2006; Andersen et al., 
2009 and 2011; Sinning et al., 2010; Tavoulari et al., 2009; Koldso et al., 2010). 
Most recently, LeuT has been engineered to display monoamine/biogenic amine 
transporter-like pharmacology by mutating key residues near the primary S1 binding 
pocket (Wang et al., 2013).  This mutated LeuT, subsequently named LeuBAT, has also 
been co-crystallized with sertraline, paroxetine, fluoxetine, and fluvoxamine as SSRIs, as 
well as the TCA clomipramine, indicating all of these compounds bind in the primary S1 
binding pocket.  However, and in sharp contrast to LeuBAT, other crystallographic 
studies with LeuT indicate the TCA desipramine (Zhou et al., 2007), and the SSRIs 
 97 
sertraline and fluoxetine (Zhou et al., 2009), bind in the homologous S2 site as non-
competitive inhibitors (Singh et al., 2007).  In addition, multiple studies of SERT indicate 
that the S2 binding site acts as a low-affinity allosteric site, wherein ligands binding to S2 
can inhibit the dissociation of S1-bound SSRIs, thus enhancing their efficacy (Plenge et 
al., 1991, 1997, 2007, and 2012; Chen, Larsen, Neubauer et al., 2005; Chen, Larsen, 
Sanchez et al., 2005; Zhong et al., 2009 and 2012; Neubauer et al., 2006).  Furthermore, 
characterization of the S2 binding site in SERT using computational modeling, as well as 
experimental support by site-directed mutagenesis, Zn+2-site engineering, and cysteine-
reactivity assays, indicates that binding to the allosteric site impedes dissociation of S1-
bound drug, most likely by steric blockade of the exit pathway (Plenge et al., 2012).  In 
short, given the roles of the S1 and S2 binding sites within SERT are not completely 
understood, there is a significant need for tool compounds and experimental methods that 
can directly interrogate the microenvironments of hSERT binding sites. 
4.2.  Long-Term Goal of This Research 
The long-term goal of this research is to understand how clinically significant 
monoamine transporter inhibitors (e.g., methylphenidate as a hDAT inhibitor and 
citalopram as a SSRI) interact with their major drug targets (i.e., hDAT for 
methylphenidate and hSERT for citalopram) at the molecular level, thus ultimately 
facilitating correlation of primary ligand-protein molecular interactions with CNS 
behavioral effects.  Additionally, acquisition of detailed 3D protein structure-function 
information is expected to validate and further refine MAT molecular models currently 
used in computer-aided drug discovery efforts (i.e., virtual / in silico screening (e.g., 
Indarte et al., 2010; Nolan et al., 2011 and 2014) and structure-based drug design) 
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targeting disease states associated with MAT proteins (e.g., depression, anxiety, post-
traumatic stress disorder, obsessive-compulsive disorder, drug abuse, and addiction). 
4.3.  Overall Objective of This Research Dissertation 
The overall objective of this research dissertation was to rationally design, 
chemically synthesize, and biochemically utilize irreversible chemical probes based on 
methylphenidate as a hDAT inhibitor, and citalopram as a SSRI, in order to map their 
corresponding binding sites and poses within their major drug targets (i.e., hDAT for 
methylphenidate and hSERT for citalopram). 
4.4.  Central Hypothesis of This Research Dissertation 
The central hypothesis of this research dissertation was that methylphenidate as a 
hDAT inhibitor, and citalopram as a SSRI, could be rationally derivatized, without 
significant loss in pharmacological activity, to contain: 1.) a photoreactive group (PRG; 
e.g., an aryl azide, benzophenone, etc.) capable of forming a covalent bond to a target 
protein (i.e., hDAT or hSERT), and 2.) a tag entity (e.g., 125I or a bioorthogonal chemistry 
handle), thus allowing a “Binding Ensemble Profiling with (f)Photoaffinity Labeling 
(BEProFL)” experimental approach (He et al., 2009) to map the binding sites and poses 
of these clinically significant compounds within their major target protein.  In short, the 
premise of the BEProFL approach begins with the employment of appropriate 
photoprobes (i.e., those compounds whose protein binding affinity is no lower than 10-
fold versus an appropriate lead parent compound) in traditional photoaffinity labeling 
experiments to generate covalent ligand-target complexes (Scheme 4.1).  This is followed 
by chemical proteomic experiments, whose results are coupled with computational 
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molecular modeling of non-covalent or covalent ligand-target complexes in order to 
directly map the ligand-binding sites and poses of lead compounds within their target 
proteins.  As proof of concept, the BEProFL approach has been successfully used to 
understand the binding modes of histone deacetylase (HDAC) inhibitors as epigenetic 
modulators (Abdelkarim et al., 2013; Vaidya et al., 2012; Neelarapu et al., 2011; He et 
al., 2009) and to probe the microenvironment of fatty acid amide hydrolase (FAAH) 
(Saario et al., 2012), a drug target implicated in the development of pain therapeutics. 
 
 
Scheme 4.1.  Schematic representation of the BEProFL experimental approach for mapping the ligand-
binding sites and poses of methylphenidate (MP) and citalopram (CIT) within hDAT and hSERT, 
respectively. 
4.5.  Rationale of This Research Dissertation 
The rationale associated with this research dissertation is that, once it is known 
how clinically relevant drugs targeting the dopamine transporter or serotonin transporter 
specifically interact with these proteins at the molecular level, this detailed 3D structure-
function information can then be rationally used to validate and further refine 3D MAT 
molecular models currently used in computer-aided drug discovery efforts (i.e., 
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improved, confident virtual / in silico screening and entrance into rational structure-based 
drug design).  Such efforts in turn are expected to generate improved drug candidates for 
a host of disease states traditionally associated with monoamine transporter proteins (e.g., 
depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, drug 
abuse, and addiction). 
4.6.  Rational Design of Methylphenidate-Based Photoprobes Suitable for Dopamine 
Transporter Structure-Function Studies 
Methylphenidate ((±)-1.18, MP, Ritalin, Concerta; Scheme 4.2) is a well known, 
U.S. Food and Drug Administration (FDA) approved drug for the treatment of attention-
deficit hyperactivity disorder (ADHD), narcolepsy, and postural orthostatic tachycardia 
syndrome (Challman and Lipsky, 2000).  Methylphenidate acts as a mild CNS stimulant, 
principally by functioning as an inhibitor of dopamine and norepinephrine transporter 
proteins, thus blocking the reuptake of dopamine and norepinephrine neurotransmitters 
into the presynaptic neuron. 
With respect to the dopamine transporter, methylphenidate displays 2-fold higher 
binding affinity upon comparison to cocaine (e.g., see Pan et al., 1994 as one source of 
representative DAT pharmacology data for methylphenidate).  Additionally, 
methylphenidate is structurally similar to cocaine in that both compounds contain a basic 
nitrogen (i.e., a 3˚ amine in cocaine versus a 2˚ amine in methylphenidate), a methyl 
ester, and an aromatic ring.  With these structural similarities in mind, perhaps it is not 
surprising that the reinforcing effects of methylphenidate in animal models are 
comparatively similar to that of cocaine.  However, methylphenidate has been shown to 
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possess decreased reinforcing effects in humans and facilitates lower cocaine cravings 
(Yano and Steiner, 2007).  Additionally and in sharp contrast to cocaine, methylphenidate 
does not function as a sodium channel blocker and does not produce harmful effects on 
nerve conductance when taken in excess (Schwartz et al., 2010).  Furthermore, 
methylphenidate is generally considered to be relatively safe drug that has been used for 
decades.  As a result of the established success of methylphenidate as a safe and effective 
clinical entity, coupled with its decreased abuse potential, methylphenidate analogs are 
currently being pursued as potential candidates for the treatment of cocaine abuse (e.g., 
Misra et al., 2010). 
However, it should be noted that despite the long-term significance of 
methylphenidate in the clinic, the specific molecular contacts this compound makes with 
the dopamine transporter, which are directly responsible for the affinity, potency, 
selectivity, and behavioral effects associated with this compound, remain unknown.  As a 
result, several methylphenidate-based dopamine transporter inhibitor photoprobes were 
rationally developed during the course of this dissertation for potential use in dopamine 
transporter structure-function studies. 
4.6.1.  A Call for Racemic threo-3-Iodo-Methylphenidate ((±)-4.29) as a Lead 
Compound and Rational Design of Racemic threo-N-Azidobenzyl-4-Iodo/3-Iodo-
Methylphenidate Compounds (±)-4.17 - (±)-4.22 as Potential Dopamine Transporter 
Photoaffinity Ligands 
At the beginning of this research dissertation, it was observed that an 
overwhelming number of dopamine transporter inhibitor photoaffinity probes (e.g., Sallee 
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et al., 1989; Grigoriadis et al., 1989; Carroll et al., 1992; Agoston et al., 1997; Dutta et 
al., 2001; Zou et al., 2001 and 2003; Cao et al., 2004; Lever et al., 2005; Newman et al., 
2006; Chen et al., 2007; Lapinsky et al., 2009; Lapinsky, Aggarwal et al., 2012) 
published before the development of methylphenidate-based photoprobes (Lapinsky et 
al., 2011; Lapinsky, Yarravarapu et al., 2012) contain a common 3-iodo-4-azido aromatic 
ring-substituted structural motif (Figure 4.1).  In particular, the 4-azido functional group 
within this common photoaffinity labeling structural motif represents a photoreactive 
group for facilitating covalent bond formation of the DAT photoprobe to the DAT.  
Additionally, the 3-iodine atom represents a position for a future radioisotope tag (i.e., 
125I) to detect probe-labeled DAT after DAT photoaffinity labeling, and also serves as an 
electron-withdrawing group proposed to stabilize the singlet nitrene of an aryl azide upon 
photodecomposition (Soundararajan and Platz, 1990).  In particular, electronic 
stabilization of highly reactive nitrenes generated upon aryl azide photoactivation is 
desired and has been shown to prevent undesirable rearrangement of nitrenes to azepines, 
which can subsequently result in non-specific protein labeling upon nucleophilic attack 
(see Section 2.2.1.1 for previous discussion).  However, DAT photoprobes containing 
this common 3-iodo-4-azido aromatic ring-substituted structural motif have frequently 
resulted in low DAT labeling efficiency (e.g., <1%) during photoaffinity labeling 
(Vaughan et al., 2005). 
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Figure 4.1.  DAT photoaffinity probes containing a 3-iodo-4-azido aromatic ring-substituted structural 
motif that were published before the development of methylphenidate-based photoprobes.   
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In particular, it has been hypothesized that the low hDAT labeling efficiency of 
photoprobes containing the 3-iodo-4-azido aromatic ring-substituted motif results from 
the photoreactive aryl azide being juxtapositioned adjacent to a sterically bulky iodine 
atom (Vaughan et al., 2005).  In order to test this hypothesis and expand the arsenal of 
non-tropane DAT photoprobes known at the time (Lapinsky et al., 2009; Lapinsky, 
Aggarwal et al., 2012), a novel, alternative strategy was subsequently pursued wherein 
the photoreactive aryl azide functional group and the bulky 125I radiotracer tag were 
placed on different parts of a methylphenidate scaffold (Lapinsky et al., 2011) (Figure 
4.2). 
 
Figure 4.2.  Structural comparison of a tropane-based hDAT photoprobe (4.7) containing the traditional 3-
iodo-4-azido aromatic ring-substituted structural motif versus a series of non-tropane methylphenidate-
based probes featuring the photoreactive aryl azide and radioisotope 125I tag on separate parts of the 
chemical scaffold. 
The rational design of target methylphenidate-based DAT photoprobes (±)-4.17 - 
(±)-4.22 (Scheme 4.2; Lapinsky et al., 2011) stemmed from several lead methylphenidate 
analogs (Scheme 4.2).  In particular, threo-methyl 2-(4-iodophenyl)-2-(piperidin-2-
yl)acetate (4-iodomethylphenidate, (±)-3.29; hDAT IC50 = 14.0 ± 0.1 nM (i.e., inhibition 
of [3H]-WIN-35,428, a radioactive cocaine analog, binding to hDAT)) was initially 
chosen as a lead compound for rational DAT photoprobe design, principally because this 
analog displayed ~6-fold higher DAT binding affinity when compared to (±)-
methylphenidate ((±)-1.18; hDAT IC50 = 83.0 ± 7.9 nM; pharmacology data from 
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Deutsch et al., 1996), thus suggesting the 4-position of methylphenidate’s aromatic ring 
as a logical place to anchor a bulky iodine atom as a future radiotracer tag (i.e., 125I) 
within rationally designed methylphenidate-based DAT photoaffinity probes.  
Additionally, N-benzyl methylphenidate analogs (±)-4.30 - (±)-4.34 (Misra et al., 2010) 
were considered lead compounds for rational photoprobe design, given these analogs 
displayed either improved or retained DAT binding affinity when compared to 
methylphenidate ((±)-1.18).  Furthermore, improved DAT binding affinity was observed 
for methylphenidate analogs bearing halogens at the 3-position of the aromatic ring ((±)-
4.26 - (±)-4.28) when compared to the 4-position ((±)-4.23 - (±)-4.25) (Deutsch et al., 
1996); however, threo-methyl 2-(3-iodophenyl)-2-(piperidin-2-yl)acetate (3-
iodomethylphenidate, (±)-4.29) was unknown at the time.  This subsequently prompted 
the Lapinsky group to rationally pursue 3-iodomethylphenidate ((±)-4.29) as an 
additional lead compound for potential DAT photoprobe design, principally under the 
hope that the 3-position of methylphenidate’s aromatic ring could represent an alternative 
location to potentially anchor a bulky iodine atom as a future 125I radiotracer tag. 
As part of this research dissertation, racemic threo-3-iodo-methylphenidate ((±)-
4.29) was synthesized as described in Section 5.1.1 and sent to the Surratt laboratory for 
pharmacological determination of this compound’s hDAT binding affinity in N2A 
neuroblastoma cells.  As expected, an ~6-fold improvement in hDAT binding affinity 
was observed upon substituting the 3-position of methylphenidate’s aromatic ring with an 
iodine atom (hDAT Ki = 25 ± 1 nM (once again, inhibition of [
3H]-WIN-35,428 (a 
radioactive cocaine analog) binding to hDAT) for racemic threo-methylphenidate ((±)-
1.18) versus hDAT Ki = 4.5 ± 1 nM for racemic threo-3-iodo-methylphenidate ((±)-4.29); 
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Lapinsky et al., 2011).  Given that this DAT pharmacological result was consistent with 
the previous observation that halogens are well-tolerated at the 3-position of 
methylphenidate’s aromatic ring (Deutsch et al., 1996), it further suggested another 
rational anchoring position for an 125I atom as a future radiotracer tag within 
methylphenidate-based DAT photoaffinity probes. 
 
Scheme 4.2.  Rational design of a series of N-azidobenzyl-4-iodo/3-iodo-methylphenidate compounds ((±)-
4.17 - (±)-4.22) as potential dopamine transporter photoaffinity ligands.   
Given these established structure–activity relationships for methylphenidate, a 
series of photoaffinity ligands ((±)-4.17 - (±)-4.22) was designed via molecular 
hybridization of iodomethylphenidates ((±)-3.29, (±)-4.29, Scheme 4.1) with N-
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benzylmethylphenidates ((±)-4.30 to (±)-4.34, Scheme 4.2).  These target probes ((±)-
4.17 to (±)-4.22, Scheme 4.2) feature systematic placement of a photoreactive azide on 
the aromatic ring of the N-benzyl group.  Racemic threo-3-iodo-methylphenidate ((±)-
4.29, Scheme 4.2) was synthesized in bulk and submitted for the synthesis of target 
probes ((±)-4.20, (±)-4.21, Scheme 4.2).  The final target probe ((±)-4.22, Scheme 4.1) 
was synthesized as described in Section 5.1.2 and was sent for pharmacological 
determination of hDAT binding affinity in N2A neuroblastoma cells.  Thus, this 
dissertation partially contributed towards a series of threo-N-azidobenzyl-3-iodo- 
methylphenidate photoaffinity ligands. 
4.6.2.  Rational Design of Racemic threo-4-Azido-3-Iodo-Methylphenidate as a 
Potential Photoaffinity Ligand for Dopamine Transporter Structure-Function 
Studies 
The traditional design of DAT photoprobes features incorporation of a 3-I, 4-N3-
phenyl substituent attached to an inhibitor scaffold by means of a variable-length linker.  
For example, [125I]-MFZ-2−24 (4.7, Figure 4.3) has been prepared and found to 
covalently attach to transmembrane domain 1 (TM1) of the DAT (Parnas et al., 2008), 
while similar results have also been achieved with benztropine probe [125I]-GA-2−34 
(4.5, Figure 4.3) (Parnas et al., 2003).  However, phenyltropane-based probe [125I]-RTI-
82 (4.3, Figure 4.3) covalently ligates to TM6 of the DAT (Vaughan et al., 2007).  
Multiple studies suggest not all tropane-based inhibitors bind to the same conformation or 
binding site within the DAT, and that covalent conjugation to the DAT protein can occur 
in different TM regions depending on the position of the photoreactive group within the 
probe (Parnas et al., 2008; Vaughan et al., 2005 and 2007).  In this regard, photoprobes 
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4.3, 4.5, and 4.7 may be viewed as potentially possessing an inherent disadvantage when 
trying to definitively map the amino acids of the inhibitor-binding pocket, or optimally 
model the photoprobe−DAT complex, via the BEProFL approach (He et al., 2009).  That 
is, the covalent point of probe attachment to the DAT, which is dictated by the location of 
the photoreactive azide group, is somewhat removed from the inhibitor scaffold by means 
of a conformationally flexible, variable-length methylene linker.  In particular, molecular 
modeling studies of photoprobe 4.7 (Figure 4.3) indicate distances of 10.5 and 15.5 Å 
between the azide and the pharmacophore tropane nitrogen, and 3β-phenyl ring, 
respectively.  Given that the azide is not directly appended to the tropane pharmacophore 
for probes 4.3, 4.5, and 4.7 (Figure 4.3), adduction may occur at a residue near, but not at, 
a direct inhibitor contact point, thus representing a significant limitation when trying to 
delineate the discrete molecular interactions between the probe and the DAT protein.  
Toward potentially addressing this point, 3-(4′-azido-3′-iodo-phenyl)-8-methyl-8-aza-
bicyclo[3.2.1]octane-2-carboxylic acid methyl ester (4.4, Figure 4.3) has been 
synthesized and displays high affinity, wash-resistant binding to the DAT (Carroll et al., 
1992), but fails to label the DAT in subsequent immunoprecipitation and proteolysis 
experiments (Vaughan et al., unpublished observations).  These results, coupled with 
those from previous DAT photolabeling experiments, have collectively indicated that 
azide must be some distance away from the tropane pharmacophore to covalently attach 
to the DAT protein near, but not within, the ligand-binding domain (Newman et al., 
2006). 
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Figure 4.3.  Structural comparison of a tropane-based hDAT photoprobes versus a compact non-tropane 
methylphenidate-based probe containing the traditional 3-iodo-4-azido aromatic ring-substituted structural 
motif. 
However, it was later successfully shown that direct substitution of the 
photoreactive azide group on the aromatic ring of the inhibitor scaffold is tolerated for 
non-tropane-based DAT photoaffinity labeling agents (Lapinsky et al., 2009).  The 
compact pyrovelorone probe (±)-4.15 (Figure 4.1) was shown to successfully label the 
dopamine transporter in contrast to tropane-based irreversible compounds where in the 
azide has to be placed at a distance (usually via a linker) from the inhibitor 
pharmacophore in order to achieve successful protein labeling (Newman et al., 2006).  
Given these previous observations, this research dissertation features the design and 
synthesis of a compact photoprobe based on MP as a non-tropane DAT inhibitor (Scheme 
4.3).  Previous SAR studies (Misra et al., 2010) indicated the 3- and 4-positions of the 
aromatic ring within (±)-1.18 could potentially be modified to include the 3-I-4-N3 motif 
without adversely affecting DAT binding affinity (Scheme 4.3).  The 4-position of 
methylphenidate’s aromatic ring was envisioned as a logical place to anchor an azide as 
photoreactive functional group as indicated by analogs (±)-4.36, (±)-4.37, (±)-4.24, and 
(±)-3.29 (Scheme 4.3) whose binding affinity increased or was retained when compared 
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to a parent compound.  Additionally, improved DAT binding affinity was observed for 
methylphenidate analogs bearing halogens at the 3-position of the aromatic ring ((±)-4.26 
to (±)-4.29, Scheme 4.3), thus suggesting a potential position for a future 125I radiotracer 
tag.  Furthermore, improved DAT affinity was observed for a methylphenidate analog 
bearing lipophilic chlorine atoms at both the 3- and 4-positions of the aromatic ring ((±)-
3.35, thus indicating that methylphenidate analogs bearing this type of disubstitution 
pattern could possess increased affinity.  With these thoughts in mind, compound (±)-
4.35 was rationally designed and envisioned as a compact DAT photoprobe bearing no 
linker functionality (Scheme 4.3).  Such a photoprobe is expected to covalently attach to 
an amino acid residue directly within the methylphenidate-binding pocket of the hDAT, 
and also result in a more conformationally restricted photoprobe-protein complex in 3D 
hDAT molecular modeling studies.  
Target compact photoprobe (±)-4.35 was synthesized as described in Section 
5.1.3, and alongside all intermediate methylphenidate analogs, was subjected to DAT 
pharmacological evaluation.  Analogous to previous reports, substituting the 4-position of 
(±)-threo-methylphenidate with a nitro group resulted in an 4.8-fold loss in hDAT 
affinity, whereas NH2 substitution at this position increased affinity 2.5-fold (Table 4.1) 
(Misra et al., 2010).  The addition of a 3-I group to aniline derivative (±)-4.36 resulted in 
only a slight decrease (1.4-fold) in binding affinity for hDAT.  However, replacing the 
aniline of compound (±)-4.40 with a photoreactive azide group, resulting in target probe 
(±)-4.35, gave an 2.3-fold increase in hDAT affinity. 
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Scheme 4.3.  Rational design of racemic threo 4-azido-3-iodo-methylphenidate as a compact dopamine 
transporter photoprobe. 
These results indicate that (±)-4.35 (Ki = 4.0 ± 0.8 nM) displays 6-fold higher 
hDAT affinity than (±)-threo-methylphenidate (±)-1.18 (Ki = 16.0 ± 2.8 nM), thus 
representing one of the highest affinity DAT photoprobes synthesized to date (Lapinsky, 
Yarravarapu et al., 2012).  In particular, an 91-fold improvement in hDAT affinity is 
seen relative to our previously reported best methylphenidate photoprobe, (±)-threo-N-(p-
azido-benzyl)-4-iodomethylphenidate (Ki = 363 ± 28 nM), which features the 
photoreactive azide appended to the pharmacophore via an N-benzyl linker (Lapinsky et 
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al., 2011).  Finally, a 125I version of target photoprobe (±)-4.35 was synthesized and 
shown to bind specifically and irreversibly to rDAT and hDAT upon UV irradiation, in 
the absence or presence of cocaine and methyphenidate as competitors (Lapinsky, 
Yarravarapu et al., 2012) (see Appendix, Section A.1). 
Table 4.1.  Inhibition of [3H]-WIN-35,428 binding by methylphenidate compounds at hDAT N2A 
neuroblastoma cells. (Lapinsky, Yarravarapu et al., 2012.  Adapted with permission from ACS Med. Chem. 
Lett. 2012, 3, 378-382. Copyright 2012, American Chemical Society) 
 
4.7.  Rational Design of Citalopram-Based Photoprobes Suitable for Serotonin 
Transporter Structure-Function Studies 
Citalopram ((±)-1.11, Figure 4.4) is a well-known, FDA-approved selective 
serotonin reuptake inhibitor (SSRI) that has been available as an antidepressant since the 
1980’s.  It is well-established that citalopram exerts its therapeutic effects mainly by 
binding to, and inhibiting, SERT as a neurotransmitter reuptake transporter, resulting in 
increased synaptic concentrations of serotonin (5-HT) (Stahl et al., 2013).  In particlar, 
citalopram has gained special attention in reference to the S1 and S2 binding sites of 
SERT.  The eutomer, escitalopram ((S)-1.11, Figure 4.4), interacts with the hSERT 
uniquely, as compared to other 5-HT inhibitors, which interact at both the S1 and S2 sites 
(Chen, Larsen, Sánchez et al., 2005).  Furthermore, (S)-citalopram has ~30-fold higher 
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binding affinity at SERT versus its enantiomer, (R)-citalopram ((R)-1.11, Figure 4.4), and 
(R)-citalopram may attenuate the effects of (S)-citalopram via allosteric modulation 
(Sanchez et al., 2004; Chen, Larsen, Sánchez et al., 2005; Zhong et al., 2009 and 2012).  
The exact binding contacts for these enantiomers with SERT is unknown, and the 
importance of allosteric site binding is not well-understood due to the lack of appropriate 
tool compounds and methods for interrogating the microenvironment of hSERT.  In order 
to address these issues, this dissertation features development of multiple citalopram-
based photoprobes potentially capable of elucidating the binding site information within 
SERT. 
 
Figure 4.4.  Chemical structures of (±)-citalopram, (S)-citalopram, and (R)-citalopram and their inhibition 
of [125I]-RTI-55 binding to hSERT in COS-1 cells (Chen, Larsen, Sánchez et al., 2005). 
4.7.1.  Rational Design of Racemic/(S)-Citalopram-Based Photoprobes Containing a 
Clickable Benzophenone-Alkyne Labeling Motif  
One of the most common ways to create a clickable photoaffinity ligand is to 
utilize a benzophenone as a photoreactive group and a terminal alkyne as a click 
chemistry handle (e.g., 4.43, Scheme 4.4) (Van Scherpenzeel et al., 2009 and 2010; Chen 
et al., 2010; Ban et al., 2010; Eirich et al., 2011 and 2012; Park et al., 2012; Cisar and 
Cravatt, 2012; Saario et al., 2012).  With this observation in mind, 5-substituted, 
citalopram-based benzophenone-alkyne SERT photoprobe (±)-4.44 (Scheme 4.4) was 
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rationally designed via the structure-activity relationship that bulky substituents at the 5-
position of citalopram (±)-1.11 are tolerated (i.e., no large reduction in SERT binding 
affinity) (Zhang et al., 2010 and 2013; Banala et al., 2013;  Kumar et al., 2014).  For 
example, 5-substituted analog (±)-4.42 (Ki = 23.6 ± 1.54 nM) displayed only a 12-fold 
loss in binding affinity towards rSERT when compared to (±)-citalopram (Ki = 1.94 ± 
0.198 nM) (Banala et al., 2013), which is borderline acceptable affinity for designing a 
future SERT photoaffinity label.   
Target citalopram photoprobe (±)-4.44 was successfully synthesized (see Chapter 
5), and submitted to Dr. Christopher Surratt’s laboratory (Duquesne University) for 
hSERT pharmacological evaluation.  Binding affinity results indicated that probe (±)-
4.44 (Ki = 4.3 ± 3.5 nM) displays similar hSERT binding affinity as (±)-citalopram ((±)-
1.11, Ki = 4.4 ± 1.3 nM), thus representing a high affinity potential SERT photoprobe.  
Even though this photoprobe was initially utilized to develop a photoaffinity labeling 
protocol for hSERT (see Section 5.3), our subsequent efforts were immediately directed 
towards synthesizing the enantiomerically pure (S)-enantiomer of this probe ((S)-4.44, 
Scheme 4.4), primarily because this would remove ambiguity associated with hSERT 
labeling by a racemic mixture (i.e., two compounds) and also allow use of (S)-citalopram 
as a competitor during photoaffinity labelling experiments.  With these thoughts in mind,  
(S)-citalopram-based photoprobe ((S)-4.44), containing the same clickable 
benzophenone-alkyne motif, was synthesized as described in Section 5.2.1 and submitted 
to Dr. Christopher Surratt’s laboratory (Duquesne University) for SERT pharmacological 
evaluation.  It was found that (S)-4.44 (Ki = 0.16 ± 0.04 nM) displays 11-fold higher 
hSERT binding affinity than (S)-citalopram ((S)-1.11, Ki = 1.77 ± 1.14 nM) and 27-fold 
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higher hSERT binding affinity than (±)-citalopram probe (±)-4.44. (S)-Probe 4.44  was 
subsequently utilized to label purified hSERT as discussed in Section 5.3.6.  As of the 
writing of this dissertation, purified hSERT (S)-citalopram-benzophenone-alkyne 
photoprobe-labeled samples were run on a SDS gel, and the labeled bands were excised, 
trypsin digested (see chapter 6), and submitted to Dr. Michael Cascio’s laboratory 
(Duquesne University) for mass spectrometry analysis. 
 
Scheme 4.4.  Rational design of 5-substituted, citalopram/escitalopram-based benzophenone-alkyne 
clickable SERT photoprobes. 
One of the goal of this dissertation was to develop multiple (S)-citalopram 
photoprobes featuring systematic placement of different photoreactive functional groups 
at different positions off on the (S)-citalopram scaffold, thus allowing potential 
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systematic mapping of the (S)-citalopram-binding site within hSERT via BEProFL.  
Towards achieving this goal, another point of attachment for the benzophenone-alkyne 
moiety to (S)-citalopram scaffold was pursued in order to potentially gain additional 3D 
information regarding the (S)-citalopram-binding site within SERT.  In particular, 
previous SAR indicated that N-substituted analogs of citalopram maintained relatively 
good binding affinity for SERT (Banala et al., 2013).  For example, N-substituted analog 
(±)-4.45 (Ki = 19 ± 2.65 nM) displayed a 10-fold loss in affinity towards rSERT when 
compared to (±)-citalopram (Ki = 1.94 ± 0.198 nM) (Banala et al., 2013), thus suggesting 
substituting the nitrogen of N-desmethyl citalopram with photoreactive group and tag 
entity could potentially result in a photoprobe with appropriate binding affinity for SERT 
photoaffinity labeling experiments.  Therefore, N-substituted-escitalopram-based 
benzophenone-alkyne photoprobe (S)-4.47 was rationally designed considering (±)-4.45 
as a lead compound (Scheme 4.5).  Initially, synthetic methodology for this target probe 
was established by successful synthesis of escitalopram N-substituted benzophenone 
analog (S)-4.46 (see Chapter 5). Escitalopram N-substituted benzophenone analog (S)-
4.46 was submitted to Dr. Christopher Surratt’s laboratory (Duquesne University) for 
SERT pharmacological evaluation to see if the bulky benzophenone is tolerable off of 
citalopram’s tertiary nitrogen with respect to maintaining high SERT binding affinity.  
Later, similar chemistry was utilized to synthesize escitalopram N-substituted 
benzophenone-alkyne clickable photoprobe (S)-4.47 (Section 5.2.1) and likewise this 
compound was submitted to Dr. Christopher Surratt’s laboratory (Duquesne University) 
for SERT pharmacological evaluation.  However, SERT pharmacology results indicated 
that photoprobe (S)-4.47 (Ki = 487 ± 97 nM) displayed 275-fold loss in SERT binding 
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affinity when compared to (S)-citalopram ((S)-1.11, Ki = 1.77 ± 1.14 nM).  As a result of 
this significant loss in SERT binding affinity, photoprobe (S)-4.47 was not advanced to 
SERT photoaffinity labeling studies. At the time of writing this dissertation, a SERT 
photoaffinity labeling protocol has been optimized using clickable high affinity (S)-
citalopram-based photoprobes (Ki < 1 nM). 
 
Scheme 4.5.  Rational design of N-substituted escitalopram benzophenone-based SERT photoprobes. 
4.7.2.  Rational Design of a Diazido-Based (S)-Citalopram Analog as a Potential 
Photoprobe for Serotonin Transporter Structure-Function Studies 
Another common approach to turn lead compounds into clickable photoaffinity 
ligands is to utilize a 1,3,5-trisubstituted phenyl moiety bearing an aryl azide as a 
photoreactive group and a methylene aliphatic azide as a click chemistry handle (e.g., 
4.49, Scheme 4.6) (Abdelkarim et al., 2013; Hosoya et al., 2004, 2005, and 2009; Sun et 
al., 2006; He et al., 2009; Gandy et al., 2011; Neelarapu et al., 2011; Vaidya et al., 
 118 
2012).  In particular, the design of target probe (S)-4.50 is based on 5-substituted high-
affinity fluorescent (S)-citalopram analog (S)-4.48 (Ki = 3 nM), which maintained equal 
binding affinity towards hSERT when compared to (S)-citalopram (Ki = 2.6 nM) (Kumar 
et al., 2014).  Based on this SAR information, diazido-based 5-substituted-(S)-citalopram 
analog (S)-4.50 (Scheme 4.6) was rationally designed by incorporating the known 1,3,5-
trisubstituted-phenyl diazide moiety at the 5-position of (S)-citalopram.   
 
Scheme 4.6.  Rational design of a 5-substituted escitalopram-based diazido clickable photoprobe for SERT 
structure-function studies. 
This (S)-citalopram-based clickable photoprobe was subsequently synthesized as 
described in Section 5.2.2 and submitted to Dr. Christopher Surratt’s laboratory 
(Duquesne University) for SERT pharmacological evaluation.  It was subsequently found 
that diazido probe (S)-4.50 (Ki = 10.7 ± 7.5 nM) shows 6-fold higher SERT binding 
affinity when compared to (S)-citalopram ((S)-1.11, Ki = 1.77 ± 1.14 nM). These 
pharmacology results indicate that (S)-citalopram-based diazide photoprobe (S)-4.50 is a 
suitable candidate for SERT photoaffinity labeling studies in Dr. Michael Cascio’s 
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laboratory (Duquesne University), principally because the probe maintains high SERT 
binding affinity (i.e., Ki < 100 nM) and is within a 10-fold SERT binding affinity range 
when compared to an appropriate parent compound (i.e., (S)-citalopram). 
4.7.3.  Rational Design of a (S)-Citalopram-Based Photoaffinity Ligands Containing 
the Traditional 3-Iodo-4-Azido Labeling Motif  
  In addition to photoprobes containing a clickable handle, the success of 
methylphenidate-based probe 4.35, which contains the traditional 3-iodo-4-azido phenyl 
ring, prompted us to apply this common Photoaffinity labeling motif to (S)-citalopram.  
(S)-Citalopram-based photoprobe (S)-4.51 containing the traditional 3-iodo-4-azido 
phenyl ring was designed based on the SAR that bulky substituents at the 5-position of 
the (S)-citalopram are well tolerated, as exemplified by (S)-citalopram fluorecent ligand 
(S)-4.48 (Scheme 4.7).  The other important factor contributing to the design of probe S)-
4.51 was the fact that the synthetic methodology developed for (S)-citalopram-based 
photoprobes (S)-4.44 and (S)-4.50 could be utilized to synthesize (S)-citalopram-based 3-
iodo-4-azido photoprobe (S)-4.51.  Photoprobe (S)-4.51 was successfully synthesized as 
described in Section 5.2.3 and was submitted to Dr. Christopher Surratt’s laboratory 
(Duquesne University) for SERT pharmacological evaluation.  It was subsequently found 
that azido-iodo (S)-4.51 (Ki = 3.45 ± 2.04 nM) displays 2-fold higher SERT binding 
affinity than (S)-citalopram ((S)-1.11, Ki = 1.77 ± 1.14 nM), once again confirming the 
SAR that bulky substituents at the 5-position of the (S)-citalopram are tolerated.  Probe 
(S)-4.51 was subsequently synthesized in its 125I form in the laboratory of Dr. John Lever 
(University of Missouri – Columbia) and advanced to SERT photoaffinity labeling 
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studies in the laboratory of Dr. Roxanne Vaughan (University of North Dakota) (see 
Appendix, Section A.2). 
 
Scheme 4.7.  Rational design of a 5-substituted escitalopram-based SERT photoprobe containing a 
traditional 3-iodo-4-azido photoaffinity labeling motif. 
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CHAPTER FIVE 
5.  Chemical Discussion  
5.1.  Synthesis of Methylphenidate-Based Photoprobes Suitable for Dopamine 
Transporter Structure-Function Studies 
As previously discussed in Section 4.6, we desired photoprobes for dopamine 
transporter structure-function studies based on the well-known attention deficit 
hyperactivity disorder (ADHD) drug, (±)-threo-methylphenidate ((±)-1.18, Ritalin®, 
Concerta®), analogs of which have received significant attention as potential cocaine 
abuse therapeutics (e.g., Kim et al., 2007).  In particular, previous SAR studies have 
indicated structural features leading to high DAT binding affinities for a number of 
methylphenidate analogs (reviewed in Misra et al., 2010), thus aiding in rational DAT 
photoprobe design from a ligand-based perspective. 
5.1.1.  Synthesis of Racemic threo-3-Iodo-Methylphenidate as an Intermediate for 
the Synthesis of Racemic threo-N-Azidobenzyl-3-Iodo-Methylphenidate 
Photoaffinity Ligands for Dopamine Transporter Structure-Function Studies 
As previously discussed in Section 4.6.1, in order to overcome inefficient DAT 
photoaffinity labeling associated with probes containing the traditional 3-iodo-4-azido 
labeling motif, racemic threo-N-azidobenzyl-4-iodo/3-iodo-methylphenidate analogs 
were pursued as potential photoaffinity ligands for dopamine transporter structure-
function studies (Lapinsky et al., 2011).  In particular, the synthesis of a series of racemic 
threo-N-azidobenzyl-4-iodo/3-iodo-methylphenidate (MP) analogs ((±)-4.17-4.22) as 
potential DAT photoaffinity ligands was envisioned via N-alkylation of either 4-iodo-
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methylphenidate ((±)-3.29) or 3-iodo-MP ((±)-4.29) with a series of known azido benzyl 
bromides (5.1-5.3; Mornet et al., 1984) (Scheme 5.1).  As a contribution towards the 
synthesis of these desired methylphenidate analogs, an efficient, relatively large-scale 
synthesis of 3-iodo-methylphenidate ((±)-4.29) was pursued as part of this dissertation. 
 
Scheme 5.1.  Proposed retrosynthesis of a series of racemic threo-N-azidobenzyl-4-iodo/3-iodo-
methylphenidate analogs as potential DAT photoaffinity ligands. 
In short, synthetic methodology previously described in Section 3.1 for the 
synthesis of racemic threo-MP ((±)-1.18, Scheme 3.2) (Axten et al., 1998; Gutman et al., 
2004) was modified in order to access racemic threo-3-iodo-MP ((±)-4.29) (Scheme 5.2).  
The synthesis began with regioselective meta-iodination of known α-keto amide 3.8 
(Gutman et al., 2004) using a solution of N-iodosuccinimide in concentrated sulfuric acid 
to provide iodo α-keto amide 5.4 in 77% yield.  Subsequent condensation of ketone 5.4 
with tosylhydrazine under acidic conditions then provided tosylhydrazone 5.5 in 
moderate yield (72%).  Next, thermal cyclization of iodo tosylhydrazone 5.5 under 
aqueous basic conditions using Aliquat 336® as a phase transfer catalyst, followed by 
column chromatography and recrystallization from diethyl ether, provided 
diastereomerically pure racemic threo-β-lactam (±)-5.6 as the major product in moderate 
yield (55%).  Finally, threo-β-lactam (±)-5.6 was converted to 3-iodo-MP ((±)-4.29) in 
quantitative yield by ring opening with methanol under acidic conditions (Lapinsky et al., 
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2011).  In particular, racemic threo-3-iodo-MP ((±)-4.29) synthesized by this route was 
determined to be ≥95% diastereomerically pure by 1H NMR upon comparison to the 
known spectroscopic data for enantiomerically pure threo- and erythro-methylphenidate 
and its para-substituted derivatives (Thai et al., 1998). 
 
Scheme 5.2.  Synthesis of racemic threo-3-iodo-methylphenidate (MP) by applying methodology 
previously described for the synthesis of racemic threo-MP (Axten et al., 1998).  
The chemistry described in Scheme 5.2 worked fairly well yielding 3-iodo-
methylphenidate ((±)-4.29) in 4 steps and 30 % overall yield.  The only troublesome 
reaction during scale up of this chemistry was the electrophilic aromatic meta-iodination 
(i.e., 3.8 to 5.4), which was initially done in multiple small batches to avoid large 
volumes of sulfuric acid.  This drawback was subsequently addressed by reducing the 
volume of sulfuric acid required for the reaction to proceed to completion.  Initially, the 
reaction was attempted on 0.5 mmol of α-keto amide 3.8 (Gutman et al., 2004) using 2 
equivalents of N-iodosuccinimide dissolved in 3 mL of concentrated sulfuric acid 
(conditions adapted from Chaikovskii et al., 2207).  As a result, the 5 mmol scale 
reaction (second attempt) required using 30 mL of concentrated sulfuric acid, which 
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necessitated tedious and careful quenching in order to isolate the product.  In order to 
address this practical concern on an even larger scale, a 5 mmol scale reaction was 
attempted and proved successful by using a minimum volume of sulfuric acid (4.5 mL) 
required for dissolving the N-iodosuccinimide (10 mmol).  Finally, the meta-iodination 
could be scaled up to a 10 mmol scale of amide 3.8 using a minimum amount of sulfuric 
acid (9 mL) required to generate a 20 mmol N-iodosuccinimide solution.  Overall, the 
chemistry described in Scheme 5.2 was scaled up to provide 3-iodo-methylphenidate 
((±)-4.29) in multigram amounts, which was utilized by Dr. Ranganadh Velagaleti for 
synthesis of racemic threo-N-azidobenzyl-3-iodo-methylphenidate probes (±)-4.20 and 
(±)-4.21 via N-alkylation (Lapinsky et al., 2011). 
5.1.2.  Synthesis of Racemic threo-N-para-Azidobenzyl-3-Iodo-Methylphenidate as a 
Potential Photoprobe for Dopamine Transporter Structure-Function Studies 
As part of this dissertation, racemic threo-N-para-azidobenzyl-3-iodo-
methylphenidate ((±)-4.22) was pursued as a potential DAT photoaffinity ligand 
(Lapinsky et al., 2011).  In particular, this compound was synthesized in moderate yield 
(65%) by N-alkylation of 3-iodo-MP with para-azido benzyl bromide (5.3, Mornet et al., 
1984) (Scheme 5.3).  Unfortunately, despite support for its rational design as described in 
Section 4.6.1, probe (±)-4.22 showed significantly higher DAT binding affinity (DAT Ki 
= 658 ± 70 nM; ~26-fold loss in DAT binding affinity when compared to (±)-MP (DAT 
Ki = 25 ± 1 nM)) and did not meet our criteria (i.e., DAT Ki < 100 nM and < 10-fold loss 
in DAT binding affinity when compared to an appropriate parent compound) for further 
pursuit of a radioiodinated version for formal DAT photoaffinity labeling. 
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Scheme 5.3.  Synthesis of racemic threo-N-para-azidobenzyl-3-iodo-methylphenidate by N-alkylation of 
racemic threo-3-iodo-methylphenidate with para-azido benzyl bromide. 
5.1.3.  Synthesis of Racemic threo-4-Azido-3-Iodo-Methylphenidate as a Compact 
Photoaffinity Ligand for Dopamine Transporter Structure-Function Studies 
As previously described in Section 4.6.2, racemic threo-4-azido-3-iodo 
methylphenidate ((±)-4.35) was desired and pursued as a compact DAT photoaffinity 
probe featuring a photoreactive aryl azide placed directly on methylphenidate’s aromatic 
ring.  Additionally, since attempted N-benzylation of iodo-methylphenidates (±)-3.29 and 
(±)-4.29 resulted in a significant decrease in DAT binding affinity upon comparison to 
racemic threo-MP, (±)-1.18 was pursued in the hopes of obtaining a methylphenidate-
based photoprobe with significantly improved DAT binding affinity (i.e., target goal 
DAT Ki < 100 nM) relative to our first successful probe in this area (i.e., [
125I]-(±)-4.19; 
Lapinsky et al., 2011). 
In terms of retrosynthesis, racemic threo-4-azido-3-iodo-methylphenidate ((±)-
4.35) as a potential DAT photoaffinity ligand was initially envisioned from known 
methylphenidate analog N-benzoyl-4-amino-methylphenidate ((±)-3.24, Pan et al., 1996) 
via 4 steps: electrophilic aromatic iodination of the aniline, conversion of the aniline to an 
azide via diazotization and azide displacement, then global hydrolysis of a benzamide 
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methyl ester analog followed by final methyl esterification of a ritalinic acid derivative 
(Scheme 5.4).  In turn, it is known that N-benzoyl-4-amino-methylphenidate analog (±)-
3.26 can be accessed from racemic threo-methylphenidate ((±)-1.18, Axten et al., 1998; 
Gutman et al., 2004) using methodology previously reported (i.e., a sequence of N-
benzoylation, nitration, and reduction; Pan et al., 1996).  With this particular 
retrosynthesis in mind, the synthesis of racemic threo-4-azido-3-iodo-methylphenidate 
((±)-4.35) was pursued according to this strategy. 
 
Scheme 5.4.  Proposed retrosynthesis of racemic threo-4-azido-3-iodo-methylphenidate as a potential DAT 
photoaffinity ligand from known methylphenidate analog (±)-3.26 (Pan et al., 1996).  
This attempted synthesis first began with efficient N-benzoylation of racemic 
threo-methylphenidate ((±)-1.18) to provide amide (±)-3.24 in quantitative yield (Scheme 
5.5).  The aromatic ring of amide analog (±)-3.24 was then subsequently nitrated with 
nitric acid to give p-nitro isomer (±)-3.25 as the major product in moderate yield (75%).  
The nitro functional group was then reduced using iron under sonicating acid conditions 
to provide aniline (±)-3.26, which was subjected to iodination using iodine monochloride 
to provide p-amino-m-iodo N-protected methylphenidate derivative (±)-5.7 in 50% yield.  
Next, aniline (±)-5.7 was diazotized and displaced with sodium azide to produce p-azido-
m-iodo derivative (±)-5.8 in moderate yield (60%).  However, attempted global 
hydrolysis of benzamide methyl ester (±)-5.8 under strong acidic conditions 
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unfortunately resulted in degradation of the azide functional group, thus forcing 
subsequent pursuit of an alternative synthetic strategy. 
 
Scheme 5.5.  Attempted synthesis of racemic threo-4-azido-3-iodo-methylphenidate photoprobe (±)-4.35 
from racemic threo-N-benzoyl-methylphenidate ((±)-3.24).   
In order to avoid azide decomposition via the harsh acidic global hydrolysis 
conditions depicted in Scheme 5.5, an alternative retrosynthesis was to first pursue global 
hydrolysis of p-nitro-benzamide (±)-3.25 to provide 4-nitro-ritalinilic acid, which could 
then potentially be converted to 4-nitro-methylphenidate ((±)-4.39) via Fischer 
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esterification (Scheme 5.6).  In turn, the synthesis of target compound racemic threo-4-
azido-3-iodo-methylphenidate ((±)-4.35) was then envisioned from 4-nitro-
methylphenidate ((±)-4.39) via three steps: reduction of the nitro group to the aniline, 
electrophilic aromatic iodination, then conversion of the aniline to the azide via 
diazotization and azide displacement. 
 
Scheme 5.6.  Alternative proposed retrosynthesis of racemic threo-4-azido-3-iodo-methylphenidate from 
racemic threo-4-nitro-methylphenidate analog (±)-5.10. 
 With this alternative retrosynthesis in mind, nitro derivative (±)-3.25 (from 
Scheme 5.5) was subjected to global hydrolysis to provide 4-nitro-ritalinilic acid, 
followed by esterification to yield 4-nitro-methylphenidate ((±)-4.39) (Scheme 5.7).  
However, these acidic reaction conditions resulted in a loss of the desired threo 
stereochemistry, generating a mixture of inseparable erythro- and threo-4-nitro-
methylphenidate diastereomers ((±)-5.10 and (±)-4.39).  In order to confirm this 
undesirable epimerization, the mixture of erythro- and threo- nitro diastereomers was 
subjected to nitro reduction to obtain a mixture of erythro- and threo-4-amino-
methylphenidate diastereomers ((±)-5.11 and (±)-4.36), whose individual literature 1H 
NMR data was available for analytical comparison (Deutsch et al., 1996).  Alternatively, 
global hydrolysis of 4-amino-N-benzoyl-methylphenidate ((±)-3.26) followed by 
esterification also resulted in a mixture of erythro- and threo-4-amino-methylphenidate 
diastereomers ((±)-5.11 and (±)-4.36), wherein once again, undesirable epimerization was 
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confirmed by comparing 1H NMR data to that known in the chemical literature  (Deutsch 
et al., 1996). 
 
Scheme 5.7.  Attempted synthesis of racemic threo-4-nitro or 4-amino-methylphenidate leads to 
epimerization and inseparable diastereomeric mixtures under acidic reaction conditions.   
Another potential approach to access racemic threo-4-nitro-methylphenidate ((±)-
4.39) is by nitration of ritalinilic acid ((±)-5.12) followed by esterification as previously 
reported by Deutsch et al., 1996 (Scheme 5.8).  This attempted synthesis began with 
acidic hydrolysis of racemic threo-methylphenidate ((±)-1.18) to provide ritalinilic acid 
((±)-5.12).  Racemic threo-ritalinilic acid ((±)-5.14) was then subjected to nitration and 
esterification to provide a mixture of racemic threo-nitro-methylphenidates in 50% yield 
over three steps.  In particular, the nitration reaction in this route resulted in formation of 
an undesirable positional isomer, i.e., threo-3-nitro-ritalinilic acid ((±)-5.14) (10-20% 
based on 1H NMR), alongside the desired threo-4-nitro-ritalinilic acid ((±)-5.13).  All 
attempts to purify the desired threo-4-nitro-methylphenidate ((±)-4.39) from the 
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undesirable positional isomer proved futile given their similar retention times during 
column chromatography and solubility in various solvent systems for attempted 
recrystallization.  As a result, synthesis of target compound racemic threo-4-azido-3-
iodo-methylphenidate using methylphenidate as a starting material was abandoned in 
pursuit of alternative synthetic strategy. 
 
Scheme 5.8.  Attempted synthesis of threo-4-nitro-methylphenidate via nitration of ritalinic acid leads to an 
inseparable mixture of positional nitro isomers.   
Ultimately, application of synthetic methodology previously developed (Axten et 
al., 1998 and Gutman et al., 2004) for the synthesis of racemic threo-methylphenidate 
(see Scheme 3.2) proved successful for the synthesis of target photoprobe racemic threo-
4-azido-3-iodo-methylphenidate (Scheme 5.9).  Ketoamide 5.17 was initially prepared in 
91% yield from commercially available nitro ester 5.16 by treatment with piperidine in 
ethanol.  Tosylhydrazone 5.18 was then generated in 59% yield by allowing ketoamide 
5.17 to react with p-toluenesulfonyl hydrazide under refluxing acidic ethanol conditions.  
Next, utilization of Aliquat 336® as a phase transfer catalyst in refluxing toluene under 
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basic conditions provided α-diazo amide 5.19 in 95% yield, which subsequently 
underwent thermal cyclization to provide a diastereomeric mixture of racemic threo- and 
erythro-β-lactams.  In turn, recrystallization from Et2O provided diastereomerically pure 
racemic threo-β-lactam (±)-5.20 as the major product in moderate yield (53% yield from 
5.19).  threo-β-Lactam (±)-5.20 was then converted to (±)-threo-4-nitromethylphenidate 
((±)-4.39) in quantitative yield by ring-opening with methanol under acidic conditions. 
It should be noted that the synthesis of racemic threo-4-nitro-methylphenidate 
((±)-4.39) via Scheme 5.9 definitively sets the position of the nitro functional group via 
starting keto-ester 5.16.  In turn, nitro reduction of racemic threo-4-nitro-methylphenidate 
yielded aniline (±)-4.36 in moderate yield (61%), followed by subsequent iodination and 
azidization using previously reported procedures (Zou et al., 2001) provided target probe 
(±)-4.35.  All (±)-threo-methylphenidate analogs via this synthetic methodology were 
determined to be ≥95% diastereomerically pure by 1H NMR upon comparison to the 
known data for enantiomerically pure threo- and erythro-methylphenidates and their 
aromatic ring-substituted derivatives (Thai et al., 1998).  This particular synthetic 
strategy also provided aniline intermediate (±)-4.36 as a valuable synthetic precursor to a 
radio-iodinated version of target probe (±)-4.35 synthesized via a collaborator of the 
Lapinsky group, Dr. John Lever (University of Missouri-Columbia; see Appendix, 
Section A.1). 
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Scheme 5.9.  Synthesis of racemic threo-4-azido-3-iodo-methylphenidate as a compact DAT photoprobe 
by applying methodology previously developed by Axten et al., 1998 and Gutman et al., 2004.   
5.2.  Synthesis of Citalopram-Based Photoprobes Suitable for Serotonin 
Transporter Structure-Function Studies 
As previously discussed in Section 4.7, a series of SSRI-based photoprobes was 
desired in order to map the binding sites and poses of these clinically relevant drugs 
within their major target protein, the serotonin transporter (SERT).  In particular, this 
dissertation focused on the well-known SSRI (±)-citalopram ((±)-1.11, Celexa) and its 
eutomer, escitalopram ((S)-1.11), as the enantiomers of citalopram are proposed to 
interact at unique binding sites within the serotonin transporter (Chen et al., 2005).  
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Additionally, previous SAR studies of citalopram analogs (e.g., Banala et al., 2013; 
Kumar et al., 2014) indicate a number of structural positions or features that lead to high 
SERT binding affinities, thus potentially aiding in rational photoprobe design from a 
ligand-based perspective. 
5.2.1.  Synthesis of Racemic and (S)-Citalopram-Based Photoprobes for Serotonin 
Transporter Structure-Function Studies That Contain a Clickable Benzophenone-
Terminal Alkyne Labeling Motif 
As previously discussed in Section 4.7.1, photoprobe (±)-4.44 was rationally 
designed based on the success of a previous photoprobe containing an identical 
benzophenone-terminal alkyne labeling motif and established SAR for 5-substituted 
analogs of (±)-citalopram.  In particular, the synthesis of target (±)-citalopram-based 
photoprobe (±)-4.44 was envisioned via coupling of amino citalopram analog (±)-5.21 
(Banala et al., 2013) with benzophenone carboxylic acid 5.22 (Van Scherpenzeel et al., 
2009) (Scheme 5.10). 
 
Scheme 5.10.  Proposed retrosynthesis of a citalopram-based SERT photoprobe containing a benzophenone 
photoreactive group and a terminal alkyne click chemistry handle. 
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Using a previously described literature procedure (Van Scherpenzeel et al., 2009), 
initial synthetic attempts towards obtaining carboxylic acid 5.22 began with 
propargylation of phenol (Scheme 5.11).  However, this previously described work 
proved troublesome, as attempted Friedel-Crafts acylation of propargyl ether 5.24 with 
terepthaloylchloride (5.25) resulted in an inseparable mixture of desired benzophenone-
alkyne carboxylic acid 5.22 and terepthalic acid (5.26) (based on 1H NMR) as an 
impurity. 
 
Scheme 5.11.  Attempted synthesis of benzophenone-alkyne carboxylic acid 5.22 according to Van 
Scherpenzeel et al., 2009. 
In order to avoid terepthalic acid (5.26) as an inseparable, undesired impurity as 
previously noted, the synthesis towards benzophenone-alkyne carboxylic acid 5.22 was 
subsequently modified (Scheme 5.12).  In this regard, the propargyl ether of phenol 
(5.24) was subjected to Friedel-Crafts acylation reaction with commercially available 
acid chloride 5.27 to generate a mixture of benzophenone positional isomers 5.28 and 
5.29.  The desired para-substituted compound 5.28 was isolated via column 
chromatography in low yield (27%).  Finally, ester 5.28 could be hydrolyzed to generate 
benzophenone-alkyne carboxylic acid 5.22 in quantitative yield. 
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Scheme 5.12.  Small-scale synthesis of benzophenone-alkyne carboxylic acid 5.22 via Friedel-Crafts 
acylation of 4-(methoxycarbonyl)benzoyl chloride.   
It should be noted that the chemistry depicted in Scheme 5.12 was not particularly 
useful for generating large quantities of desired carboxylic acid 5.22, principally due to  
difficulty separating 5.28 from positional isomer 5.29.  As a result, a previously reported 
synthetic protocol (Bandyopadhyay and Bong, 2011) was slightly modified in order to 
synthesize benzophenone-alkyne carboxylic acid 5.22 large quantities (Scheme 5.13).  
This synthesis began with Friedel-Crafts acylation of anisole using mono-
methylterepthalate (5.30) and methanesulfonic anhydride in order to obtain 72 % yield of 
benzophenone 5.32 (Wilkinson, 2011), which could easily be isolated from any positional 
isomers formed via filtration.  Benzophenone 5.32 was then demethylated and 
propargylated to obtain methyl ester 5.28 in 87% yield over two steps.  Subsequently, 
carboxylic acid 5.22 was accessed in quantitative yield by ester hydrolysis using lithium 
hydroxide. 
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Scheme 5.13.  Large-scale synthesis of benzophenone-alkyne carboxylic acid 5.22 starting from anisole.  
With benzophenone-alkyne carboxylic acid 5.22 in hand, attention was turned to 
generating 5.21 as the desired primary amine coupling partner needed for synthesis of 
(±)-citalopram-based photoprobe (±)-4.44 (Scheme 5.14).  Initially, the nitrile functional 
group of (±)-citalopram was reduced using lithium aluminium hydride to provide primary 
amine (±)-5.21 in 98% yield (Banala et al., 2013).  This amine was then coupled with 
carboxylic acid 5.22 using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 
hydroxybenzotriazole (HOBT) to provide target citalopram-based photoprobe (±)-4.44 in 
moderate yield (63%). 
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Scheme 5.14.  Synthesis of a (±)-citalopram-based photoprobe containing a benzophenone as a 
photoreactive functional group and a terminal alkyne as a click chemistry handle.   
In turn, (S)-citalopram-based photoprobe (S)-4.44, which contains the same 
benzophenone-alkyne labeling motif as found in the racemic version (i.e., (±)-4.44), was 
synthesized in a similar manner (Scheme 5.15).  Initially, (S)-citalopram was subjected to 
nitrile reduction in order to obtain enantiomerically pure amine (S)-5.21 (Kumar et al., 
2014).  Subsequent EDC and HOBT coupling of enantiomerically pure amine (S)-5.21 
with carboxylic acid 5.22 provided target photoprobe (S)-4.44 in good yield (80%). 
 
Scheme 5.15.  Synthesis of an escitalopram-based photoprobe containing a benzophenone as a 
photoreactive functional group and a terminal alkyne as a click chemistry handle.   
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Attention was next turned to escitalopram N-substituted benzophenone-alkyne 
clickable photoprobe (S)-4.47 in order systematically map the (S)-citalopram binding site 
within SERT via BEProFL.  The rational design of target probe (S)-4.47 was previously 
described in Section 4.7.1.  In particular, initial methodology for the synthesis target 
probe (S)-4.47 was established by successful synthesis of escitalopram N-substituted 
benzophenone analog (S)-4.46 (Scheme 5.16).  In this regard, N-desmethylation of 
escitalopram was initially carried out according to a previously established protocol (Jin 
et al., 2007) to generate (S)-desmethylcitalopram ((S)-5.33).  In brief, escitalopram was 
treated with 1-chloroethylchloroformate to generate a carbamate, which was further 
subjected to methanolysis to obtain (S)-desmethylcitalopram ((S)-5.33) in 30 % yield 
over three steps.  In particular, the methanolysis also hydrolysed a small amount of the 
nitrile functional group to a methyl ester, which was separated by converting this ester 
into a carboxylate salt by treatment with sodium hydroxide.  Subsequent N-alkylation 
(conditions adapted from Moore et al., 2005) of (S)-desmethylcitalopram with 
commercially available benzylbromide 5.34 gave escitalopram analog (S)-4.46 in 
moderate yield (59%). 
 
Scheme 5.16.  Synthesis of a N-substituted escitalopram analog containing a benzophenone photoreactive 
group.   
Towards synthesizing a N-substituted escitalopram-based benzophenone-alkyne 
clickable SERT photoprobe via this N-alkylation methodology, mesylate 5.38 was 
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desired and pursued as a proposed key synthetic building block (Scheme 5.17). In this 
regard, the ketone functional group in previously synthesized benzophenone alkyne 5.28 
(see Scheme 5.13) was initially protected as a ketal using ethylene glycol, 1,2-
bis(trimethylsiloxy)ethane, and a catalytic amount of p-toluenesulfonic acid (conditions 
adapted from Lippert et al., 2009).  The ester within benzophenone alkyne 5.35 was then 
reduced to benzyl alcohol 5.36 using lithium aluminum hydride.  The ketal was 
subsequently converted back to the ketone under acidic hydrolysis conditions to provide 
benzophenone 5.37 in moderate yield (67%).  Finally, the benzyl alcohol was converted 
into a mesylate leaving group (conditions adapted from Oyelere et al., 2009). 
 
Scheme 5.17.  Synthesis of a benzophenone-alkyne mesylate required for the synthesis of a N-substituted 
(S)-citalopram-based photoprobe.   
 With benzophenone-alkyne mesylate 5.38 in hand, the synthesis of N-substituted 
benzophenone-alkyne clickable SERT photoprobe (S)-4.47 was achieved analogous to 
methodology previously described in Scheme 5.16 for the synthesis of escitalopram 
benzophenone analog (S)-4.46.  In particular, N-alkylation of (S)-desmethylcitalopram 
(synthesized as described in Scheme 5.16) with benzophenone mesylate 5.38 provided 
target probe (S)-4.47 in relatively low yield (31%) (Scheme 5.18). 
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Scheme 5.18.  Synthesis of a N-substituted escitalopram-based benzophenone-alkyne clickable photoprobe 
for SERT structure-function studies.   
5.2.2.  Synthesis of a Diazido-Based Escitalopram Analog as a Potential Photoprobe 
for Serotonin Transporter Structure-Function Studies 
As previously discussed in Section 4.7.2, target photoprobe (S)-4.50 was 
rationally designed based on the success of a well-known aryl diazido photoaffinity 
labeling motif and well-established citalopram SAR indicating a wide variety of 5-
substituted escitalopram analogs retain high SERT binding affinity.  In particular, 
synthesis of escitalopram-based diazide photoprobe (S)-4.50 was envisioned by coupling 
previously described amino citalopram analog (S)-5.21 with 3-azido-5-
(azidomethyl)benzoic acid (5.39) (Scheme 5.19). 
 
Scheme 5.19.  Proposed retrosynthesis of an escitalopram-based diazido clickable photoprobe for SERT 
structure-function studies.   
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With this retrosynthesis in mind, the synthesis of 3-azido-5-(azidomethyl)benzoic 
acid (5.39) was pursued according to that previously described (Neelarapu et al., 2011) 
(Scheme 5.20).  This synthesis was initiated from a commercially available dimethyl-5-
amino-isophthalate (5.40), which was subjected to mono-reduction using lithium 
borohydride to provide amino ester 5.41 in 53% yield.  Aniline 5.41 was then converted 
to the azide 5.42 using t-BuONO and TMS-N3.  Next, the one step conversion of benzyl 
alcohol 5.43 to the corresponding aliphatic azide was performed using bis(2,4-
dichlorophenyl)chlorophosphate, DMAP, and NaN3.  Subsequent hydrolysis of ester 5.43 
under basic conditions then provided diazido-acid 5.39 in near quantitative yield. 
 
Scheme 5.20.  Synthesis of 3-azido-5-(azidomethyl)benzoic acid as a key building block for generating an 
escitalopram-based diazido SERT photoprobe.  
With diazido carboxylic acid 5.43 in hand, coupling with 5-aminomethyl 
substituted (S)-citalopram ((S)-5.21) (see Scheme 5.14 for synthesis) was performed 
using EDC and HOBT to provide target photoprobe (S)-4.50 in 75% yield (Scheme 5.21). 
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Scheme 5.21.  Synthesis of an escitalopram-based diazido photoprobe for SERT structure-function studies.   
5.2.3.  Synthesis of an Escitalopram-Based Photoaffinity Ligand for Serotonin 
Transporter Structure-Function Studies Containing the Traditional 4-Azido-3-Iodo 
Photoaffinity Labeling Motif  
 
Scheme 5.22.  Proposed retrosynthesis of an escitalopram-based photoprobe containing a traditional 4-
azido-3-iodo photoaffinity labeling motif.   
As previously discussed in Section 4.7.3, target photoprobe (S)-4.51 was 
rationally designed based on previously established citalopram SAR with respect to 
SERT and a number of successful DAT structure-function studies employing 
photoprobes that contain a traditional 4-azido-3-iodo photoaffinity labeling motif.  In 
particular, synthesis of target (S)-citalopram-based photoprobe (S)-4.51 containing the 
traditional 4-azido-3-iodo photoaffinity labeling motif was envisioned by coupling amino 
 158 
escitalopram analog (S)-5.21 with 4-azido-3-iodobenzoic acid (5.44) (Scheme 5.22).  
With this retrosynthesis in mind, synthesis of 4-azido-3-iodobenzoic acid (5.44) was 
pursued according to that previously described in the chemical literature (Shu et al., 
1996) (Scheme 5.23).  In particular, monoiodination of commercially available methyl 4-
aminobenzoate (5.45) using N-iodosuccinimide provided iodoester 5.46 in 67 % yield.  
Subsequent conversion of aniline 5.46 to the diazonium salt followed by displacement 
with NaN3 provided azide 5.47 in 40% yield.  Final hydrolysis of ester 5.47 under basic 
conditions provided 4-azido-3-iodobenzoic acid (5.44) in near quantitative yield. 
 
Scheme 5.23.  Synthesis of 4-azido-3-iodobenzoic acid as a key building block for synthesizing an 
escitalopram-based azido-iodo SERT photoprobe.   
Analogous to methodology previously described for the synthesis of amide-
containing citalopram analogs, 5-aminomethyl substituted (S)-citalopram ((S)-5.21) was 
coupled with 4-azido-3-iodobenzoic acid (5.44) using EDC and HOBT to give target 
photoprobe (S)-4.51 in 67% yield (Scheme 5.24).  In particular, photoprobe (S)-4.51 
retained high SERT binding affinity (Ki = 3.45 ± 2.04 nM) when compared to 
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escitalopram (Ki = 1.77 ± 1.14 nM) as a lead compound, thus justifying further 
development of this probe into a radioiodinated version for SERT photoaffinity labeling 
experiments.  In this regard, tri-n-butyl stannyl analog (S)-5.48 was synthesized as a 
precursor to (S)-[125I]-4.51.  Specifically, azido-iodo photoprobe (S)-4.51 was subjected 
to Pd-catalyzed Stille coupling with bis(tributyltin) to provide tri-n-butyl stannyl 
derivative (S)-5.48 in 52% yield.  Dr. John Lever (University of Missouri-Columbia) then 
synthesized (S)-[125I]-4.51 via a radio-iodo destannylation protocol (see Appendix, 
Section A.2). 
 
Scheme 5.24.  Synthesis of escitalopram-based azido-iodo photoprobe (S)-[125I]-4.51 for SERT structure-
function studies.   
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5.3.  Development of a Protocol for Serotonin Transporter Tandem Photoaffinity 
Labeling-Bioorthogonal Conjugation Using Citalopram-Based Clickable 
Photoprobes 
As previously discussed in Section 4.7, a strategy towards potentially 
understanding the 3D structural features of SERT is expected to be achieved by 
developing and applying citalopram-based SSRI photoprobes in a BEProFL experimental 
approach.  Specifically, application of the BEProFL approach to SERT is proposed to 
feature rational coupling of proteomic results from photoaffinity labeling of SERT with 
SSRI-based photoprobes and SERT computational homology modeling, towards the goal 
of mapping the binding sites and poses of SSRIs within their major drug target (i.e., 
SERT).  In particular, this experimental approach is expected to validate and refine 
current SERT computational homology models for future drug discovery and 
development. 
Therefore, in order to practically pursue the BEProFL experimental approach with 
respect to SERT, (±)-citalopram and (S)-citalopram as SSRIs were functionalized with a 
photoreactive group (PRG) (i.e., a benzophenone or an aryl azide) and a reporter group 
(RG) (i.e., a terminal alkyne or an aliphatic azide as click chemistry handles, or 125I) as 
previously described in this dissertation.  In turn, the next research goal of this 
dissertation was to develop a practical protocol for SERT tandem photoaffinity labeling-
bioorthogonal conjugation by employing clickable high affinity citalopram-based 
photoprobes. 
 161 
5.3.1.  Initial Attempts of SERT Tandem Photoaffinity Labeling-Bioorthogonal 
Conjugation Using a Racemic Citalopram-Based Photoprobe Containing a 
Benzophenone-Alkyne Structural Motif 
As previously described in Section 5.2.1, 5-substituted citalopram-based 
benzophenone alkyne photoprobe (±)-4.44 was synthesized as part of this research 
dissertation for BEProFL purposes.  Given citalopram-based photoprobe (±)-4.44 
displayed very high SERT binding affinity (Ki = 4.3 ± 3.5 nM) comparable to that of (±)-
citalopram (Ki = 4.4 ± 1.3 nM), this compound was identified as a suitable candidate 
photoprobe for attempted SERT tandem photoaffinity labeling-bioorthogonal 
conjugation. 
Initially, a protocol developed in Dr. Michael Cascio’s lab (Duquesne University) 
was attempted to try and photolabel hSERT overexpressed in T-Rex 293 (HEK293) cells 
(Takayama and Sugio, 2011) (Scheme 5.25).  Briefly, T-Rex 293 cells in phosphate 
buffer (25 mM potassium phosphate buffer, anti-proteolytic cocktail) were lysed using a 
dounce homogenizer (3 x 15 strokes at 4˚C) and ultra-centrifuged (100,000g, 45 min) to 
obtain the membrane fraction.  This process was repeated twice in order to make sure all 
cells were lysed.  The membrane fraction was then dispersed in phosphate buffer (25 mM 
potassium phosphate buffer), to which (±)-citalopram photoprobe (±)-4.44, dissolved in 
DMSO (concentration: 500 µM), was added.  The mixture was then transferred to quartz 
cuvettes and exposed to UV light (350-450 nm) for 20 minutes (2 X 10 minutes on ice) 
with 5 minutes cooling in between.  Following this covalent ligation step, the mixture 
was ultra-centrifuged to remove any excess probe that was not covalently labeled to the 
proteome using phosphate buffer.  Later, the membrane fraction was dispersed in 
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phosphate saline buffer (PBS) and reacted with biotin azide in the presence of CuSO4 and 
TCEP as a click chemistry reaction.  Excess click reagents were then removed via 
ultracentrifugation and the membrane fraction was solubilized in 50 mM Tris containing 
0.1% Triton.  Samples were then subsequently analyzed using a Western blot to detect 
biotinylated proteins via streptavidin IR dye (Figure 5.1).  Additionally, the solubilized 
membrane fraction was also subjected to avidin column chromatography in an attempt to 
purify biotinylated proteins.  Proteins on the avidin resin were digested using trypsin and 
the eluents were treated with C-18 ziptips for mass spectrometry sample preparation.  In 
particular, mass spectrometry data indicated that there were polymers peaks, and as a 
result for subsequent experiments, trypsin digestion on avidin beads was avoided.  
Instead, mass spectrometry samples were prepared by excising bands from an SDS-
PAGE gel and trypsin was used to digest the protein in the gel. 
 
Scheme 5.25.  Initial attempt of SERT tandem photoaffinity labeling-bioorthogonal conjugation using (±)-
citalopram based photoprobe (±)-4.44.   
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As described, samples from Scheme 5.25 were analyzed by Western blot to detect 
biotinylated proteins via a streptavidin IR dye (Figure 5.1).  Although a biotinylated 
protein band was detected in lane 1 (hSERT labeled with photoprobe (±)-4.44 and click 
reacted with biotin azide), unfortunately this band did not match the molecular weight of 
hSERT (70 kDa).  In particular, it was assumed that hSERT was present as its oligomer 
(i.e., a higher molecular weight band) instead of the monomer.  This higher molecular 
weight band was subsequently excised in order to generate samples for mass 
spectrometry analysis. 
 
Figure 5.1.  Initial results of attempted SERT tandem photoaffinity labeling-bioorthogonal conjugation 
using (±)-citalopram based photoprobe (±)-4.44.  These results indicate that the T-Rex cells used in the 
experiment express endogenously biotinylated proteins. 
 Careful observation from these experiments indicated that the negative 
control lane (i.e., lane 2; hSERT membrane without any photolabeling) showed some 
biotinylated proteins.  This prompted subsequent utilization of an hSERT antibody for 
simultaneous detection of hSERT (i.e., in addition to potential probe-labeled proteins) in 
future Western blots, such that other endogenously biotinylated proteins were not excised 
for mass spectrometry analysis. 
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5.3.2.  Attempted Adaptation of a Protocol Used for DAT Photoaffinity Labeling 
Experiments to SERT Tandem Photoaffinity Labeling-Bioorthogonal Conjugation  
Since multiple attempts using the protocol described in Scheme 5.25 did not lead 
to successful photoaffinity labeling or detection of hSERT via Western blot, the next 
strategy attempted was to adapt a protocol that gave successful results in DAT 
photoaffinity labeling using (±)-4-azido-3-iodo-methylphenidate ((±)-4.35; Lapinsky, et 
al., 2012) as a photoprobe (Scheme 5.26). 
For this experimental protocol, the media was initially removed from the HEK-
293 cells and the cells were subsequently washed with Krebs Ringer HEPES (KRH) 
buffer.  Citalopram photoprobe (±)-4.44 was then added to the cells in KRH buffer at two 
different concentrations (experiment 1a = 10 nM of photoprobe (±)-4.44; experiment 2a = 
100 nM of photoprobe (±)-4.44).  Competition experiments were also performed using 
escitalopram at a high concentration (1 µM) in the presence of photoprobe (±)-4.44 
(experiment 1b = 10 nM of photoprobe (±)-4.44 + 1 µM escitalopram as a competitor; 
experiment 2b = 100 nM of photoprobe (±)-4.44 + 1 µM escitalopram as a competitor).  
After incubating on ice for 1 hour, the six-well plate containing the HEK-293 cells was 
exposed to UV light (350-450 nm for 5 minutes).  The KRH buffer with the probe was 
subsequently discarded and the cells were washed with KRH buffer.  The cells were then 
collected in a microcentrifuge tube and lysed with RIPA buffer along with an anti-
proteolytic cocktail.  Specifically, the cell lysate was centrifuged at 14,000g for 15 
minutes and the supernatant was transferred to a fresh microcentrifuge tube.  The 
procedure was then modified as follows from the known DAT photoaffinity labeling 
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protocol, as photoprobe (±)-4.44 contains a terminal alkyne instead of 125I as a reporter 
group. 
Specifically, the cell lysates were subjected to click chemistry reaction conditions 
by adding biotin azide, TBTA (tris[91-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine), 
CuSO4, and TCEP (tris(2-carboxyethy)phosphine hydrochloride) (Weerapana et al., 
2007).  After click chemistry, excess click chemistry reagents were removed by adding 
trichloroacetone/acetone (1:1) to the aforementioned reaction mixture followed by 
centrifuge for 5 min at 10,000g at 4˚C to pellet the protein (Koopmans et al., 2012).  The 
resulting protein pellet was then solubilized in 50 mM Tris containing 0.1% Triton for 
analysis. 
 
Scheme 5.26.  Attempted adaptation of a known protocol from DAT photoaffinity labeling for attempted 
SERT tandem photoaffinity labeling-bioorthogonal conjugation using (±)-citalopram based photoprobe (±)-
4.44.   
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Final samples from the experimental protocol highlighted in Scheme 5.26 were 
analyzed using Western blot to detect biotinylated proteins via a streptavidin IR dye 
(Figure 5.2).  In particular, the Western blot indicated multiple bands of biotinylated 
proteins, and since these bands did not disappear with excess cold escitalopram present as 
a photoaffinity labeling competitor (i.e., lanes 1b and 2b), these experimental results 
appear to indicate non-specific protein labeling.  However, these results are not 
definitively conclusive, as an alternative possibility is that the whole cell lysate may 
contain a significant number endogenously biotinylated proteins.  Simultaneously, similar 
experiments were carried out in other wells of the six-well plate using citalopram 
photoprobe (S)-4.44; however, similar results were obtained compared to that of the 
racemic version of the citalopram photoprobe. 
 
Figure 5.2.  Potential results of non-specific labeling from attempted SERT tandem photoaffinity labeling-
bioorthogonal conjugation using (±)-citalopram based photoprobe (±)-4.44.   
In order to rule out the possibility of non-specific protein labeling, the protocol 
described in Scheme 5.26 was subsequently modified to incorporate a washing step prior 
to exposing the cells to UV light (lanes 1a and 1b, Figure 5.3).  The rationale behind this 
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experimental modification was to keep only reversibly-bound probe in the binding pocket 
of SERT to be available for photoaffinity labeling, wherein washing away any excess 
photoprobe would be expected to reduce the likelihood of non-specific protein labeling.  
Appropriate control experiments were also performed by washing the cells after UV light 
exposure (lanes 2a and 2b, Figure 5.3).  Unfortunately, the Western blot indicated that 
this attempted variation in experimental conditions did not result in any significant 
difference in terms of improved photoaffinity labeling (Figure 5.3).  
 
Figure 5.3.  Results of attempted SERT tandem photoaffinity labeling-bioorthogonal conjugation using 
(±)-citalopram based photoprobe (±)-4.44.  Results appear to indicate that the whole cell lysate contains 
numerous biotinylated proteins.  
By comparing the bands detected by hSERT antibody (i.e., detecting hSERT) to 
the bands detected by streptavidin IR dye (i.e., detecting biotin) and previous results, it 
was concluded that the whole cell lysate has a significant amount of endogenously 
biotinylated proteins versus the membrane fraction alone.  Even experiments utilizing 
citalopram photoprobe (S)-4.44 indicated either non-specific protein labeling, or that 
photolabeled biotinylated protein would be very difficult to isolate from other 
endogenously biotinylated proteins present in the whole cell lysate.  As a result, 
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subsequent photoaffinity labeling experiments from this point forward were modified to 
collect just the membrane fraction of lysed cells, instead of generating a whole cell lysate. 
5.3.3.  Adaptation of an Activity-Based Protein Profiling / Click Chemistry Protocol 
for Attempted SERT Tandem Photoaffinity Labeling-Bioorthogonal Conjugation 
After learning that the whole cell lysate might contain numerous biotinylated 
proteins that could confound data interpretation, an experimental protocol outlined in 
Scheme 5.7 was subsequently implemented.  This particular experimental protocol is 
based on well-established protocols developed for activity-based protein profiling and 
click chemistry for mass spectrometry analysis (Speers and Cravatt, 2009). 
Specifically for this protocol, cells were initially grown to 90% confluency in a 
six well plate, washed with KRH buffer before photoaffinity labeling, followed by 
addition of fresh KRH buffer.  To these cells, citalopram photoprobe (S)-4.44 was added 
yielding a final concentration of 500 nM, and for competition experiments, (S)-
citalopram was added to give a concentration of 10 µM.  The cells were then incubated 
on ice for 1 hour and subjected to UV light (350-450 nm for 1 hour on ice) (Tantama et 
al., 2008).  After photoaffinity labeling, the cells were then washed to remove excess 
probe, lysed, and then ultra-centrifuged in order to obtain the membrane fraction.  The 
membrane fraction was then subsequently dissolved in PBS buffer containing 0.1% 
Triton X-100 in order to carry out the click chemistry reaction with biotin azide 
(Weerapana et al., 2007).  In particular, the proteome sample was subjected to 
chloroform/methanol protein precipitation conditions in order to remove excess click 
reagents (Speers and Cravatt, 2009). 
 169 
 
Scheme 5.27.  Attempted activity-based protein profiling / click chemistry protocol for SERT tandem 
photoaffinity labeling-bioorthogonal conjugation. 
The protein pellet from Scheme 5.27 in turn was resuspended in PBS with 2.5% 
SDS (sodium dodecyl sulfate) with the aid of heating and sonication, then the proteome 
sample was subjected to a streptavidin enrichment protocol in order to isolate biotinylated 
proteins (Speers and Cravatt, 2009).  Specifically, the eluents from the streptavidin beads 
were analyzed by Western blot in order to detect biotinylated proteins via a streptavidin 
IR dye, and also hSERT antibody for confirmation of hSERT. 
In particular for this experimental protocol, the eluents from the streptavidin resin 
(lanes 1a and 1b, Figure 5.4) did not show any bands corresponding to hSERT.  
Additionally, the bands being detected by hSERT antibody from samples unbound to 
streptavidin resin (lanes 2a and 2b, Figure 5.4) corresponded to a molecular weight below 
50 kDa.  As a result, experimental results from this attempted protocol in turn prompted 
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subsequent use of FLAG epitope within the SERT being used for detection in future 
photoaffinity labeling experiments (Section 5.2.4). 
 
Figure 5.4.  Results from applying an activity-based protein profiling / click chemistry protocol for 
attempted SERT tandem photoaffinity labeling-bioorthogonal conjugation. 
5.3.4.  Single-Step Affinity Chromatography Purification of hSERT Bearing a 
FLAG-Epitope Tag 
It should be noted that the T-Rex (tetracycline inducible) HEK 293 cell line 
expressing hSERT being used for this part of the dissertation was developed using a 
synthetic human SERT gene produced by a PCR-based self-assembly method (Takayama 
and Sugio, 2011).  Specifically, the synthetic DNA sequence corresponding to the human 
SERT gene was modified to include a FLAG-epitope tag, followed by two glycine spacer 
linkers, and a Tobacco Etch Virus (TEV) protease cleavage site just prior to the N-
terminus of SERT (Figure 5.5).  Subsequent overexpression of this modified hSERT was 
achieved by transfecting the expression vector pCDNA4TO-FLAG-gg-TEV-SERT into 
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the T-Rex HEK 293 cell line, followed by purification using anti-FLAG M2 antibody 
beads. 
 
Figure 5.5.  Topologocal representation of SERT indicating the FLAG-epitope tag and TEV protease 
cleavage site attached to the N-terminus (Takayama and Sugio, 2011.  Adapted with permission from 
Protein Expression and Purification 2011, 76, 211-220.  Copyright 2010, Elsevier). 
Specifically, T-Rex HEK 293 cells were lysed and ultra-centrifuged to obtain the 
membrane fraction, followed by solubilizing this membrane fraction in a solubilization 
buffer containing 1% digitonin detergent.  This solution was then absorbed onto anti-
FLAG affinity beads in a batch mode.  The beads were subsequently washed with a wash 
buffer then eluted with an elution buffer (i.e., wash buffer containing 3X FLAG peptide).  
As a positive control experiment to detect a known protein bearing a FLAG epitope, a 
solubilizing buffer solution of commercially available FLAG-fusion protein of E. coli 
bacterial alkaline phosphatase (BAP) was used, which bears a molecular weight of 49.1 
kDa.  For a negative control experiment, solubilizing buffer was used as is. 
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Specifically, eluents from the affinity beads were analyzed using Western blot to 
detect FLAG-fused proteins via an anti-FLAG antibody (Figure 5.6, C).  In particular, 
results depicted in part C of Figure 5.6 indicate that this single-step affinity purification 
protocol proved successful for purifying the modified hSERT from the T-Rex HEK 293 
cells.  Additionally, all fractions from this purification protocol, including whole cell 
lysate, cytosolic supernatant, crude soluble membrane, cell debris, solubilized membrane, 
material unbound to anti-FLAG beads, washes of the beads, and elution of the beads, 
were analyzed using coommassie blue staining (Figure 5.6, A) and Western blot for 
detecting FLAG peptides (Figure 5.6, B). 
 
Figure 5.6.  Single-step affinity chromatography purification of hSERT bearing a FLAG-epitope tag via 
anti-FLAG M2 antibody beads.  (A) Proteins detected via coommassie staining; (B) Western blot detection 
of proteins bearing a FLAG epitope using an anti-FLAG antibody; (C) Western blot detection of control 
experiments using an anti-FLAG antibody. 
 To conclude, results from this work indicate development of a single-step affinity 
purification protocol that is able to purify hSERT from multiple proteins found in the cell 
lysate (Figure 5.6, A).  After this affinity purification, the concentration of eluted SERT 
protein was found to be 155 µg/mL using a modified Lowry’s assay (see Section 6.2.4).  
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Additionally, it was found that 71% of the SERT protein purified via this protocol was 
fully functional based on [3H]-imipramine radioligand binding experiments. 
5.3.5.  Attempted SERT Tandem Photoaffinity Labeling-Bioorthogonal Conjugation 
Based on an Activity-Based Protein Profiling / Click Chemistry Protocol Involving 
Solubilizing Buffer That Contains Digitonin 
As described in the previous section of this research dissertation, the single-step 
affinity chromatography protocol employed for purification of hSERT confirmed that: 1.) 
hSERT protein expressed in the T-Rex HEK293 cells being used for photoaffinity 
labeling bears a FLAG epitope tag attached to its N-terminus, and 2.) this hSERT protein 
moves as a good monomeric band corresponding to 70 kDa via SDS-PAGE.  As a result, 
the next photoaffinity labeling experiments were modified to incorporate the previously 
mentioned solubilizing buffer into an attempted activity-based protein profiling / click 
chemistry photoaffinity labeling protocol (Scheme 5.28, routes “a” and “b”). 
For this work, a hSERT membrane fraction was initially prepared as previously 
discussed in Section 5.2.1.   For route “a”, enantiomerically pure citalopram photoprobe 
(S)-4.44 was first added to the hSERT membrane fraction dispersed in Tris-buffered 
saline (TBS), incubated for 1 hour, then exposed to UV light for photoaffinity labeling.  
The reaction mixture was then ultracentrifuged to remove excess photoprobe (route “a”, 
Scheme 5.28).  The resultant membrane fraction was then dissolved in the solubilizing 
buffer containing 1% digitonin and subjected to click chemistry reaction with biotin azide 
(Weerapana et al., 2007).  The click reaction was ultimately quenched by adding 5X 
loading dye and the samples were analyzed using Western blot (i.e., anti-FLAG antibody 
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for detecting FLAG-tagged hSERT and Streptavidin IR dye for detecting biotinylated 
proteins) (Figure 5.7). 
As previously mentioned, affinity purified hSERT protein solubilized in 
solubilizing buffer is still fully functional (> 70%) based on [3H]-imipramine radioligand 
binding (Takayama and Sugio, 2011).  As a result, an alternative route was also 
investigated wherein the hSERT membrane fraction was dissolved in solubilizing buffer 
prior to photoaffinity labeling (i.e., route “b”; Scheme 5.28). 
 
Scheme 5.28.  Attempted SERT tandem photoaffinity labeling-bioorthogonal conjugation employing an 
activity-based protein profiling / click chemistry protocol using solubilizing buffer. 
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As indicated in Figure 5.7, results from route “a” and route “b” of Scheme 5.28 
did not indicate any SERT photoaffinity labeling with citalopram photoprobe (S)-4.44 at 
5 µM and 100 µM concentrations.  In particular, the use of solubilizing buffer and the 
anti-FLAG antibody for Western blot did confirm that these samples do contain hSERT; 
however, the SERT present was clearly not being photolabeled by photoprobe (S)-4.44. 
 
Figure 5.7.  Results from attempted SERT tandem photoaffinity labeling-bioorthogonal conjugation using 
solubilizing buffer with 1% digitonin plus (S)-citalopram-based photoprobe (S)-4.44. 
 One possible explanation for these experimental results observed was that 
photoaffinity labeling was not efficient enough to be detected via Western blot.  
Therefore, the next strategy pursued was to attempt photoaffinity labeling of purified 
hSERT protein (i.e., instead of a hSERT membrane fraction), as this would be expected 
to improve the efficiency of detection of probe-labeled protein after photoaffinity 
labeling via Western blot.  Another strategy employed to potentially improve detection of 
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probe-labeled protein after photoaffinity labeling was to utilize an IRDye® 800CW azide 
during the click chemistry reaction instead of biotin azide, as this IRDye would allow 
direct scanning of an SDS-PAGE gel for probe-labeled proteins and avoid relying on 
streptavidin-biotin interactions needed for detection. 
5.3.6.  Successful Tandem Photoaffinity Labeling-Bioorthogonal Conjugation of 
Purified hSERT Using a Clickable (S)-Citalopram-Based Photoprobe 
For this part of the research, hSERT was initially purified in its fully functional 
form (as previously described in Section 5.2.4) and utilized for attempted tandem 
photoaffinity labeling-bioorthogonal conjugation according to a protocol similar that 
described for route “b” in Scheme 5.28.  Initial experiments were tried using racemic 
citalopram photoprobe (±)-4.44 and enantiomerically pure escitalopram photoprobe (S)-
4.44 at various concentrations. 
Briefly, probe (±)-4.44 or (S)-4.44 was added to purified hSERT in a 96 well 
plate, incubated for 1 hour, then exposed to UV light for photoaffinity labeling.  The 
resulting mixture was then subjected to click chemistry reaction with biotin azide 
(Weerapana et al., 2007) and quenched by adding 5X loading dye.  Samples were then 
analyzed using Western blot (i.e., anti-FLAG antibody to detect the FLAG epitope within 
the modified SERT being used and Streptavidin IR dye to detect biotinylated proteins) 
(Figure 5.8). 
In particular, the results from these experiments indicated that lower 
concentrations (50 nM and 500 nM) of the photoprobes (lanes 2 and 3) did not show any 
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photoaffinity labeling, whereas higher concentration (0.2 mM) of the photoprobe (lanes 
4) showed some degradation of protein (Figure 5.8). 
 
Figure 5.8.  Attempted tandem photoaffinity labeling-bioorthogonal conjugation of purified hSERT using 
5-substituted racemic/(S)-citalopram-based benzophenone-alkyne photoprobes.   
Subsequently, intermediate concentrations of enantiomerically pure escitalopram 
photoprobe (S)-4.44 were utilized in attempted SERT photoaffinity labeling.  In 
particular, successful SERT photoaffinity labeling was observed at a concentration of 1 
µM for citalopram photoprobe (S)-4.44, wherein click chemistry was performed with 
biotin azide or IRDye® 800CW azide (Scheme 5.29).  Thus, the optimum concentration 
of citalopram photoprobe (S)-4.44 required for SERT photoaffinity labeling was 
determined to be 1µM. 
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Scheme 5.29.  Tandem photoaffinity labeling-bioorthogonal conjugation of purified hSERT using an 
optimum concentration (1 µM) of (S)-citalopram based photoprobe (S)-4.44.   
Additionally, experiments were carried out to determine the optimum time 
required for UV light exposure during photoaffinity labeling of purified hSERT modified 
with a FLAG epitope.  Specifically, samples were removed from UV light at 10 minute 
time intervals, and it was identified that 20 minutes of UV light exposure was optimum 
for SERT photoaffinity labeling to occur using benzophenone-alkyne photoprobe (S)-
4.44 (Figure 5.9).  These experiments also indicate the specificity of escitalopram 
photoprobe (S)-4.44 for labeling SERT, since SERT photoaffinity labeling by probe (S)-
4.44 was completely blocked by the presence of escitalopram as a competing ligand 
(lanes b, Figure 5.9). 
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Figure 5.9.  Successful tandem photoaffinity labeling-bioorthogonal conjugation of purified hSERT: 
Optimization of time required for UV exposure using 1 µM of (S)-citalopram based photoprobe (S)-4.44. 
As a final effort, photoaffinity labeling was performed for 20 minutes of UV light 
exposure and click chemistry was carried using IR-dye 800CW azide (see Section 6.2.6) 
(Figure 5.10) with respect to the following experiments: 1.) without UV (lane “a”; a 
control experiment to show that UV light is indeed needed to covalently link the 
benzophenone functional group within the citalopram photoprobe to the SERT protein), 
2.) DMSO (lane “b”; no photoprobe is present, only hSERT protein is present), 3.) 1 µM 
of escitalopram photoprobe (S)-4.44 (lane “c”), and 4.) 1 µM of escitalopram photoprobe 
(S)-4.44 in the presence of 100 µM of (S)-citalopram as a competitor (lane d). 
In particular, results from these experiments indicate that escitalopram photoprobe 
(S)-4.44 is photoaffinity labeling SERT only in lane “c” as expected / desired, whereas 
control experiments (i.e., lanes “a” and “b”) show negligible SERT photoaffinity labeling 
by the photoprobe.  Additionally, SERT photoaffinity labeling by escitalopram 
photoprobe (S)-4.44 was also successfully inhibited in lane “d”, due to the presence of 
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100-fold excess of (S)-citalopram as a competitor to displace photoprobe (S)-4.44 from 
photolabeling hSERT. 
Subsequently, the probe-labeled protein bands that were visualized with the aid of 
the IR-dye were excised from the SDS-PAGE gel and subjected to trypsin digestion in 
order to generate samples for mass spectrometry analysis (see Section 6.2.7).  These 
samples are currently in the hands of Dr. Michael Cascio’s laboratory (Duquesne 
University) for mass spectrometric analysis of the generated photoprobe-SERT complex. 
 
Figure 5.10.  Successful tandem photoaffinity labeling-bioorthogonal conjugation of purified hSERT using 
1 µM of (S)-citalopram based photoprobe (S)-4.44 in the presence (lane “d”) or absence (lane “c”) of 100 
µM of (S)-citalopram as a competitor.  Control experiments such as a negative control experiment (i.e., lane 
“b”, DMSO solution of hSERT without probe (S)-4.44 present) and a UV control experiment (i.e., lane “a”, 
1 µM of (S)-citalopram based photoprobe (S)-4.44 in the presence of hSERT, but not exposed to UV light 
conditions for photoaffinity labeling) are also included. 
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5.4.  Summary of the Significance, Innovation, and Research Accomplishments 
Associated With This Dissertation Work  
Despite decades of research, 3D structural details of how the dopamine 
transporter (DAT) and the serotonin transporter (SERT) interact with therapeutically 
relevant drugs, is not well understood.  Specifically, there are fundamental gaps in 
understanding: 1) the mechanism of DAT and SERT inhibitors at the molecular level, 2) 
3D structural details with respect to ligand-binding sites within DAT and SERT, and 3) 
conformational states associated with DAT and SERT.  These prodigious voids, in turn, 
hinder rational structure-based drug discovery efforts for numerous disease states 
associated with DAT and SERT.  As a result, a detailed understanding of the ligand-
binding sites within DAT and SERT is essential for developing new therapeutics to treat 
a host of diseases traditionally associated with these proteins (e.g., drug abuse, anxiety, 
depression, and ADHD). 
The overall aim of this dissertation was to develop irreversible chemical probes 
and chemical proteomic methods in order to understand how the pharmacology profile 
(i.e., binding affinity, potency, selectivity, behavioral phenotype, etc.) of therapeutically 
significant DAT and SERT inhibitors is dictated by their reversible, non-covalent 
interactions with DAT and SERT at the molecular level.  In particular, this aim was 
pursued via rational design and chemical synthesis of photoaffinity ligands based on 
methylphenidate, a well-known ADHD drug and DAT inhibitor, and citalopram, a well-
known antidepressant and SERT inhibitor, in order to map the binding sites and poses of 
these compounds within the DAT or SERT.  Additionally, a chemical proteomics method 
was developed as part of this dissertation for irreversibly labeling hSERT via a tandem 
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photoaffinity labeling-bioorthogonal conjugation experimental approach by employing 
clickable citalopram-based photoprobes. 
One of the long-term research goals of the Lapinsky group is to understand how 
the DAT discriminates abused (e.g., cocaine, amphetamine, cathinones) versus 
therapeutic compounds (e.g., methylphenidate, bupropion) at the molecular level.  With 
this goal in mind, the initial objective of this research dissertation was to continue the 
group’s chemical development of non-tropane-based DAT inhibitor photoaffinity ligands 
in order to map the drug-binding pocket(s) of these compounds within the DAT at the 
molecular level.  Specifically, the rationale for this portion of the dissertation was that 
non-tropane-based DAT inhibitor photoaffinity ligands could serve as complimentary 
probes to known tropane-based (e.g., cocaine, benztropine) DAT inhibitor photoaffinity 
ligands, which have previously proved valuable in several 3D DAT structure-function 
studies. 
In particular, the non-tropane DAT inhibitor methylphenidate was chosen as a 
lead compound for the design of potential DAT photoaffinity ligands by carefully 
considering previous SAR studies in the chemical literature (e.g., Misra et al., 2010).  
Specifically, the hypothesis for this portion of work was that methylphenidate could be 
structurally modified, without significant loss in DAT binding affinity, to contain an aryl 
azide as a photoreactive functional group and an 125I atom as a radiotracer reporter group, 
such that the resulting photoprobes could potentially covalently label DAT via 
photoaffinity labeling.  Synthesized methylphenidate-based photoprobes bearing these 
functionalities were then evaluated for their DAT binding affinity by Dr. Christopher 
Surratt’s laboratory (Duquesne University).  Subsequently, candidate photoprobes (i.e., 
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compounds whose DAT binding affinity was <100 nM and within 10-fold of 
methylphenidate’s DAT binding affinity) were identified for DAT photoaffinity labeling 
experiments performed by Dr. Roxanne Vaughan’s laboratory (University of North 
Dakota). 
It should be noted that within this dissertation, several innovative 
methylphenidate-based DAT photoaffinity ligands were systematically designed in order 
to address experimental shortcomings associated with previously established tropane-
based DAT photoaffinity ligands.  Most notably, essentially all previously established 
tropane-based DAT photoaffinity ligands prior to this dissertation employed a variable 
length methylene linker between the photoreactive functional group and the DAT 
pharmacophore.  As a result, such photoprobes potentially possess an inherent 
disadvantage when trying to optimally model the DAT-photoprobe complex via 
BEProFL or definitively map the amino acids of the DAT inhibitor-binding pocket.  
Additionally, methylphenidate-based DAT photoaffinity ligands are expected to be 
scientifically significant because the binding sites and conformational preferences for 
non-tropane DAT inhibitors (e.g., methylphenidate, bupropion, pyrovalerone) are 
unknown relative to tropane-based DAT inhibitors (e.g., cocaine, benztropine).  With 
these thoughts in mind and as previously described in Section 5.1.3, racemic threo-3-
iodo-4-azido-methylphenidate ((±)-4.35) represents the first successful example of a 
DAT photoaffinity ligand, either tropane- or non-tropane-based, wherein the 
photoreactive azide and iodine tag are placed directly on the DAT inhibitor 
pharmacophore (Lapinsky et al., 2012).  As a result, photoprobe (±)-4.35 is expected to: 
1.) covalently attach to amino acids directly within the methylphenidate-binding site of 
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DAT, and 2.) result in a more conformationally restricted DAT-photoprobe complex 
during 3D hDAT molecular modeling studies, thus representing an important 
contribution to the growing battery of chemical probes for understanding DAT structure 
and function at the molecular level. 
In terms of practical organic synthesis and as previously described in Section 
5.1.1, a novel, efficient large-scale synthesis of racemic threo-3-iodo-methylphenidate 
((±)-4.29) was developed in order to generate a series of racemic threo-N-azidobenzyl-3-
or-4-iodo-methylphenidate photoaffinity ligands ((±)-4.17 to (±)-4.22) as potential 
candidates for DAT structure-function studies.  This novel synthesis of racemic threo-3-
iodo-methylphenidate (Scheme 5.2) utilized four steps and produced the target compound 
in 30% overall yield (Lapinsky et al., 2011).  Additionally and as previously described in 
Section 5.1.3, synthesis of racemic threo-4-nitro-methylphenidate ((±)-4.39) was needed 
towards producing racemic threo-3-iodo-4-azido-methylphenidate ((±)-4.35) as a 
potential DAT photoprobe.  However, initial syntheses of threo-4-nitro-methylphenidate 
((±)-4.39) were problematic wherein global hydrolysis of N-benzoyl threo-4-nitro-
methylphenidate ((±)-3.25) lead to epimerization (Scheme 5.7) and direct nitration of 
racemic threo-ritalinic acid ((±)-5.12) lead to a mixture of positional nitro isomers 
(Scheme 5.8).  Therefore, in order to overcome these problems, a novel, efficient large-
scale synthesis of racemic threo-4-nitro-methylphenidate ((±)-4.39) was developed 
(Scheme 5.9) by employing previously disclosed methodology (Axten et al., 1998; 
Gutman et al., 2004) for the synthesis of methylphenidate analogs via alpha-keto amides 
as starting materials.  
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Another long-term research goal of the Lapinsky group is to understand how 
selective serotonin reuptake inhibitors (SSRIs, well-known clinically significant 
antidepressants) interact with their major target protein (i.e., SERT) at the molecular 
level.  In particular, the SSRI (±)-citalopram, which displays a very unique binding 
profile with respect to the S1 and S2 binding sites of SERT (i.e., (R)-citalopram is 
proposed to bind to the S2 binding site within SERT, whereas the (S)-enantiomer is 
proposed to bind to the S1 binding site of SERT), was chosen as lead compound for 
developing SSRI-based photoprobes.  Therefore, much like the methylphenidate / DAT 
work, photoaffinity ligands based on the enantiomers of citalopram would be expected to 
be important tool compounds for mapping the binding sites and poses of SSRIs within 
SERT via BEProFL and give important structural information regarding the primary 
substrate binding site (S1) and allosteric binding site (S2) within this protein. 
Analogous to the previously mentioned methylphenidate / DAT work, the 
hypothesis for this portion of the dissertation was that racemic and enantiomerically pure 
(S)-citalopram could be derivatized, without significant loss in SERT binding affinity, to 
contain a photoreactive functional group (i.e., an aryl azide or a benzophenone) capable 
of forming a covalent bond to hSERT via photoaffinity labeling and a reporter group (i.e., 
125I, a terminal alkyne, or an aliphatic azide) for application of a BEProFL experimental 
approach with respect to SERT.  In turn, several citalopram-based probes were rationally 
designed based on previously disclosed citalopram-SERT SAR studies.  These 
compounds were then chemically synthesized and pharmacologically evaluated in order 
to identify appropriate candidates for SERT photoaffinity labeling studies.  In particular, 
the SERT binding affinity of synthesized citalopram analogs were pharmacologically 
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determined by the laboratory of Dr. Christopher Surratt (Duquesne University) in order to 
identify candidate photoprobes for SERT photoaffinity labeling experiments performed 
by Dr. Roxanne Vaughan’s lab (North Dakota University; i.e., for 125I probes) or within 
Dr. Michael Cascio’s lab (Duquesne University; i.e., for clickable photoprobes). 
Once again and analogous to the DAT / methylphenidate work, an innovative, 
systematic design of citalopram-based SERT photoaffinity ligands was employed in this 
dissertation towards ultimately determining the exact binding site(s) of citalopram as an 
SSRI within SERT in the future.  This is significant because the binding sites and 
conformational preferences for citalopram, particularly with respect to the enantiomers of 
citalopram and the S1 versus S2 binding sites within SERT, are not well understood.  
Additionally, it should be noted that radioisotopes have been the primary reporter groups 
used in the development of DAT and SERT photoprobes prior to this dissertation.  
However, given the recent development of numerous click chemistry reactions / 
bioorthogonal conjugation methodologies, radioactive tags are no longer needed for the 
detection of probe-labeled proteins after photoaffinity labeling.  Instead, “clickable” 
reporter functional groups, such as aliphatic azides and terminal alkynes, have been 
routinely shown to readily enable click chemistry techniques post photoaffinity labeling 
and are mainstream in current photoprobe development.  Specifically with respect to this 
dissertation, once an irreversible SERT-photoprobe complex is generated via SERT 
photoaffinity labeling and then “clicked” with an appropriate detection or purification 
moiety (e.g., biotin for easy enrichment, isolation, and detection, or fluorophores for 
sensitive detection and imaging applications), the irreversible SERT-photoprobe complex 
can be then purified, proteolyzed, and analyzed by mass spectrometry in order to 
 187 
determine the exact sites of covalent photoprobe ligation to SERT with a reliable level of 
sensitivity. 
Importantly, it must be noted that previous attempts to determine the adduction 
sites of radioisotope-based DAT photoprobes in DAT has relied on labor-intensive 
peptide mapping strategies or the construction of mutant proteins, constraints of which 
limit the utility and resolution of proteomic analysis.  In particular and as described in 
this dissertation, the ability to attach biotin as a purification and detection moiety to a 
photoprobe via click chemistry after SERT photoaffinity labeling is expected to permit 
microlevel analysis of probe-labeled protein fragments when coupled to sequential LC-
MS/MS.  In this regard and as previously described in Section 5.2, 5-substituted 
benzophenone-alkyne (±)-citalopram analog (±)-4.44, 5-substituted benzophenone-
alkyne (S)-citalopram analog (S)-4.44, N-substituted benzophenone-alkyne (S)-citalopram 
analog (S)-4.47, and 5-substituted diazido (S)-citalopram analog (S)-4.50 represent the 
first clickable photoaffinity ligands for SERT structure-function studies, thus representing 
an important contribution towards understanding the binding site(s) and pose(s) of SSRIs 
as clinically important antidepressants by coupling future SERT photoaffinity labeling 
experiments with SERT molecular modeling studies.  Additionally, 5-substituted azido-
iodo (S)-citalopram-based photoprobe (S)-4.51 was also synthesized as part of this 
dissertation and evaluated for SERT binding affinity by Dr. Christopher Surratt’s 
laboratory.  Subsequently, photoprobe (S)-4.51 was also synthesized in its 125I form by 
Dr. John Lever (University of Missouri) and preliminary irreversible SERT photoaffinity 
labeling experiments were performed by Dr. Roxanne Vaughan’s laboratory (University 
of North Dakota). 
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The final aim of this dissertation was to examine whether 5-substituted 
benzophenone-alkyne (S)-citalopram analog (S)-4.44 could be successfully employed in a 
SERT tandem photoaffinity labeling-bioorthogonal conjugation experiment.  As 
discussed in Section 5.3 and after numerous attempts, a successful tandem photoaffinity 
labeling-bioorthogonal conjugation protocol was ultimately developed using purified 
hSERT protein and (S)-citalopram-based clickable photoprobe (S)-4.44 (Scheme 5.30).  
In this regard, this represents the first time tandem photoaffinity labeling-bioorthogonal 
conjugation techniques have ever been successfully applied to the monoamine transporter 
field, thus representing a significant advance versus previously mentioned photoaffinity 
labeling experiments involving radioactive DAT or SERT photoprobes. 
 
Scheme 5.30.  Tandem photoaffinity labeling-bioorthogonal conjugation of hSERT via citalopram (CIT)-
based photoprobes. 
To conclude, the chemical development of DAT and SERT compounds to date 
has been limited to a ligand-based perspective.  However, the photoaffinity ligands and 
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biochemical proteomic experiments described in this dissertation are expected to: 1.) 
facilitate transition of the DAT and SERT fields towards a rational, structure-based 
perspective, and 2.) experimentally validate and further refine current DAT and SERT 
homology models for improved virtual screening drug discovery efforts.  As a result of 
these expectations, the chemical probes described in this dissertation arguably represent 
very valuable compounds towards developing improved therapeutics for numerous DAT- 
and SERT-implicated diseases. 
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5.5.  Summary of Final Compounds Synthesized During This Dissertation 
Table 5.1.  Final compounds synthesized during this dissertation. 
Compound Name Novel/ 
Known 
(±)-threo-3-Iodo-MP hydrochloride ((±)-4.29) Novel 
(±)-threo-N-(p-Azido-benzyl)-3-iodo-MP ((±)-4.22)  Novel 
(±)-threo-4-Nitro-MP hydrochloride ((±)-4.39)  Known 
(±)-threo-4-Amino-MP ((±)-4.36) Novel 
(±)-threo-4-Amino-3-iodo-MP ((±)-4.40) Novel 
(±)-threo-4-Azido-3-iodo-MP ((±)-4.35) Novel 
(±)-threo-4-Azido-MP ((±)-4.41) Novel 
(±)-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-
dihydroisobenzofuran-5-yl)methyl)-4-(4-(prop-2-yn-1-
yloxy)benzoyl)benzamide ((±)-4.44) 
Novel 
(S)-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-
dihydroisobenzofuran-5-yl)methyl)-4-(4-(prop-2-yn-1-
yloxy)benzoyl)benzamide ((S)-4.44) 
Novel 
(S)-1-(3-((4-benzoylbenzyl)(methyl)amino)propyl)-1-(4-
fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile ((S)-4.46) 
Novel 
(S)-1-(4-fluorophenyl)-1-(3-(methyl(4-(4-(prop-2-yn-1-
yloxy)benzoyl)benzyl)amino)propyl)-1,3-dihydroisobenzofuran-5-
carbonitrile ((S)-4.47) 
Novel 
(S)-3-azido-5-(azidomethyl)-N-((1-(3-(dimethylamino)propyl)-1-
(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)methyl)benzamide 
((S)-4.50) 
Novel 
(S)-4-azido-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-
1,3-dihydroisobenzofuran-5-yl)methyl)-3-iodobenzamide ((S)-4.51) 
Novel 
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CHAPTER SIX 
6.  Experimental 
6.1.  Synthesis 
Reaction conditions and yields were not optimized.  All reactions were performed 
using flame-dried glassware under an inert atmosphere of argon unless otherwise noted.  
All solvents and chemicals were purchased from Aldrich Chemical Co. or Fisher 
Scientific and used without further purification unless otherwise noted.  Flash column 
chromatography was performed according to the method of Still et al., 1978 using Fisher 
S826-25 silica gel sorbent (70–230 mesh) and eluting solvent mixtures as specified.  
Thin-layer chromatography (TLC) was performed using TLC Silica Gel 60 F254 plates 
obtained from EMD Chemicals, Inc. and compounds were visualized under UV light 
and/or I2
 
stain. Proportions of solvents used for TLC are by volume.  1H and 13C NMR 
spectra were recorded on either a Bruker 400 or 500 MHz Oxford spectrospin cryostat, 
controlled by a Bruker Avance system, and were acquired using Bruker TOPSPIN 2.0 
acquisition software.  Acquired FIDs were analyzed using MestReC 3.2.  Chemical shifts 
for 1H and 13C NMR spectra are reported as parts per million (δ ppm) relative to 
tetramethylsilane (0.00 ppm) as an internal standard. Coupling constants are measured in 
hertz (Hz).  HRMS samples were analyzed at Old Dominion University (Norfolk, VA) by 
positive ion electrospray on a Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II 
ion source.  Combustion analyses of selected solid compounds were performed by 
Atlantic Microlab, Inc. (Norcross, GA) and are in agreement within 0.4% of calculated 
values. Melting point determinations were conducted using a Thomas-Hoover melting 
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point apparatus and are uncorrected.  Infrared spectra were recorded using a Perkin–
Elmer Spectrum RZ I FT-IR spectrometer.  On the basis of NMR and combustion data, 
all compounds were ≥ 95% pure.  
 
1-(3-Iodophenylglyoxylyl)piperidine (5.4) 
N-iodosuccinimide (0.23g, 1 mmol) was added to 96% H2SO4 (3 mL) and cooled 
to 0 C.  The resulting suspension was stirred for 20-30 min until it became homogeneous 
black solution.  1-(Phenylglyoxylyl)piperidine (3.8, Axten, et al., 1998; Gutman, et al., 
2004) (0.11g, 0.5 mmol) was added to the solution and the mixture was stirred at 0 C for 
20 min.  The reaction mixture was poured into 10 mL of ice-H2O mixture and treated 
with Na2SO3 to adjust the pH to 7.  This mixture was then extracted with CH2Cl2, washed 
with brine, dried (MgSO4), and concentrated to obtain 0.13g of 5.4 as yellow oil (77%).  
Rf = 0.45 (EtOAc/hexanes, 3:7).  
1H NMR (CDCl3, 400 MHz): δ 8.27 (s, 1H), 7.95 (d, 
1H, J = 7.8 Hz), 7.89 (d, 1H, J = 7.8 Hz), 7.26 (t, 1H, J = 7.8 Hz), 3.3.69 (t, 2H, J = 4.79 
Hz), 3.27 (t, 2H, J = 5.54 Hz), 1.80-1.60 (m, 4H), 1.60-1.50 (m, 2H).  13C NMR (CDCl3, 
100 MHz): δ 190.2, 164.5, 143.2, 138.0, 134.9, 130.6, 128.7, 94.5, 47.0, 42.2, 26.1, 25.4, 
24.2.  HRMS calcd for C13H14INO2Na+ 365.9961, found 365.9960 
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1-(3-Iodophenylglyoxylyl)piperidine p-toluenesulfonylhydrazone (5.5) 
Ketone 5.4 (7.3 g, 21.2mmol) was added to a stirred mixture of p-toluenesulfonyl 
hydrazide (4.26 g, 22.89 mmol) in EtOH (194 mL) containing H2SO4 (0.03g, 0.3 mmol).  
The mixture was refluxed at 85 C overnight, then cooled to room temperature.  The 
precipitated solid was filtered, washed with cold MeOH and cold hexanes, then dried 
under reduced pressure to give 7.8 g of 5.5 (72%).  Rf = 0.1 (EtOAC/hexanes, 3:7).  
1H 
NMR (CDCl3, 400 MHz): δ 8.93 (s, 1H), 7.94 (s, 1H), 7.78 (d, 2H, J = 8.25 Hz), 7.69 (d, 
1H, J = 7.88 Hz), 7.51 (d, 1H, J = 7.88 Hz), 7.19 (d, 2H, J = 8.14 Hz), 7.09 (t, 1H, J = 
7.87 Hz), 3.70-3.60 (m, 2H), 3.20-3.10 (m, 2H), 2.34 (s, 3H), 1.76-1.52 (m, 4H), 1.48-
1.38 (m, 2H).  13C NMR (CDCl3, 100 MHz): δ 161.3, 148.4, 144.1, 139.2, 135.0, 134.7, 
134.2, 130.3, 129.4, 127.9, 127.9, 125.5, 94.5, 47.2, 42.3, 26.2, 25.4, 24.0, 21.5.  HRMS 
calcd for C20H22IN3O3SNa
+ 534.0319, found 534.0314.  Mp: 158-159 C. 
 
(±)-7-(3-Iodophenyl)-1-azabicyclo[4.2.0]octan-8-one ((±)-5.6)  
50% aq NaOH (1.3 mL, 15.96 mmol) was added to a stirred mixture of hydrazone 
5.5 (7.8 g, 15.2 mmol) and Aliquat 336® (61 mg, 0.16 mmol) in toluene (140 mL).  The 
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mixture was refluxed at 130 C overnight, then cooled to room temperature, diluted with 
H2O, and extracted with toluene. The organic layer was dried (MgSO4), filtered, 
concentrated and chromatographed (EtOAc/hexanes, 2:8) to afford (±)-5.6 as a yellow 
solid.  Further recrystallization from Et2O provided 2.7 g of (±)-5.6 (55%).  This reaction 
provided a mixture of threo and erythro diastereomers and the relative configuration is 
easily determined by 1H NMR spectrum analysis of the coupling constants between the 
benzylic and bridge-head protons.  The coupling constant for trans diastereomers ((±)-
5.6) is 2-2.5 Hz and the impurity which are the cis diastereomers have a coupling 
constant of 4.5-6 Hz (Backes, 2014).  Rf = 0.13 (EtOAc/Hexanes, 2:8).  
1H NMR (CDCl3, 
400 MHz): δ 7.63-7.57 (m, 2H), 7.25 (d, 1H, J = 7.65 Hz), 7.05 (t, 1H, J = 7.76 Hz), 
4.05-3.80 (m, 2H), 3.40-3.30 (m, 1H), 2.85-2.70 (m, 1H), 2.20-2.10 (m, 1H), 2.05-1.90 
(m, 1H), 1.72-1.65 (m, 1H), 1.45-1.35 (m, 3H).  13C NMR (CDCl3, 100 MHz): δ 165.4, 
137.9, 136.3, 136.1, 130.4, 126.6, 94.6, 62.6, 56.5, 39.0, 30.4, 24.3, 22.1.  HRMS calcd 
for C13H14INONa
+ 350.0012, found 350.0013.  Mp: 126-127 C. 
 
(±)-threo-3-Iodomethylphenidate hydrochloride ((±)-4.29)  
  (±)-threo--Lactam (±)-5.6 (0.19 g, 0.58 mmol) was refluxed with 1.25 M HCl in 
MeOH for 7 hrs, then concentrated under reduced pressure to afford 229 mg of (±)-4.29 
(99%).  This threo-iodomethylphenidate was determined to be >95% diastereomerically 
pure by 1H NMR upon comparison to the known data for enantiomerically pure threo- 
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and erythro-methylphenidate and its para-substituted derivatives (Thai et al., 1998).  Rf = 
0.55 (MeOH/CHCl3, 1:9).  
1H NMR (CD3OD, 400 MHz): δ 7.74 (d, 1H, J = 9.6 Hz), 7.70 
(t, 1H, J = 1.68 Hz), 7.31 (d, 1H, J = 8.37 Hz), 7.18 (t, 1H, J = 7.8 Hz), 3.89-3.81 (m, 
2H), 3.74 (s, 3H), 3.43 (d, 1H, J = 12.81 Hz), 3.10 (t, 1H, J = 12.89 Hz), 1.91-1.79 (m, 
2H), 1.74-1.63 (m, 1H), 1.57-1.46 (m, 2H), 1.41-1.32 (m, 1H).  13C NMR (CD3OD, 100 
MHz): δ 172.8, 139.0, 138.6, 137.4, 132.2,128.9, 95.6, 58.9, 54.7, 53.6, 46.7, 27.8, 23.3, 
22.7.  HRMS calcd for C14H19INO2Na
+ 382.0274, found 382.0271.  Mp: 191-192ºC. 
 
(±)-threo-N-(p-Azido-benzyl)-3-iodomethylphenidate ((±)-4.22)  
(±)-threo-3-Iodomethylphenidate hydrochloride ((±)-4.29) (0.14 g, 0.35 mmol) 
was added to a suspension of K2CO3 (0.19 g, 1.43 mmol) in DMF (7 mL).  The mixture 
was stirred at room temperature for 10 min then p-N3-N-BnBr (Mornet et al., 1984)  (80 
mg, 0.39 mmol) was added.  The reaction was allowed to stir at room temperature in the 
dark for 30 hrs, Et2O (20 mL) was added and the mixture was decanted followed by 
rinsing with Et2O (2 × 20 mL).  The combined organic layers were washed with H2O, 
dried (MgSO4), concentrated and chromatographed (EtOAc/hexanes, 5: 95) to give 0.11 
g of (±)-4.22 as a yellow gum (63%).  Rf = 0.23 (EtOAc/hexanes, 5: 95).  
1H NMR 
(CDCl3, 400 MHz):  δ 7.74 (s, 1H), 7.60 (d, 1H, J = 7.89 Hz), 7.36 (d, 1H, J = 7.83 Hz), 
7.26 (d, 2H, J = 8.62 Hz), 7.05 (t, 1H, J = 7.81 Hz), 6.97 (d, 1H, J = 8.41 Hz), 4.08 (d, 
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1H, J = 11.52 Hz), 3.89 (d, 1H, J = 13.60 Hz), 3.74 (d, 1H, J = 13.60 Hz), 3.66 (s, 3H), 
3.46-3.42 (m, 1H), 2.97-2.90 (m, 1H), 2.53-2.49 (m, 1H), 1.58-1.48 (m, 5H), 1.07-1.03 
(m, 1H).  13C NMR (CDCl3, 100 MHz): δ 173.4, 139.2, 138.4, 137.0, 136.6, 130.3, 129.9, 
128.0, 118.7, 94.5, 62.5, 55.9, 52.5, 51.9, 44.6, 21.1, 20.6, 19.4.  HRMS calcd for 
C21H23IN4O2H
+ 491.0938, found 491.0945.  IR: azide, 2111 cm-1. 
 
1-(4-Nitrophenylgloxylyl)piperidine (5.17)  
A solution of 4- nitrophenylglyoxylate 5.16 (1 g, 4.48 mmol) in EtOH (6 mL) was 
treated with piperidine (1.3 mL, 13.44 mmol).  The mixture was stirred at 68 °C 
overnight then cooled to room temperature, diluted with 1 M aq. HCl, and extracted with 
EtOAc.  The combined organic extracts were washed with H2O and brine, then dried 
(MgSO4), filtered, and concentrated.  The crude material was chromatographed 
(EtOAc/hexanes, 3:7) to provide 1.07 g of amide 5.17 as a yellow solid (91%).  Rf = 0.2 
(EtOAc/hexanes, 3:7).  1H NMR data proved identical to that previously reported (Song 
et al., 2007).  
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1-(4-Nitrophenylglyoxylyl)piperidine p-toluenesulfonylhydrazone (5.18) 
Ketone 5.17 (5.7 g, 21.86 mmol) was added to a stirred mixture of p-
toluenesulfonyl hydrazide (4.4 g, 23.6 mmol) and H2SO4
 
(0.03 g, 0.33 mmol) in EtOH 
(170 mL).  The reaction mixture was refluxed at 85 °C overnight, then cooled to room 
temperature.  The yellow solid precipitate was collected by filtration, washed with cold 
MeOH then cold hexanes, and dried in vacuo to give 9.4 g of hydrazone 5.18 (59%).  Rf
 
= 
0.18 (EtOAc/hexanes, 1:1).  1H NMR (CDCl3, 400 MHz): δ 8.51 (s, 1H), 8.23 (d, 2H, J = 
8.88 Hz), 7.85 (d, 2H, J = 8.27 Hz), 7.74 (d, 2H, J = 8.76 Hz), 7.30 (d, 2H, J = 8.37 Hz), 
3.75-3.70 (m, 2H), 3.20-3.15 (m, 2H), 2.40 (s, 3H), 1.70-1.65 (m, 4H), 1.55-1.45 (m, 
2H).  13C NMR (CDCl3, 100 MHz): δ 161.0, 148.6, 147.2, 144.5, 138.1, 134.9, 129.7, 
127.9, 127.0, 124.1, 47.3, 42.5, 26.4, 25.5, 24.0, 21.6.  HRMS calcd for 
(C20H22N4O5S)Na
+ 453.1203, found 453.1206.  Mp: 179-180 °C. 
 
2-Diazo-2-(4-nitrophenyl)-1-(piperidin-1-yl)ethanone (5.19)  
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50% aq. NaOH (0.7 mL, 9.02 mmol) was added to a stirred mixture of hydrazone 
5.18 (3.7 g, 8.6 mmol) and Aliquat 336® (0.035 g, 0.086 mmol) in toluene (60 mL).  The 
reaction mixture was refluxed at 130 °C for 20 minutes, then cooled to room temperature, 
diluted with H2O, and extracted with toluene.  The combined organic layers were dried 
(MgSO4), filtered, concentrated, and recrystallized in Et2O to give 2.24 g of α-diazo 
amide 5.19 as a reddish brown solid (95%).  Rf
 
= 0.33 (EtOAc/hexanes, 3:7).  1H NMR 
(CDCl3, 400 MHz): δ 8.19 (d, 2H, J = 9.06 Hz), 7.33 (d, 2H, J = 9.1 Hz), 4.00-3.45 (m, 
4H), 1.70- 1.65 (m, 2H), 1.65-1.60 (m, 4H).  13C NMR (CDCl3, 100 MHz): δ 162.8, 
144.7, 136.2, 124.4, 123.1, 46.7, 25.8, 24.4.  HRMS calcd for (C13H14N4O3)2Na
+ 
571.2024, found 571.2027.  Anal. calcd for: C13H14N4O3: C, 56.93; H, 5.14; N, 20.43. 
Found: C, 57.13; H, 5.2; N, 20.2.  Mp: 62-65 °C.  
 
(±)-threo-(6S,7S)-7-(4-Nitrophenyl)-1-azabicyclo[4.2.0]octan-8-one ((±)-5.20) 
A solution of α-diazo amide 5.19 (2.24 g, 8.16 mmol) in toluene (60 mL) was 
refluxed overnight, cooled to room temperature, then concentrated, chromatographed 
(EtOAc/hexanes, 1:1), and recrystallized from Et2O to give 1.07 g of (±)- threo-β-lactam 
(±)-5.20 as a yellow solid (53%).  This reaction provided a mixture of threo and erythro 
diastereomers and the relative configuration is easily determined by 1H NMR spectrum 
analysis of the coupling constants between the benzylic and bridge-head protons.  The 
coupling constant for trans diastereomers ((±)-5.20) is 1.4 Hz and the impurity which are 
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the cis diastereomers have a coupling constant of 5.0 Hz (Backes, 2014).  Rf
 
= 0.3 
(EtOAc/hexanes, 1:1).  1H NMR (CDCl3, 400 MHz): δ 8.19 (d, 2H, J = 8.78 Hz), 7.47 (d, 
2H, J = 8.68 Hz), 4.08-4.07 (m, 1H), 3.95-3.90 (m, 1H), 3.45- 3.40 (m, 1H), 2.85-2.75 
(m, 1H), 2.25-2.21 (m, 1H), 2.00-1.94 (m, 1H), 1.75-1.71 (m, 1H), 1.50-1.40 (m,3H).  13C 
NMR (CDCl3, 100 MHz): δ 164.7, 147.1, 143.1, 128.2, 123.9, 62.8, 56.3, 39.2, 30.5, 
24.3, 22.0.  HRMS calcd for (C13H14N2O3)2Na
+ 515.1901, found 515.1902.  Mp: 115-116 
°C.  
 
(±)-threo-4-Nitromethylphenidate hydrochloride ((±)-4.39)  
(±)-threo-β-lactam (±)-5.20 (0.5 g, 2.03 mmol) was refluxed in 1.25 M HCl in 
MeOH (40 mL) for 7 hrs, cooled to room temperature, then concentrated to provide 0.63 
g of (±)-4.39 (99%) as the HCl salt.  Rf
 
= 0.39 (CHCl3/MeOH, 9:1).  
1H NMR (CDCl3, 
400 MHz): δ 8.28 (d, 2H, J = 8.79 Hz), 7.60 (d, 2H, J = 8.79 Hz), 4.15-4.10 (m, 1H), 4.0-
3.9 (m, 1H), 3.75 (s, 3H), 3.5-3.4 (m, 1H), 3.2-3.0 (m, 1H), 2.0-1.3 (m, 6H).  13C NMR 
(MeOD, 100 MHz): δ 172.3, 142.2, 131.2, 125.3, 58.8, 54.8, 53.8, 46.8, 27.7, 23.2, 22.7.  
HRMS calcd for (C14H19N2O2)+ 279.1339, found 279.1340.  Anal. calcd for: 
C14H19ClN2O4: C, 53.42; H, 6.08; N, 8.90; Cl, 11.26. Found: C, 53.5; H, 6.0; N, 9.01; Cl, 
11.02.  Mp: 163-165 °C.  
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(±)-threo-4-Aminomethylphenidate ((±)-4.36) 
Concentrated HCl (5.8 mL) was slowly added to a 0˚C solution of hydrochloride 
salt (±)-4.39 (0.5 g, 1.58 mmol) in MeOH (11.7 ml).  The mixture was then treated with 
SnCl2 (1.16 g, 6.11 mmol) and stirred at room temperature overnight.  The reaction was 
quenched with H2O (50 mL), adjusted to pH >12 using solid NaOH, then extracted with 
EtOAc (50 mL x 2).  The combined organic layers were washed with brine (50 mL), then 
dried (MgSO4), filtered, and concentrated to give 0.24 g of aniline (±)-4.36 as a yellow 
solid (61%).  Rf = 0.42 (CHCl3/MeOH/Et3N, 95:3:2).  
1H NMR (CDCl3, 400 MHz): δ 
7.06 (d, 2H, J = 8.45 Hz), 6.62 (d, 2H, J = 8.47 Hz), 3.63 (s, 5H), 3.35-3.25 (m, 1H), 3.1-
3.0 (m, 2H), 2.8-2.6 (m, 1H), 2.0-1.9 (br s, 1H), 1.75-1.65 (m, 1H), 1.6-1.5 (m, 1H), 1.45-
1.15 (m, 3H), 1.0-0.85 (m, 1H).  13C NMR (MeOD, 100 MHz): δ 174.3, 145.7, 129.4, 
126.3, 115.2, 58.9, 57.8, 51.8, 46.9, 29.9, 26.2, 24.4.  HRMS calcd for (C14H20N2O2)Na
+ 
271.1417, found 271.1420.  Anal. calcd for: C14H19ClN2O4: C, 67.71; H, 8.12; N, 11.28.  
Found: C, 67.62; H, 8.02; N, 11.09.  Mp: 123-125˚C. 
 
(±)-threo-4-Amino-3-iodomethylphenidate ((±)-4.40).   
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Iodine monochloride (36 mg, 0.2 mmol) was added to a solution of aniline (±)-
4.36 (50 mg, 0.2 mmol) in glacial AcOH (3.5 mL).  The mixture was stirred overnight at 
room temperature, then concentrated to dryness.  The residue was partitioned between 1 
M aq. NaOH and EtOAc, then the separated organic layer was washed with brine, dried 
(MgSO4), filtered, concentrated, and chromatographed (CHCl3/MeOH/Et3N, 95:3:2) to 
give 26 mg of iodo-aniline (±)-4.40 as brown gum (35%).  Rf = 0.45 (CHCl3/MeOH/Et3N, 
95:3:2).  1H NMR (CDCl3, 400 MHz): δ 7.54 (d, 1H, J = 2.01 Hz), 7.05 (dd, 1H, J = 2.03 
Hz, 8.22 Hz), 6.67 (d, 1H, J = 8.21 Hz), 4.11 (s, 2H), 3.64 (s, 3H), 3.3-3.2 (m, 1H), 3.1-
2.9 (m, 2H), 2.75-2.60 (m, 1H), 2.0-1.9 (br s, 1H), 1.75-1.65 (m, 1H), 1.60-1.55 (m, 1H), 
1.4-1.2 (m, 3H), 1.0-0.85 (m, 1H).  13C NMR (CDCl3, 100 MHz): δ 173.8, 146.2, 138.5, 
129.4, 127.7, 114.5, 84.0, 58.8, 57.2, 51.9, 46.8, 29.9, 26.1, 24.3.  HRMS calcd for 
(C14H19IN2O2)Na
+ 397.0383, found 397.0381.  Anal. calcd for: C14H19ClN2O4: C, 44.93; 
H, 5.12; N, 7.49; I, 33.91.  Found: C, 45.00; H, 5.19; N, 7.48; I, 31.91. 
 
 
(±)-threo-4-Azido-3-iodomethylphenidate ((±)-4.35)  
A solution of iodo-aniline (±)-4.40 (0.14 g, 0.38 mmol) in 1 M aq. HCl (2 mL) at 
0˚C was treated with NaNO2 (29 mg, 0.42 mmol).  The mixture was stirred in the dark for 
1 hr at 0˚C, then treated with NaN3 (26 mg, 0.39 mmol), stirred for 2 hrs at 0˚C, and 
diluted sat. aq. NaHCO3 solution.  The resulting mixture was extracted with EtOAc and 
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the combined organic layers were washed with brine, dried (MgSO4), filtered, and 
concentrated to provide 150 mg of azido-iodo (±)-4.35 as a gray solid (99%).  Rf = 0.30 
(CHCl3/MeOH/Et3N, 95:3:2).  
1H NMR (CDCl3, 400 MHz): δ 7.72 (d, 1H, J = 1.98 Hz), 
7.33 (dd, 1H, J = 2.00 Hz, 8.26 Hz), 7.08 (d, 1H, J = 8.23 Hz), 3.66 (s, 3H), 3.40-3.35 
(m, 1H), 3.1-3.0 (m, 2H), 2.75-2.60 (m, 1H), 2.0-1.9 (br s, 1H), 1.75-1.65 (m, 1H), 1.65-
1.55 (m, 1H), 1.4-1.2 (m, 3H), 1.0-0.85 (m, 1H).  13C NMR (CDCl3, 100 MHz): δ 173.1, 
141.0, 139.7, 134.8, 129.7, 118.4, 88.0, 58.8, 57.4, 52.2, 46.8, 30.0, 26.0, 24.2.  HRMS 
calcd for (C14H17IN4O2)Na
+ 423.0288, found 423.0284.  Anal. calcd for: 
C14H17IN4O2•0.1535 EtOAc: C, 42.42; H, 4.44; N, 13.54; I, 30.67.  Found: C, 42.67; H, 
4.38; N, 13.65; I, 30.71.  IR: azide, 2124 cm-1.  Mp: 98-100˚C. 
 
(±)-threo-4-Azidomethylphenidate ((±)-4.41) 
  A solution of aniline (±)-4.36 (0.11 g, 0.44 mmol) in 1 M aq. HCl (2 mL) at 0˚C 
was treated with NaNO2 (33 mg, 0.48 mmol).  The mixture was stirred in the dark for 1 
hr at 0˚C then treated with NaN3 (30 mg, 0.46 mmol).  The resulting mixture was stirred 
for 2 hrs at 0˚C, diluted sat. aq. NaHCO3 solution, then extracted with EtOAc.  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and 
concentrated to provide 0.12 g of azide (±)-4.41 as a brown gum (99%).  Rf = 0.45 
(CHCl3/MeOH/Et3N, 95:3:2).  
1H NMR (CDCl3, 400 MHz): δ 7.28 (d, 2H, J = 8.52 Hz), 
6.98 (d, 2H, J = 8.55 Hz), 3.65 (s, 3H), 3.45-3.4(m, 1H), 3.15-3.0 (m, 2H), 2.75-2.65 (m, 
 208 
1H), 2.05-1.95 (br s, 1H), 1.75-1.65 (m, 1H), 1.65-1.55 (m, 1H), 1.45-1.15 (m, 3H), 1.05-
0.85 (m, 1H).  13C NMR (CDCl3, 100 MHz): δ 173.6, 139.4, 133.2, 129.9, 119.2, 58.9, 
58.0, 52.0, 46.8, 30.0, 26.1, 24.3.  HRMS calcd for (C14H18N4O2)Na
+ 297.1322, found 
297.1329.  IR: azide, 2121 cm-1. 
 
N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-
yl)methyl)-4-(4-(prop-2-yn-1-yloxy)benzoyl)benzamide ((±)-4.44) 
To a solution of carboxylic acid 5.22 (Bandyopadhyay and Bong, 2011) (84 mg, 
0.30 mmol) in DMF (2 mL) at 0˚C was added EDC (49 mg, 0.31 mmol) and HOBT (43 
mg, 0.31 mmol) and the mixture was stirred in the dark for 1 hr.  To this mixture, a 
solution of (±)-5-(aminomethyl)-citalopram (±)-5.21 (Banala et al., 2013) (119 mg, 0.36 
mmol) in DMF (1 mL) and Et3N (0.2 mL) were added and the mixture was stirred in the 
dark at room temperature overnight.  The mixture was partitioned between H2O and 
EtOAc and the combined organic layers were washed with 1 M NaOH, brine, dried 
(MgSO4), concentrated and chromatographed (CHCl3/MeOH/Et3N, 95:3:2) to give 112 
mg of (±)-4.44 as a pale yellow semisolid (63%).  Rf = 0.19 (CHCl3/MeOH/Et3N, 95:3:2).  
1H NMR (CDCl3, 400 MHz): δ 7.87 (d, 2H, J = 8.4 Hz), 7.77 (d, 2H, J = 8.9 Hz), 7.71 (d, 
2H, J = 8.4 Hz), 7.46-7.40 (m, 2H), 7.28-7.18 (m, 3H), 7.11 (t, 1H, J = 5.7 Hz), 7.02 (d, 
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2H, J = 8.9 Hz), 6.95 (t, 2H, J = 8.7 Hz), 5.12 (d, 1H, J = 12.6 Hz), 5.07 (d, 1H, J = 12.5 
Hz), 4.76 (d, 2H, J1 = 18.1 Hz), 4.61 (d, 2H, J1 = 5.7 Hz), 2.58 (d, 2H, J1 = 2.4 Hz) 2.30-
2.0 (m, 10H), 1.60-1.20 (m, 2H).  13C NMR (CDCl3, 100 MHz): δ 194.7, 166.6, 162. 9, 
161.3, 160.5, 143.7, 141.0, 140.9, 140.6, 139.8, 137.8, 137.2, 132.5, 130.2, 129.7, 127.4, 
127.0, 126.8, 126.7, 122.1, 120.7, 115.1, 114.8, 114.6, 90.8, 77.7, 76.4, 71.7, 59.6, 55.9, 
45.4, 43.9, 39.3, 22.3.  HRMS calcd for (C37H35FN2O4)Na
+ 613.2473, found 613.2476.  
Anal. calcd for: C37H35FN2O4•0.5506CH3CO2C2H5: C, 73.66; H, 6.21; N, 4.38; F, 2.97.  
Found: C, 73.53; H, 5.99; N, 4.68; F, 3.11. 
 
(S)-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-
5-yl)methyl)-4-(4-(prop-2-yn-1-yloxy)benzoyl)benzamide ((S)-4.44) 
 Propargyloxy benzophenone carboxylic acid 5.22 (Bandyopadhyay and Bong, 
2011) (0.43 g, 1.52 mmol) was activated with EDC (0.25 g, 1.6 mmol) and HOBT (0.22 
g, 1.6 mmol), by dissolving in 4 mL DMF and stirring at 0 °C for 1 hr in dark.  A solution 
of 5-(aminomethyl)-S-Citalopram (S)-5.21 (Kumar et al., 2014) (0.5 g, 1.52 mmol) in 
DMF was added to this mixture, followed by Et3N (1 mL) and allowed to stir at room 
temperature overnight.  The reaction is quenched with 100 mlL water and extracted with 
ethylacetate (2 x 100 mL).  The combined organic layers were washed with 1 M NaOH, 
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Brine, dried (MgSO4), concentrated and chromatographed (EtOAc:Et3N, 95:05) to give 
724 mg probe (S)-4.44 as pale yellow semisolid (80.5%).  Rf = 0.258 (EtOAc:Et3N, 
95:05).  1H NMR (CDCl3, 400 MHz) 7.87 (d, 2H, J = 8.3 Hz), 7.74 (d, 2H, J = 8.9 Hz), 
7.67 (d, 2H, J = 8.32 Hz), 7.55-7.45(m, 1H), 7.44-7.40 (m, 2H), 7.3-7.20 (m, 2H), 7.16 
(s, 1H), 7.0 (d, 2H, J = 8.9 Hz), 6.96-6.91 (m, 2H), 5.1 (d, 1H, J =12.7 Hz), 5.05 (d, 1H, J 
= 12.7 Hz), 4.75(d, 2H, J = 2.4 Hz) 4.58 (d, 2H, J = 5.74 Hz), 2.6 (t, 1H, J = 2.4 Hz), 
2.26-2.0 (m, 10H), 1.5-1.2 (m, 2H).  13C NMR (CDCl3, 100 MHz): 194.7, 166.7, 162.9, 
161.3, 160.4, 143.6, 141.0, 140.9, 140.5, 139.7, 137.9, 137.2, 132.4, 130.2, 129.6, 127.3, 
127.1, 126.7, 126.6, 121.9, 120.6, 115.0, 114.8, 114.5, 90.7, 77.7, 76.4, 71.7, 59.6, 55.8, 
45.3, 43.8, 39.3, 22.2.  HRMS calcd for C37H35FN2O4H
+ 591.265362, found 591.264776.  
Anal. calcd for: C37H35FN2O4•0.5815CH3CO2C2H5: C, 73.58; H, 6.22; N, 4.36; F, 2.95.  
Found: C, 73.38; H, 5.96; N, 4.72; F, 3.34.  [α]23D = +0.22 (c = 10, CHCl3).  
 
(S)-1-(3-((4-benzoylbenzyl)(methyl)amino)propyl)-1-(4-fluorophenyl)-1,3-
dihydroisobenzofuran-5-carbonitrile ((S)-4.46) 
To a solution of  (S)-Desmethylcitalopram (S)-5.33 (Jin et al., 2007) (150 mg, 
0.48 mmol) in CH3CN (3 mL) and N,N-diisopropylethylamine (0.12 mL) was added 4-
(bromomethyl)benzophenone 5.34 (136 mg, 0.53 mmol) and the mixture was stirred at 
room temperature for 5 hrs.  The mixture is then concentrated, diluted with saturated 
NaHCO3, extracted with EtOAc, washed with brine, dried (MgSO4), filtered, 
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concentrated, and chromatographed (EtOAc/hexanes, 2:8) to give 143 mg of (S)-4.46 as a 
pale yellow gum (59%).  Rf = 0.325 (EtOAc/hexanes, 2:8).  
1H NMR (CDCl3, 400 MHz): 
δ 7.81-7.74 (m, 4H), 7.61-7.57 (m, 2H), 7.51-7.46 (m, 3H), 7.44-7.36 (m, 5H), 7.0 (t, 2H, 
J = 8.6 Hz), 5.18 (d, 1H, J = 12.9 Hz), 5.14 (d, 1H, J = 12.9 Hz), 3.48 (s, 2H), 2.36 (t, 2H, 
J = 7.1 Hz), 2.30-2.10 (m, 5H), 1.60-1.35 (m, 2H).  13C NMR (CDCl3, 100 MHz): δ 
196.5, 163.2, 149.5, 144.3, 140.3, 139.5, 137.7, 136.3, 132.4, 131.9, 130.2, 129.9, 128.6, 
128.3, 126.8, 126.7, 125.2, 122.7, 118.6, 115.5, 115.2, 111.7, 91.1, 71.3, 62.0, 57.2, 42.2, 
38.9, 21.9.  HRMS calcd for (C33H29FN2O2)H
+ 505.2286, found 505.2279.  [α]24D = -1.7 
(c = 5.7, CHCl3). 
 
Methyl 4-(2-(4-(prop-2-yn-1-yloxy)phenyl)-1,3-dioxolan-2-yl)benzoate (5.35) 
A mixture of benzophenone analog (5.28) (Bandyopadhyay and Bong, 2011) (100 
mg, 0.34 mmol), ethane-1,2-diol (1.67 g, 26.9 mmol), 1,2-bis(trimethylsilyloxy)ethane 
(2.52 g, 12.2 mmol), p-toluenesulfonic acid hydrate (4.5 mg, 0.024 mmol), and toluene 
(1.6 mL) was heated under reflux for 4 hrs. The mixture was then cooled to room 
temperature and washed with a sat. aq. NaHCO3 solution (10 mL). The organic layer was 
separated, the aqueous layer was extracted with hexanes/EtOAc (6:4 (v/v); 3 x 20 mL).  
The combined organic layers were dried (MgSO4), filtered, concentrated and 
chromatographed (EtOAc/hexanes, 1:9) to give 87 mg of cyclic ketal 5.35 as a colorless 
oil (75%).  Rf = 0.26 (EtOAc/hexanes, 2:8).  
1H NMR (CDCl3, 400 MHz): δ 7.99 (d, 2H, 
J = 8.6 Hz), 7.60 (d, 2H, J = 8.6 Hz), 7.40 (d, 2H, J = 8.9 Hz), 6.90 (d, 2H, J = 8.9 Hz), 
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4.65 (d, 2H, J = 2.4 Hz), 4.10-4.0 (m, 4H), 3.90 (s, sH), 2.50 (t, 1H, J = 2.4 Hz).  13C 
NMR (CDCl3, 100 MHz): δ 166.7, 157.4, 147.1, 134.6, 129.7, 129.5, 127.4, 126.1, 114.4, 
108.8, 78.3, 75.6, 64.9, 55.6, 52.0. HRMS calcd for (C20H18O5)Na
+ 361.1046, found 
361.1044. 
 
(4-(2-(4-(Prop-2-yn-1-yloxy)phenyl)-1,3-dioxolan-2-yl)phenyl)methanol (5.36) 
Lithium Aluminium Hydride (1 M in THF, 3.98 mL) was added to a solution of 
ester 5.35 (290 mg, 0.86 mmol) in THF (16 mL) and Et2O (32 mL) at 0˚C.  The mixture 
was then removed from ice bath and refluxed at 70˚C for 5 hrs.  The mixture was cooled 
to room temperature, quenched by sequential addition of H2O (0.16 mL), 15% aqueous 
NaOH (0.16 mL) and H2O (0.4 mL).  The mixture is then filtered, washed with brine, 
dried (MgSO4), filtered, concentrated and chromatographed (EtOAc/hexanes, 2:8) to 
provide 168 mg of alcohol 5.36 as colorless oil (70%).  Rf = 0.31 (EtOAc/hexanes, 4:6).  
1H NMR (CDCl3, 400 MHz): δ 7.47 (d, 2H, J = 8.3 Hz), 7.40 (d, 2H, J = 8.9 Hz), 7.30 (d, 
2H, J = 8.4 Hz), 6.90 (d, 2H, J = 8.9 Hz), 4.64 (d, 2H, J = 2.4 Hz), 4.60 (s, 2H), 4.10- 
3.90 (m, 4H), 2.50 (t, 1H, J = 2.4 Hz), 2.06 (s, 1H).  13C NMR (CDCl3, 100 MHz): δ 
157.3, 141.5, 140.6, 135.1, 127.5, 126.7, 126.4, 114.3, 109.1, 78.4, 75.5, 64.9, 64.7, 55.7.  
HRMS calcd for (C19H18O4)Na
+ 333.1097, found 333.1096. 
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(4-(Hydroxymethyl)phenyl)(4-(prop-2-yn-1-yloxy)phenyl)methanone (5.37)  
A solution of cyclic ketal 5.36 (220 mg, 0.72 mmol) in 10% aqueous HCl (4 mL) 
was refluxed at 120˚C for 4 hrs.  The mixture was then cooled to room temperature, 
diluted with H2O and extracted with EtOAc.  The organic layer was washed with brine, 
dried (MgSO4), filtered, concentrated and chromatographed (EtOAc/hexanes, 4:6) to give 
128 mg of ketone 5.37 as a colorless gum (67%).  Rf = 0.15 (EtOAc/hexanes, 4:6).  
1H 
NMR (CDCl3, 400 MHz): δ 7.78 (d, 2H, J = 8.9 Hz), 7.70 (d, 2H, J = 8.2 Hz), 7.42 (d, 
2H, J = 8.4 Hz), 7.02 (d, 2H, J = 8.9 Hz), 4.80-4.70 (m, 4H), 2.91 (s, 1H), 2.58 (t, 1H, J = 
2.4 Hz).  13C NMR (CDCl3, 100 MHz): δ 195.5, 161.0, 145.4, 136.9, 132.4, 130.8, 130.4, 
126.3, 114.4, 77.8, 76.3, 64.5, 55.9.  HRMS calcd for (C17H14O3)Na
+ 289.0835, found 
289.0835. 
 
4-(4-(prop-2-yn-1-yloxy)benzoyl)benzyl methanesulfonate (5.38) 
To a solution of alcohol 5.37 (125 mg, 0.47 mmol) in CH2Cl2 (5 mL) and 
triethylamine (0.07 mL, 0.52 mmol) was added mesyl chloride (0.04 mL, 0.52 mmol) at 0 
°C, and the mixture was allowed to warm to room temperature.  Stirring continued for 2 
hrs and the mixture was then partitioned between saturated NaHCO3 and CH2Cl2.  The 
organic layer was washed with brine, dried (MgSO4), filtered, concentrated and 
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chromatographed (EtOAc/hexanes, 4:6) to give 106 mg of mesolate 5.38 as a colorless 
gum (66%).  Rf = 0.27 (EtOAc/hexanes, 4:6).  
1H NMR (CDCl3, 400 MHz): δ 7.83 (d, 
2H, J = 8.9 Hz), 7.80 (d, 2H, J = 8.3 Hz), 7.53 (d, 2H, J = 8.3 Hz), 7.10 (d, 2H, J = 8.9 
Hz), 5.32 (s, 2H), 4.80 (d, 2H, J = 2.4 Hz), 3.02 (s, 3H), 2.58 (t, 1H, J = 2.4 Hz).  13C 
NMR (CDCl3, 100 MHz): δ 194.7, 161.2, 138.9, 137.2, 132.5, 130.5, 130.215, 128.3, 
114.5, 77.7, 76.3, 70.3, 55.6, 38.3. 
 
(S)-1-(4-Fluorophenyl)-1-(3-(methyl(4-(4-(prop-2-yn-1-yloxy)benzoyl)benzyl)amino) 
propyl)-1,3-dihydroisobenzofuran-5-carbonitrile ((S)-4.47)  
To a solution of  (S)-Desmethylcitalopram (S)-5.33 (Jin et al., 2007) (110 mg, 
0.35 mmol) in CH3CN (5 mL) and N,N-Diisopropylethylamine (0.09 mL) was added 
mesylate 5.38 (134 mg, 0.39 mmol) and the mixture was stirred at room temperature for 
12 hrs.  The mixture was then concentrated, diluted with saturated NaHCO3, extracted 
with EtOAc, washed with brine, dried (MgSO4), filtered, concentrated, and 
chromatographed (EtOAc/hexanes, 2:1) to give 62 mg of (S)-4.47 as a pale yellow gum 
(31%).  Rf = 0.15 (EtOAc/hexanes, 2:1).  
1H NMR (CDCl3, 400 MHz): δ 7.83 (d, 2H, J = 
8.9 Hz), 7.71 (d, 2H, J = 8.2 Hz), 7.58 (d, 1H, J = 7.9 Hz), 7.50 (s, 1H), 7.44-7.34 (m, 
5H), 7.06-6.90 (m, 4H), 5.18 (d, 1H, J = 12.9 Hz), 5.14 (d, 1H, J = 12.9 Hz), 4.78 (d, 2H, 
J = 2.4 Hz), 3.48 (s, 2H), 2.57 (t, 1H, J = 2.4 Hz), 2.35 (t, 2H, J = 7.1 Hz), 2.30-2.10 (m, 
4H), 1.60-1.30 (m, 2H).  13C NMR (CDCl3, 100 MHz): δ 195.2, 163.1, 160.9, 160.7, 
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149.4, 143.8, 140.2, 139.5, 136.7, 132.3, 131.8, 130.9, 129.8, 128.5, 126.7, 126.6, 125.2, 
122.6, 118.6, 115.4, 115.2, 114.3, 111.6, 91.0, 77.7, 76.1, 71.2, 61.9, 57.1, 55.8, 42.2, 
38.8, 21.8. HRMS calcd for (C36H31FN2O3)H
+ 559.2391, found 559.2389.  [α]24D = -3.36 
(c = 5.8, CHCl3). 
 
(S)-3-azido-5-(azidomethyl)-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-
1,3-dihydroisobenzofuran-5-yl)methyl)benzamide ((S)-4.50) 
 To a solution of carboxylic acid 5.39 (Neelarapu et al., 2011) (78 mg, 0.36 mmol) 
in DMF (2 mL) at 0 °C was added EDC (59 mg, 0.38 mmol) and HOBT (51 mg, 0.38 
mmol) and the mixture was stirred in the dark for 1 hr.  To this mixture, a solution of (S)-
5-(aminomethyl)-citalopram (S)-5.21 (Kumar et al., 2014) (118 mg, 0.36 mmol) in DMF 
(1 mL) and Et3N (0.25 mL) were added and the mixture was stirred in the dark at room 
temperature overnight.  The mixture was partitioned between H2O and EtOAc and the 
combined organic layers were washed with 1 M NaOH, brine, dried (MgSO4), 
concentrated and chromatographed (EtOAc/Et3N, 95:5) to give 142 mg of (S)-4.50 as a 
pale yellow semisolid (75%). Rf = 0.26 (EtOAc/Et3N, 95:5).  
1H NMR (CDCl3, 
400 MHz): δ 7.47-7.41 (m, 4H), 7.27-7.20 (m, 2H), 7.17 (s, 1H), 7.07 (s, 1H), 7.00-6.93 
(m, 2H), 6.72 (t, 1H, J = 5.5 Hz), 5.14 (d, 1H, J = 12.8 Hz), 5.09 (d, 1H, J = 12.8 Hz), 
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4.58 (d, 2H, J = 17.5 Hz), 4.36 (s, 2H), 2.29-2.00 (m, 10H), 1.6-1.2 (m, 2H).  13C NMR 
(CDCl3, 100 MHz): δ 165.9, 163.0, 160.6, 143.9, 141.4, 141.0, 140.9, 139.9, 138.1, 
137.5, 136.6, 127.4, 126.8, 126.7, 122.6, 122.1, 121.2, 120.8, 117.6, 115.1, 114.9, 90.8, 
71.7, 59.7, 53.9, 45.4, 43.9, 39.3, 22.3.  HRMS calcd for (C28H29FN8O2)H
+ 529.2470, 
found 529.2468.  IR: azide, 2100 cm-1.  [α]24.5D = +1.3 (c = 4.3, CHCl3). 
 
(S)-4-azido-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-
dihydroisobenzofuran-5-yl)methyl)-3-iodobenzamide ((S)-4.51)  
To a solution of 4-azido-3-iodobenzoic acid 5.44 (Shu et al., 1996) (87 mg, 0.30 
mmol) in DMF (2 mL) at 0 °C was added EDC (49 mg, 0.31 mmol) and HOBT (43 mg, 
0.31 mmol) and the mixture was stirred in the dark for 1 hr.  To this mixture, a solution of 
(S)-5-(aminomethyl)-citalopram (S)-5.21 (kumar et al., 2014) (99 mg, 0.30 mmol) in 
DMF (1 mL) and Et3N (0.2 mL) were added and the mixture was stirred in the dark at 
room temperature overnight.  The mixture was partitioned between H2O and EtOAc and 
the combined organic layers were washed with 1 M NaOH, brine, dried (MgSO4), 
concentrated and chromatographed (EtOAc/Et3N, 95:5) to give 120 mg of (S)-4.51 as a 
colorless semisolid (67%). Rf = 0.257 (EtOAc/Et3N, 95:5).  
1H NMR (CDCl3, 400 MHz): 
δ 8.18 (d, 1H, J = 1.9 Hz), 7.81 (dd, 1H, J1 = 8.3, J2 = 1.9 Hz), 7.50-7.40 (m, 2H), 7.30-
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7.20 (m, 2H), 7.16 (s, 1H), 7.10 (d, 1H, J = 8.3 Hz), 6.97 (t, 2H, J = 8.7 Hz), 6.75 (t, 1H, 
J = 5.5 Hz), 5.12 (d, 1H, J = 12.6 Hz), 5.09 (d, 1H, J = 12.6 Hz), 4.56 (d, 2H, J = 5.7 Hz), 
2.3-2.0 (m, 10H), 1.5-1.2 (m, 2H).  13C NMR (CDCl3, 100 MHz): δ 164.9, 162.9, 144.9, 
143.8, 140.9, 139.8, 138.7, 137.6, 131.9, 128.5, 127.4, 126.7, 126.6, 122.1, 120.8, 117.9, 
115.1, 114.8, 90.8, 87.5, 71.7, 59.6, 45.4, 43.9, 39.3, 22.3.  HRMS calcd for 
C27H27FIN5O2H
+ 600.1266, found 600.1268.  IR: azide, 2117 cm−1.  The oxalate salt was 
precipitated from acetone; Mp: 83-84 °C.  Anal calcd for: C29H29FIN5O6•0.78CH3COCH3 
•0.40C2O4H2: C, 50.07; H, 4.51; N, 9.07; F, 2.46; I, 16.44.  Found: C, 50.09; H, 4.46; N, 
9.18; F, 2.39; I, 16.39.  [α]23.5D = +2.13 (c = 6, MeOD). 
 
(S)-4-azido-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-
dihydroisobenzofuran-5-yl)methyl)-3-(tributylstannyl)benzamide ((S)-5.48) 
A mixture of (S)-4-azido-N-((1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-
1,3-dihydroisobenzofuran-5-yl)methyl)-3-iodobenzamide (S)-4.51 (170 mg, 0.28 mmol), 
Pd(PPh3)2Br2 (13.5 mg, 0.02 mmol), and bis(tri-n-butyltin) (0.26 mL, 0.51 mmol) in 
toluene (10 mL) was heated at 105˚C for 4 hrs.  The mixture was then cooled to room 
temperature, diluted with saturated aq. K2CO3 solution, and then extracted with EtOAc.   
The organic phase was washed with brine, dried (MgSO4), filtered, concentrated, and 
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chromatographed (EtOAc/Et3N, 95:5) to give 110 mg of organostannane (S)-5.48 as a 
brown oil (52%).  Rf = 0.25 (EtOAc/Et3N, 95:5).  
1H NMR (CDCl3, 400 MHz): δ 7.83 (d, 
1H, J = 2.1 Hz), 7.74 (dd, 1H, J1 = 8.3 Hz, J2 = 2.1 Hz), 7.50-7.40 (m, 2H), 7.25 (s, 2H), 
7.19 (s,1H), 7.13 (d, 1H, J = 8.3 Hz), 6.97 (t, 2H, J = 8.7), 6.42 (t, 1H, J = 5.6 Hz), 5.14 
(d, 1H, J = 12.8 Hz), 5.10 (d, 1H, J = 12.8 Hz), 4.62 (d, 2H, J = 5.7 Hz), 2.30-2.0 (m, 
10H), 1.60-1.40 (m, 7H), 1.4-1.2 (m, 7H), 1.2-1.0 (m, 6H), 0.9-0.8 (m, 9H).  13C NMR 
(CDCl3, 100 MHz): δ 166.9, 162.9, 160.5, 149.2, 143.6, 140.9, 139.7, 137.9, 136.3, 
135.1, 130.0, 128.5, 127.2, 126.7, 126.6, 121.9, 120.6, 116.5, 114.9, 114.7, 90.7, 71.6, 
59.6, 45.3, 43.7, 39.3, 28.9, 27.2, 22.3,13.6, 10.1.  HRMS calcd for C39H54FN5O2SnH
+ 
764.3356, found 764.3369.  IR: azide, 2109 cm−1.  [α]23D = +1.3 (c = 2.25, CHCl3) 
6.2.  Materials and Methods for Proteomics 
6.2.1.  Materials and Equipment 
Materials 
Cell line 
 
TRex- HEK 293 cell line (HEK 293 cells stably expressing synthetic human serotonin 
transporter) 
 
Chemicals 
 
3X FLAG® Peptide 
Sigma-Aldrich Co., St. Louis, MO 
 
Acetic acid 
Fisher Scientific, Waltham, MA 
 
Acetonitrile HPLC grade 
Fisher Scientific, Waltham, MA 
 
Acrylamide:Bis 37.5:1 
Calbiochem, Gibbstown, NJ 
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Albumin standard 
Thermo Scientific, Rockford, IL 
 
Ammonium bicarbonate 
Fisher Scientific, Waltham, MA 
 
Ammonium persulfate 
Fisher Scientific, Waltham, MA 
 
ANTI-FLAG® M2 Affinity Gel, 
Sigma-Aldrich Co., St. Louis, MO 
 
Aprotinin 
MP Biomedicals Inc., Santa Ana, CA 
Benzamidine 
Sigma-Aldrich Co., St. Louis, MO 
 
Benzethonium chloride 
Sigma-Aldrich Co., St. Louis, MO 
 
Bromophenol blue 
Fisher Scientific, Waltham, MA 
 
Copper sulfate 
Sigma-Aldrich Co., St. Louis, MO 
 
Deoxycholic acid 
Sigma-Aldrich Co., St. Louis, MO 
 
Digitonin 
Calbiochem, La Jolla, CA 
 
Dithiothreitol (DTT) 
Fisher Scientific, Waltham, MA 
 
DMSO 
Sigma-Aldrich Co., St. Louis, MO 
 
Dulbecco’s modified eagle medium (DMEM)  
Hyclone, Logan, UT 
 
EDTA 
Fisher Scientific, Waltham, MA 
 
Fetal Bovine Serum (FBS) 
Hyclone, Logan, UT 
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Folin-Ciocalteu’s phenol reagent 2N 
Sigma-Aldrich Co., St. Louis, MO 
 
Glycerol 
Sigma-Aldrich Co., St. Louis, MO 
 
Glycine 
Invitrogen, Carlbad, CA 
 
HBSS/Modified  
Hyclone, Logan, UT 
 
HEPES Free acid 
Amresco, Solon, OH 
 
Iodoacetamide 
Sigma-Aldrich Co., St. Louis, MO 
 
IRDye 680LT goat anti mouse IgG (H+L) 
LI-COR, Lincoln, NE 
 
IRDye 800CW azide infrared dye 
LI-COR, Lincoln, NE 
 
IRDye 800CW goat anti mouse IgG (H+L) 
LI-COR, Lincoln, NE 
 
MeOH HPLC grade 
Fisher Scientific, Waltham, MA 
 
Modified lowry protein assay reagent 
Thermo Scientific, Rockford, IL 
 
Molecular weight markers (928-40000) 
LI-COR, Lincoln, NE 
 
Monoclonal ANTI-FLAG M2, Clone M2 
Sigma-Aldrich Co., St. Louis, MO 
 
Odyssey blocking buffer 
LI-COR, Lincoln, NE 
 
Odyssey nitrocellulose membrane 
LI-COR, Lincoln, NE 
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Penicillin-Streptomycin-Glutamine (PSQ) 
Gibco-BRL, Grand Island, NY 
 
Phenylmethylsulfonyl fluoride (PMSF) 
Sigma-Aldrich Co., St. Louis, MO 
 
Potassium chloride 
Fisher Scientific, Waltham, MA  
 
Potassium phosphate monobasic 
Fisher Scientific, Waltham, MA  
 
Sodium chloride 
VWR Scientific, Bridgeport, NJ 
 
Sodium dodecyl sulfate 
Fisher Scientific, Waltham, MA  
 
Sodium phosphate dibasic 
Fisher Scientific, Waltham, MA  
 
Temed (JT Baker) 
Capitol Scientific, Inc. Austin, TX 
 
Tetracycline hydrochloride 
Sigma-Aldrich Co., St. Louis, MO 
 
Trichloroacetic acid 
MP Biomedicals Inc., Santa Ana, CA 
 
Trifluoroacetic acid (TFA) 
Sigma-Aldrich Co., St. Louis, MO 
 
Tris[1-benzyl-1H-1,2,3 triazol-4yl)methyl]amine (TBTA) 
Sigma-Aldrich Co., St. Louis, MO 
 
Tris-2-carboxyethyl phosphine hydrochloride (TCEP) 
Molecular Probes, Grand Island, NY 
 
Tris base 
Sigma-Aldrich Co., St. Louis, MO 
 
Tris hydrochloride 
Sigma-Aldrich Co., St. Louis, MO 
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Trypsin-EDTA 10X  
Gibco-BRL, Grand Island, NY 
 
Trypsin gold, mass spectrometry grade 
Prmega, Madison, WI 
 
Tween-20  
Biorad, Hercules, CA 
 
Zeocin 
Invitrogen, Carlbad, CA 
 
 
Equipment 
 
Biorad power PAC 300 
Biorad, Hercules, CA 
 
Branson sonifier 250 
Branson Ultrasonics Corporation, Danbury, CT 
 
Cell culture incubator  
Forma Scientific, Worcester, MA  
 
Dry bath incubator 
Fisher Scientific, Waltham, MA  
 
Newport mercury arc lamp, Model 97435-1000-1  
Newport Corporation, Irvine, CA 
 
Odyssey classic imager 
LI-COR, Lincoln, NE 
 
Optima XE-90 ultracentrifuge 
Beckman Coulter, Inc. Brea, CA 
 
Refrigerated tabletop centrifuge, Model 5810R  
Eppendorf Scientific, Hauppauge, NY 
 
Themolyne rotomix type 48200 
SER, Mountain View. CA 
 
Thermix stirring hot plate, Model 210T 
Fisher Scientific, Waltham, MA 
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Type 70.1 Ti rotor, Titanium, Fixed angle 
Beckman Coulter, Inc. Brea, CA 
 
UV-visible spectrophotometer DU 530  
Beckman Instruments Inc., Fullerton, CA  
 
Vacufuge concentrator 5301 
Eppendorf, Hamburg, Germany 
 
Vortex genie-2, Model G560 
VWR Scientific, Bridgeport, NJ 
 
VWR mini vertical PAGE system 
VWR Scientific, Bridgeport, NJ 
 
6.2.2.  Cell Culture 
A T-Rex-HEK-293-human SERT cell line employed in the study was kindly 
provided by Dr. Shigetoshi Sugi’s laboratory, Mitsubishi Chemical Group Science and 
Technology Research Center, Inc., Yokohama, Japan.  The cells were grown in growth 
media (DMEM media supplemented with 10% fetal bovine serum (FBS), 1X PSQ, 
zeocin (100µg/ml)).  Cells were grown as monolayers in 75 cm2 flasks at 37˚С and 5% 
CO2 and subcultured twice a week or every 3 days.  For subculturing the cells, the 
exhausted media in the flask was aspirated and the confluent adherent cells were washed 
with 10 mL of Hanks buffered salt solution (HBSS).  To detach the cells from the flask, 2 
mL of trypsin-EDTA was added and swirled to cover the cell monolayers.  When the 
cells were detached from the flask, 8 mL of growth media was added to inactivate the 
trypsin-EDTA.  The cell suspension was then transferred into a 15 mL tube and 
centrifuged at 1000g for 5 minutes.  The supernatant was decanted and cell pellet was 
resuspended in 10 mL growth media.  From this cell suspension, 2 mL was then 
transferred into a new flask containing 18 mL of fresh growth media.  The flask was 
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tightly capped and then gently swirled to evenly suspend the cells. The flask was placed 
in the incubator and the cells were allowed to grow until the next subculture. 
 For tetracycline-induction, cells were grown in growth media as monolayers in 10 
cm-diameter-tissue culturing plates at 37˚С and 5% CO2.  At around 90% confluence, the 
exhausted media in the flask was aspirated and new tetracycline-containing induction 
medium (DMEM media supplemented with 10% fetal bovine serum (FBS), 1X PSQ, 
tetracycline (1 µg/ml)) was added to the cells.  The cells were grown at 37˚С and 5% CO2 
for 24 hrs and then harvested for experiments.  The medium was completely removed by 
aspiration, added phosphate buffrered saline  (1X PBS, 137 mm NaCl, 2.7mm KCl, 
8.1mM Na2HPO4, 1.47 mM KH2PO4) (4 °C) and scraped cells to 50 mL falcon tube.  
Centrifuged at 1000g for 5 minutes to collect cells and discarded the supernatant.  The 
cell pellet in the falcon tube was then dipped into liquid nitrogen for 4 sec to snap freeze 
and stored at -80 °C until used. 
6.2.3.  Purification of hSERT: Single-Step Immuno-Affinity Chromatography with 
FLAG-Epitope Tag 
The HEK293 cell pellet (collected from 10 plates) was dispersed in 10 mL lysis 
buffer (10 mM Tris-HCl, 1 mM EDTA, pH = 7.4, anti-proteolytic cocktail (APC) 
containing 1.6 µu/mL aprotinin, 100 µM phenylmethylsulfonyl fluoride, 1 mM 
benzamidine and 100 µM benzethonium chloride) and sonicated using a probe sonicator 
microtip at maximum power and 50% cycle setting (15 strokes).  The cell homogenate 
was ultracentrifuged at 100,000g for 20 min at 4 °C, and membrane fraction was again 
homogenized and centrifuged in the same way.  The resultant membrane fraction can be 
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snap frozen in liquid nitrogen and stored at -80 °C until further use.  The membrane 
fraction was then solubilized by resuspending and incubating at 4 °C overnight in 10 mL 
of solubilization buffer (20 mM Tris-HCl, pH = 7.4, 500 nM NaCl, 10% v/v glycerol, 1 
mM EDTA, APC, 1% w/v digitonin).  The solubilized SERT was ultracentifuged at 
100,000g for 20 min at 4 °C and the supernatant was subjected to affinity 
chromatography using ANTI-FLAG M2 affinity gel according to the manufacturer 
instructions for batch mode. Briefly, 1 mL resin (50% solution) was transferred to a 15 
mL falcon tube. Centrifuged at 3200g for 2 min at 4 °C and removed the supernatant 
without discarding any resin.  The resin was then washed (2X) with 10 mL of TBS (50 
mM Tris HCl, 150 mM NaCl, pH = 7.4) at 4 °C.  To this resin, 10 mL of solubilized 
hSERT was added and incubated for 2 hrs at 4 °C with gentle agitation (nutator).  The 
sample was centrifuged at 3200g for 2 min at 4 °C and unbound supernatant was 
removed from the resin.  The resin was then washed (2X) with 8 mL wash buffer (25mM 
HEPES, 150 mM NaCl, 10% glycerol, pH 7.4, 0.07 % digitonin).  The resin was then 
incubated with 2 mL elution buffer (the wash buffer with 250 ng/µL 3X FLAG-peptide) 
for 30 min at room temperature.  The sample was centrifuged at 3200g for 2 min at 4°C 
and elute (purified hSERT) was stored at -20 °C until further use.  
6.2.4.  Protein Assay: Modified Lowry Assay 
Protein concentrations were determined using modified Lowry assay (Peterson, 
1977).  Protein samples or bovine serum albumin (BSA) standards were diluted to 1.0 mL 
with distilled H2O and proteins were precipitated by adding 0.15 mL 1.0% deoxycholate 
and vortexed and incubated for 10 min at room temperature.  Then 0.1 mL 72% 
tricholoracetic acid was added, mixed by vortexing and centrifuged at 11,000 rpm for 10 
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min.  The supernatant was discarded and the pellet was resuspended in 0.2 ml distilled 
H2O. At 15 sec intervals, 1 mL of modified lowry protein assay reagent was added to 
each sample. The samples were mixed by vortexing and allowed to stand for exactly 10 
min at room temperature.  Exactly, after the end of each sample’s 10 min incubation 
period, 100 µL of 1X Folin-Ciocalteu reagent was added and immediately mixed 
vigorously.  The color was developed for 30 min in the dark and absorbance at 750 nm 
was recorded.  All samples were run in duplicate.  To determine protein sample 
concentration, the standard curve was plotted using various concentrations of BSA 
standard.  The concentration of protein samples was determined by fitting the 
experimentally obtained absorbance of protein samples to the BSA standard curve.  
6.2.5.  SDS-PAGE and Western blot 
All protein samples were treated with SDS-PAGE sample buffer containing 2% 
SDS.  Proteins were separated on 10% SDS-PAGE gels at a constant voltage of 120 V 
and transferred to a nitrocellulose membrane at 90 mA constant current overnight at 4 °C.  
The membrane was blocked with Odyssey blocking buffer, washed twice and incubated 
with the primary antibody with a dilution of 1 µg/mL (monoclonal ANTI-FLAG M2, 
Clone M2 produced in mouse, Sigma-Aldrich) for 2 hr at room temperature in blocking 
buffer with 0.1% Tween-20.  The membrane was washed with PBS-T (Phosphate 
buffered saline with 0.1% Tween-20) buffer for 5 min (4X) and incubated with the IR-
conjugated 680LT goat anti-mouse secondary antibody with a dilution of 1:5,000 for 1 
hr.  The membrane was again washed with PBS-T buffer for 5 min (4X) and scanned on 
Odyssey imager. 
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6.2.6.  SERT Photoaffinity Labeling and Click-Chemistry 
Purified hSERT (100 µL) was taken in 96 well-plate and add (S)-4.44 (1 µL of 
100 mM stock in DMSO) and incubate on ice for 1 hr. Then, the 96 well-plate without lid 
(on ice) was irradiated with UV light (350-450 nm) for 20 min. The click reaction was 
initiated by adding IRDye® 800CW azide (1 µL of 2.5 mM stock in H2O, LI-COR), 
TCEP (2 µL of 50 mM stock in H2O), tris((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)amine 
(6 µL of 2 mM stock in DMSO:t-BuOH, 1:4), CuSO4 (2 µL of 50 mM stock in H2O) and 
allowed to react for 1 hr at room temperature.  The reaction was quenched by adding 28 
µL of 5X loading dye and the samples were analysed within two days by storing at -20ºC 
to visualize crosslinking using Western blot.  For in-gel scanning, proteins separated by 
SDS-PAGE were visualized by first soaking the gel in 40% MeOH, 10% acetic acid in 
water with shaking for 20 mins and directly scanning the gel on Odyssey imager. 
6.2.7.  In-gel Trypsin Digestion 
Before trypsin digestion, cysteine residues were reduced and alkylated with 
iodoacetamide.  Briefly, the gel pieces (each band) were incubated with 100 % 
acetonitrile (300 µL), and then 50 µL of 10 mM DTT in 100 mM ammonium bicarbonate 
at 60 °C for 1 hr.  After two washes with 100 mM ammonium bicarbonate, the gel pieces 
were incubated with 50 µL of 50 mM iodoacetamide in 100 mM ammonium bicarbonate 
for 30 min in dark at room temperature.  Then, the gel pieces were washed with 300 L 
of wash buffer (20 mM ammonium bicarbonate in 50% acetonitrile) twice for 10 min 
with gentle agitation.  The gel plugs were dehydrated by adding 100 µL acetonitrile.  
After the gel plugs turned whitish, acetonitrile was removed and dried in a SpeedVac for 
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about 15 min.  Then 20 μL of trypsin buffer (20 µg/mL of trypsin gold in 40 mM 
ammonium bicarbonate in 10 % acetonitrile) was added to each sample and incubated at 
room temperature for 1 hr.  Then 40 mM ammonium bicarbonate in 10% acetonitrile was 
added to cover the gel pieces and incubated overnight at 37 °C.  The trypsin buffer was 
transferred to a new tube (labeled).  Later, 60 L of extraction buffer (1% TFA in 50:50 
acetonitrile: H2O) was added to the gel plugs and incubated for 30 min with gentle 
agitation.  Then the 60 L of extraction buffer was transferred to the above labeled 
sample tube and the gel plugs were incubated with 40 L of extraction buffer (1% TFA 
in acetonitrile/H2O, 50:50) for 30 min with gentle agitation and then transferred to the 
above labeled sample tube.  Samples were dried in SpeedVac for about 3 hr. 
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APPENDIX 
A.1.  Radiosynthesis, Pharmacological Evaluation, and Photoaffinity Labeling 
Experiments of Racemic 4-Azido-3-Iodo-Methylphenidate ((±)-[125I]-4.35) for DAT 
Structure-Function Studies 
 With methylphenidate derivatives aniline (±)-4.36, 4-amino-3-iodo (±)-4.40 and 
target 4-azido-3-iodo (±)-4.35 in hand, ligand affinities (Ki values) were determined for 
inhibition of [3H]-WIN-35,428 (1.25) binding to hDAT expressed in N2A neuroblastoma 
cells by Dr. Christopher Surratt’s group (Duquesne University).  These results indicated 
that (±)-4.35 (Ki  = 4.0 ± 0.8 nM) displays 4-fold higher hDAT affinity than (±)-threo-
methylphenidate ((±)-1.18). Given that racemic threo-4-azido-3-iodo-MP ((±)-4.35) 
represented one of the highest affinity DAT photoprobes synthesized to date, further 
development of this compound into a potential DAT photoprobe was pursued. 
Table A.1.  Inhibition of [3H]-WIN 35,428 binding of methylphenidate-based compounds at hDAT N2A 
neuroblastoma cells (Lapinsky, Yarravarapu et al., 2012). 
 
Compound No. Aromatic 
substituent 
(R) 
[3H]-WIN binding 
inhibition Ki (nM) 
(±)-4.35 4-N3-3-I 4.0 ± 0.8 
(±)-4.36 4-NH2 6.3 ± 2.0 
(±)-4.40 4-NH2-3-I 9.1 ± 1.5 
 
 Given that wash-resistant binding experiments involving non-radioactive azido-
containing compounds frequently give false positives in assessment of covalent 
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attachment (Agoston et al., 1997), a radio-iodinated [125I] version of (±)-4.35 was 
pursued to determine if photoactivation could produce covalent ligation to the hDAT 
protein.  In this regard, (±)-[125I]-4.35 was synthesized by Dr John Lever (University of 
Missouri-Columbia) via electrophilic radioiodination of aniline (±)-4.36 with [125I]-NaI 
(1.49 mCi) under no-carrier-added conditions using Chloramine-T (N-chloro-4-
toluenesulfonamide trihydrate) as an oxidant, followed by diazotization and subsequent 
treatment with sodium azide (Scheme A.1).  Reversed-phase HPLC purification provided 
final photoprobe (±)-[125I]-4.35 in 54% isolated yield with high purity (98%) and high 
specific activity (1986 mCi/mol).  Furthermore, purified (±)-[125I]-4.35 co-eluted with a 
fully characterized sample of non-radioactive (±)-4.35 under the same reverse-phase 
HPLC conditions. 
 
Scheme A.1.  Radioiodination and DAT covalent ligation of methylphenidate-based photoprobe (±)-[125I]-
4.35 (Lapinsky, Yarravarapu et al., 2012). 
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Figure A.1.  Photoaffinity labeling of hDAT with (±)-[125I]-4.35 performed by the Vaughan group.  
LLCPK1 cells expressing 6Xhis-hDAT were photolabeled with 10 nM (±)-[125I]-4.35 in the absence or 
presence of 10 M (-)-cocaine or D-methylphenidate (D-MPH).  Cells were solubilized and DATs were 
immunoprecipitated followed by analysis by SDS–PAGE and autoradiography.  The relevant portion of a 
representative autoradiograph is pictured followed by a histogram that quantitates relative band intensities 
(mean ± SE of three independent experiments are shown; ***, p < 0.001 versus control).  (Lapinsky, 
Yarravarapu et al., 2012.  Reprinted with permission from ACS Med. Chem. Lett. 2012, 3, 378-382. 
Copyright 2012, American Chemical Society). 
With radioactive photoprobe (±)-[125I]-4.35 in hand, Dr Roxanne A. Vaughan’s 
group (University of North Dakota) conducted preliminary photoaffinity labeling 
experiments with the DAT.  In particular, rat striatal membranes and LLCPK1 cells 
expressing 6Xhis-human DAT were incubated with 10 nM (±)-[125I]-4.35 in the absence 
or presence of 10 µM (-)-cocaine or D-(+)-methylphenidate.  The membrane and cells 
were then irradiated with 254 nm UV light for 5 min to photoactivate the azido group and 
allow irreversible binding of the probe to DAT.  Next, the membrane and cells were 
detergent-solubilized, and the lysates were immunoprecipitated with DAT antibody and 
analyzed by SDS-PAGE and autoradiography.  The isolated ~80 kDa labeled proteins 
obtained from both LLCPK1 hDAT cells (see Figure A.1) and rat striatal tissue (see 
Figure A.2) clearly demonstrated the photoincorporation of (±)-[125I]-4.35 into DAT.  
Incorporation of photoprobe was >90% blocked by either (-)-cocaine or D-(+)-
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methylphenidate, demonstrating the pharmacological specificity of (±)-[125I]-4.35 
attachment to the DAT. 
 
Figure A.2.  Photoaffinity labeling of rDAT with (±)-[125I]-4.35 performed by the Vaughan group.  Rat 
striatal membranes were photolabeled with 10 nM (±)-[125I]-4.35 in the absence or presence of 10 M (-)-
cocaine or D-methylphenidate (D-MPH).  Cells were solubilized and DATs were immunoprecipitated 
followed by analysis by SDS–PAGE and autoradiography.  The relevant portion of a representative 
autoradiograph is pictured followed by a histogram that quantitates relative band intensities (mean ± SE of 
three independent experiments are shown; ***, p < 0.001 versus control).  (Lapinsky, Yarravarapu et al., 
2012.  Reprinted with permission from ACS Med. Chem. Lett. 2012, 3, 378-382. Copyright 2012, American 
Chemical Society) 
A.2. Radioiodination, and Serotonin Transporter Covalent Ligation of 
Escitalopram-Based Photoaffinity Ligand ((±)-[125I]-4.51) Containing the 
Traditional 4-Azido-3-Iodo Photoaffinity Labeling Motif for  
 Given escitalopram-based photoaffinity ligand (S)-4.51 retained high SERT 
binding affinity (Ki = 3.45 ± 2.04 nM) when compared to escitalopram (Ki = 1.77 ± 1.14 
nM) as a lead compound, further development of this compound into a potential serotonin 
transporter photoprobe was pursued.  Once again, given that wash-resistant binding 
experiments involving non-radioactive azido-containing compounds frequently give false 
positives in assessment of covalent attachment (Agoston et al., 1997), synthesis of a 
radio-iodinated [125I] version of (S)-4.51 was pursued to determine if photoactivation 
could produce covalent ligation to the hSERT protein.  In this regard, tri-n-butyl stannyl 
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analog (S)-5.48 (synthesis described in section 5.2.3) was converted to radioactive iodine 
derivative (S)-[125I]-4.51 by Dr. John Lever at the University of Missouri-Columbia.   
 
Scheme A.2.  Radiosynthesis and SERT covalent ligation of methylphenidate-based photoprobe (S)-[125I]-
4.51. 
 Since carryover of trace amounts of (S)-4.51 would dramatically lower the 
specific radioactivity of (S)-[125I]-4.51 prepared from (S)-5.48 (Lever, 1996), this material 
was purified by reversed-phase HPLC prior to radiolabeling.  As shown in Scheme A.2, 
Dr.Lever treated the stannyl derivative (S)-5.48 with [125I]NaI (2.07 mCi) in the presence 
chloramine-T as the oxidant in methanolic acetic acid, followed by reversed-phase HPLC 
isolation to provide (S)-[125I]-4.51 in 46% yield with high purity (≥ 98%) and specific 
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radioactivity of 2096 mCi / µmol.  Furthermore, this radioligand exhibited a 
chromatographic profile identical to that of non-radioactive (S)-4.51.  
To determine if the SERT could be irreversibly labeled (Scheme A.2) with (S)-
[125I]-4.51, Dr. Roxanne Vaughan’s group (University of North Dakota) performed 
photoaffinity labeling with LLCPK cells expressing HA-hSERT incubated with 10 nM 
(S)-[125I]-4.51 in the absence or presence of 10 µM escitalopram (Scheme A.2). The cells 
were then detergent-solubilized and the lystates were immunoprecipitated with Anti-HA 
antibody linked sepharose A beads and samples eluted from the beads were analyzed by 
SDS-PAGE/autoradiography. Labeled proteins of ~100 kDa were obtained from LLCPK 
HA-hSERT cells, demonstrating the incorporation of (S)-[125I]-4.51 into the SERT. 
Incorporation of the enantiomerically pure photoaffinity ligand was blocked by 
escitalopram, demonstrating the appropriate pharmacological specificity for (S)-[125I]-
4.51 attachment to the SERT (Figure A.3).  In summary, (S)-[125I]-4.51 represents a 
successful example of an enantiopure SERT photoaffinity ligand based on a CIT scaffold, 
thus representing an important contribution to the arsenal of chemical probes useful for 
characterizing SERT function and 3D structure.  
 
Figure A.3.  Photoaffinity labeling of hSERT with (S)-[125I]-4.51 performed by the Vaughan group.  
LLCPK1 cells expressing HA-hSERT were photolabeled with 10 nM (±)-[125I]-4.51 in the absence or 
presence of 10 M (S)-citalopram (S-Cit).  Cells were solubilized and DATs were immunoprecipitated 
followed by analysis by SDS–PAGE and autoradiography. 
